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 Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory 
disease characterized by persistent airflow limitation that is not fully reversible and is 
usually caused by cigarette smoke (CS). The disease is predicted to be the fourth 
leading cause of death by 2030, but none of the currently available treatments can 
alleviate the progressive decline in lung function.  
Mesenchymal stem cells (MSCs) are fibroblast-like multipotent stem cells that 
can be isolated from various tissues such as bone marrow (BM-MSCs). Despite 
numerous reports of their efficacy in COPD-related pre-clinical models, BM-MSCs 
have not demonstrated efficacy in a clinical trial of COPD, highlighting the need for 
improved MSC-based therapy. The in vitro derivation of MSCs from induced 
pluripotent stem cells (iPSCs) has provided a new source of MSCs. Compared to 
BM-MSCs, iPSC-derived MSCs (iPSC-MSCs) are a more abundant source, have a 
higher expanding capacity and are possibly not subject to the ageing-associated 
dysfunction seen in BM-MSCs.  
In this study I determined the effects of human iPSC-MSCs in a rat COPD model 
using BM-MSCs as comparison. Rats were exposed to CS for 1 hr/day for 56 days. 
iPSC-MSCs or BM-MSCs were administrated at days 29 and 43. iPSC-MSCs 
demonstrated superior effects over BM-MSCs in attenuating CS-induced lung 
airspace enlargement, fibrosis, inflammation and apoptosis. In a mouse model of 
ozone-induced lung damage, intravenous administration of iPSC-MSCs 24 hours 
before ozone exposure for 3 hours alleviated airway hyper-responsiveness, 
inflammation and apoptosis in the lung. 
There is increasing evidence demonstrating that mitochondrial dysfunction may 
play an important role in COPD pathogenesis, indicating mitochondria as a potential 
therapeutic target. Meanwhile, mitochondrial transfer from MSCs to injured airway 
cells has been reported as a novel mechanism of action for MSCs. 
In this study mitochondrial transfer from iPSC-MSCs to the airway epithelium of 
CS-exposed rats was detected. iPSC-MSCs also transferred mitochondria to bronchial 
epithelial BEAS-2B cells and primary airway smooth muscle cell (ASMCs) in vitro in 
a direct co-culture system, an effect that was enhanced by CS medium (CSM). Direct 
co-culture with iPSC-MSCs alleviated CSM-induced ATP deprivation in BEAS-2B 
cells, as well as CSM-induced mitochondrial reactive oxygen species (ROS), 
apoptosis and reduction of mitochondrial membrane potential (ΔΨm) in ASMCs. 
Administration of iPSC-MSCs also prevented ozone-induced mitochondrial ROS and 
ΔΨm reduction in mouse lungs. 
The paracrine effects of iPSC-MSCs were also investigated. iPSC-MSC-derived 
conditioned medium (iPSC-MSCs-CdM) protected BEAS2-B cells from 
CSM-induced apoptosis. The effect was reduced by depleting stem cell factor (SCF) 
from iPSC-MSCs-CdM. However, both iPSC-MSCs-CdM and trans-well inserts 
containing iPSC-MSCs were only able to alleviate CSM-induced mitochondrial ROS, 
but not ΔΨm reduction and apoptosis, in ASMCs. 
I demonstrated the capacity of iPSC-MSCs to alleviate oxidative stress-induced 
COPD phenotype in vivo. Mitochondrial transfer from iPSC-MSCs was able to 
alleviate oxidative stress-induced mitochondrial dysfunction and apoptosis in target 
cells. The full capacity of iPSC-MSCs to achieve these effects may rely on a 
combination of cell-cell contact and release of paracrine factors. These findings define 
iPSC-MSCs as a promising candidate for the development of MSCs-based therapy of 
COPD. 
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Chapter 1. Introduction 
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1.1. Introduction to Chronic Obstructive Pulmonary Disease 
(COPD) 
1.1.1. Definition and diagnosis of COPD 
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) defines 
chronic obstructive pulmonary disease (COPD) as „a common preventable and 
treatable disease‟ which is „characterized by persistent airflow limitation that is 
usually progressive and associated with an enhanced chronic inflammatory response 
in the airways and the lung to noxious particles or gases‟ (263). The chronic 
inflammation drives small airways disorder named obstructive bronchiolitis leading to 
structural alterations and narrowing of small airways, and emphysema characterized 
by destruction of parenchyma which causes separation of alveolar from the small 
airways and loss of lung elastic recoil (263). Obstructive bronchiolitis and 
emphysema together causes the persistent airway flow limitation in patients with 
COPD (Figure 1.1), but the contribution from each of them varies within individual 
patients (263). 
COPD is diagnosed by post-bronchodilator spirometry to measure persistent 
airway limitation. Spirometry measures volume of air that a patient can exhale at a 
maximal force (as long and as quickly as possible) after a maximal deep inspiration 
(208). The total volume of air exhalation with greatest effort of the patient is defined 
as forced vital capacity (FVC) (208). The total volume of air exhalation with greatest 
effort of the patient in the first second is defined as forced expiratory volume in 1 s 
(FEV₁) (208). Persistent airway limitation is confirmed when the ratio of FEV₁ to 
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FVC is less than 0.7 (263) (Figure 1.2). 
 
 
 
 
Figure 1.2 Measurement of airflow limitation by spirometry. Patients are asked to 
exhale as long and as quickly as possible. Exhalation volume from (A) normal lungs 
or (B) obstructive lungs is plotted against time. FVC: forced vital capacity; FEV1: 
forced expiratory volume in the first second; Airway obstruction is defined if 
FEV1/FVC is less than 0.7. The figure is reproduced based on plots by Ranu H et al, 
Ulster Med J (208). 
Figure 1. 1 Cause of airflow limitation in airways of patients with 
COPD. Compared to (A) healthy lungs, lungs with (B) COPD demonstrate 
parenchymal destruction leading to emphysema, mucosal and peribronchial 
inflammation and fibrosis leading to obliterative bronchiolitis, and mucus 
hypersecretion leading to luminal obstruction. As a result, patients with 
COPD develop irreversible airflow limitation. Adapted from Barnes PJ, N 
Engl J Med (22). 
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Further assessment of COPD includes determination of levels of symptoms, 
severity of airflow limitation, exacerbation risk and comorbidities. The major 
symptoms of the disease include chronic and progressive dyspnea, cough and sputum 
production. The levels of symptoms can be assessed by questionnaires such as 
Modified British Medical Research Council (mMRC) questionnaire on breathlessness 
and COPD Assessment Test (CAT). The severity of airflow limitations is graded into 
four different stages by GOLD based on the post-bronchodilator FEV₁ (Table 1.1). 
The spirometric criteria for Mild, Moderate, Severe and Very Severe severities are 
80%, 50% and 30% of predicted FEV₁. Exacerbations refer to short periods (at least 
48 hours) of symptom worsening such as increased cough and dyspnea which is 
beyond normal variations (65, 263). Exacerbations lead to reduced quality of life, 
accelerated disease progression and increased risk of death (65, 71, 236). 
Exacerbations usually call for changes in medication by which their severity can be 
defined, including change of inhaled treatment (mild exacerbation), medical 
intervention such as antibiotic and oral steroids (moderate exacerbation) and 
hospitalization (severe exacerbation). A combined assessment of COPD which 
integrates levels of symptoms, severity of airway limitation and exacerbation history 
is suggested by GOLD. The assessment groups patients with COPD into four 
sub-groups demonstrating different burden of symptom and risk of exacerbation 
(Group A, low risk and less symptoms; Group B, low risk and more symptoms; Group 
C, high risk and less symptoms; Group D, high risk and more symptoms). The burden 
of symptoms is defined high or low by mMRC or CAT grade. The risk of 
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exacerbation is defined high if the severity of airway limitation is GOLD 3-4 or there 
are two or more exacerbations in the preceding year. In addition to the combined 
assessment approach, assessment of comorbidities is also important. COPD is highly 
associated with comorbidities including ischaemic heart disease, diabetes, skeletal 
muscle wasting, cachexia, osteoporosis, depression and lung cancer (65, 263). The 
comorbidities can increase the risk of admission to hospital and death (234).  
 
Table 1.1 GOLD Severity of airflow limitation in COPD (FEV₁/FVC<0.70) 
GOLD stage Severity Post-bronchodilator FEV₁ 
Stage 1 Mild FEV₁≥ 80% of predicted 
Stage 2 Moderate 50% ≤FEV₁< 80% of predicted 
Stage 3 Severe 30% ≤FEV₁< 50% of predicted 
Stage 4 Very severe FEV₁< 30% of predicted 
 
1.1.2. Epidemiology of COPD 
The prevalence of COPD varies among different reports, maybe due to different 
assessing criteria and methods of survey and analysis (96). A recent meta-analysis 
report estimated that the worldwide COPD cases in people aged 30 or more had 
increased from 227.3 million in 1990 to 384.0 million in 2010, while the prevalence 
was 10.7% in 1990 and 11.7% in 2010 (3). The actual prevalence may be higher than 
the data from epidemiological studies as COPD is considered to be under-diagnosed 
in general (259). It is estimated that 60-85% patients with COPD may be undiagnosed, 
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especially for the mild and moderate severities (GOLD stage 1 or 2) (114). 
COPD prevalence varies among different countries and different groups of people 
(e.g. gender and smoking history) (Figure 1.3). For example, the estimation of male 
population with COPD of GOLD 2 severity or above was estimated as 22.2% in Cape 
Town, South Africa, in comparison to 8.5% in Reykjavik, Iceland (168). Based on the 
data from two large multinational studies, the Burden of Obstructive Lung Disease 
(BOLD) study and the Latin American Project for Investigation of Obstructive Lung 
Disease (PLATINO) study, the prevalence of COPD in different countries ranges from 
3% to 23% (39, 168). The prevalence of COPD has been stable in some developed 
countries, while in the United States, it is the only common cause of death that has 
increased over the last 40 year (23). In developing countries such as some African 
countries, the prevalence increased more dramatically (65). Variations among nations 
were also observed in mortality studies. For example, the death rate of patients with 
COPD was estimated to be 130.5/100,000 in China in comparison to 4.4/100,000 in 
Japan, although the prevalence is similar between the two countries (168). COPD was 
ranked as the 6th leading cause of death worldwide in 1990, and was predicted to be 
the 3rd leading cause by 2020. A more recent study estimated COPD as 4th leading 
cause of death in 2030 (172). Based on the data of 2010 Global Burden of Disease 
(GBD) study, COPD led to 2.9 million deaths, accounting for about 5% of total deaths 
globally (161, 181).  
The economic burden associated with COPD is huge. For example, in 2003 the 
United States spent US$ 32.1 billion in total on COPD, US$ 18.0 billion of which on 
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direct healthcare costs and the rest on indirect morbidity and mortality costs (168). In 
2010 the number increased to US$ 49.9 billion in total and US$ 29.5 billion on direct 
healthcare costs (49). In United Kingdom, in 2007 the healthcare cost of COPD is 
three fold higher than asthma and the consultation rate of COPD is two to four-fold 
higher than ischemic heart disease (23).  
 
 
Figure 1. 3 Prevalence of COPD (GOLD stage 2 or higher) in 2007. Combined 
results from BOLD study and PLATINO study are demonstrated in the figure. The 
data were collected from a city or region of the country thus do not represent national 
population. Adapted from Mannino DM et al, the Lancet (169). 
 
1.1.3. Risk factors of COPD 
 COPD results from the interaction between gene and environmental stimuli (65). 
The most common genetic risk for COPD is deficiency of α1 antitrypsin, a circulating 
inhibitor of serine proteases. Mutation of genes encoding matrix metalloproteinase-12 
(MMP-12) (113) and transforming growth factor β1 (47) have also been reported in 
association with COPD. 
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 Cigarette smoking is the most common worldwide risk factor for COPD. 
Cigarette smoking is associated with an increase in prevalence of respiratory 
symptoms, lung function abnormalities, annual rate of FEV1 decline, and COPD 
mortality rate (136). The association between development of COPD and cigarette 
smoking is dose-dependent (292), and smoking cessation reduces rates of morbidity 
and mortality in comparison to continued smoking (209). Besides normal cigarette 
smoking, passive exposure to cigarette smoke in the environment is also a risk factor 
for COPD (73). For example, in China where 30% of the world‟s cigarettes are 
consumed (277), 12.1% of male and 51.3% of female nonsmokers are exposed to 
environmental smoke at home, while 26.7% of male and 26.2% of female 
non-smokers are exposed to environmental smoke in the work place in 2001 (92). In 
never-smokers with COPD, the passive exposure to cigarette smoke contributed to 1.9 
million additional deaths in China (280). Maternal smoking during pregnancy may 
also increase the risk of COPD to the fetus (245). Although cigarette smoking is 
recognized as the major risk factor for COPD, COPD does not develop in some 
people with the same smoking history (263). In addition, COPD may also develop in 
some nonsmokers (48, 141), indicating the importance of other risk factors. 
 In addition to environmental smoke, other particles and gases in environment can 
also contribute to development of COPD, such as occupational exposure to 
hazardous dusts and fume (17) and indoor pollutant from biomass burning for family 
cooking and heating (36, 75, 191, 207). 
 Age is commonly considered as a risk factor for COPD as the prevalence, 
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morbidity and mortality increases along with increased age (38, 126, 137). Gender 
was regarded as one risk factor in the past with men presenting higher prevalence and 
mortality of COPD than women (233). However, the prevalence of COPD in men and 
women from high-income countries has become more similar now (39, 233). 
Development of COPD can be also associated with many other risk factors 
including impaired lung development, asthma, bronchial hyper-responsiveness, 
asthma, infections and social status (168). 
  
1.1.4. Pathogenesis of COPD 
The most significant pathophysiological feature of COPD is airflow limitation 
resulting from narrowing of the small airway compartment and destruction of 
parenchyma, both leading to gas trapping and subsequently hyperinflation (186). 
Other pathophysiological changes that may present in patients with COPD include gas 
exchange abnormalities, mucus hypersecretion, pulmonary hypertension and other 
comorbidities (263). The pathological changes in patients with COPD mainly include 
infiltration of various inflammatory cells, structural changes of small airways such as 
thickening of walls and mucus overproduction, and destruction of parenchyma (60, 
263). The pathogenesis of COPD, including the mechanisms driving the chronic 
inflammation, remodeling of small airways and parenchymal destruction is still not 
fully understood (65). Current evidence indicates a complex interplay between 
oxidative stress, inflammatory responses, protease and anti-protease imbalance, 
ageing, and changes in apoptosis, proliferation and tissue repair process (57). A 
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simple illustration of the factors that leads to emphysema is shown in figure 1.4. The 
details are described in following sections. 
 
 
Figure 1. 4 Interplay of multiple events leading to emphysema. Cigarette smoke 
exposure activates airway epithelial cells, which release early inflammatory cytokines 
that recruit macrophages and neutrophils. They can also activate dendritic cells and 
the subsequent formation of CD8+ or CD4+ T cells. Along the chronic inflammation, 
various cell types are activated by inflammatory mediators and in response their 
secretory function may also become activated. Their anti-oxidant system may become 
defective, while cells such as neutrophils will release ROS, leading to 
oxidant/anti-oxidant imbalance. The resulting oxidative stress can induce senescence 
and mitochondrial dysfunction. Mitochondrial dysfunction and accelerated ageing can 
further amplify the oxidative stress. Apoptosis can be induced by external cytokines 
such as perforin and granzymes, as well as by cytochrome c release due to 
mitochondrial damage. Both accelerated ageing and apoptosis may lead to airspace 
enlargement. The immune cells and structural cells, especially neutrophils and 
macrophages can release protease. When the anti-protease of the cells is not enough to 
counterbalance such effect, excess protease activity can lead to destruction of alveolar 
structures.  
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1.1.4.1. Oxidative stress 
COPD is associated with persistent oxidative stress. Markers of oxidative stress, 
such as lipid peroxidation byproducts 4-hydroxy-2-nonenal, 8-isoprostane and 
malondialdehyde (MDA), are found increased in lungs of patients with COPD (135, 
206). The exhaled breath or breath condensates collected from patients with COPD 
also contains increased levels of various markers of oxidative stress including 
hydrogen peroxide, carbon monoxide, myeloperoxidase (MPO), 8-isoprostane and 
MDA (27, 176, 194, 195). Exacerbations are associated with further enhanced 
oxidative stress (263). 
Reactive oxygen species (ROS) are free oxygen radicals with unpaired elections 
that can oxidize various molecules such as proteins, DNA and lipids (133). Typical 
forms of ROS include superoxide radical (O2
-
), hydroxyl radical (OH
-
) and hydrogen 
peroxide (H2O2). Under normal conditions, the major sources of ROS are respiration 
of mitochondria, xanthine oxidase activity and NADP oxidase activity (167). During 
cigarette smoking, the structural and immune cells in the lung are exposed to high 
levels of exogenous oxidants from inhaled cigarette smoke (CS). One puff of CS 
contains about 10
15 
oxidants in the gas phase and 10
18
 oxidants in the tar phase, as 
well as 3000 ppm of nitric oxide (NO) (57, 58). Exposure to CS leads to release of 
inflammatory mediators and ROS from epithelial cells and immune cells, leading to 
release of various inflammatory mediators and ROS (164). Although CS is an obvious 
source of oxidants and indeed a major risk factor for COPD, oxidative stress is 
persistent after smoking cessation in patients with COPD (160), indicating that the 
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cellular accumulation and release of ROS is an important source of oxidative stress 
during the progression of COPD. Increased release of ROS was reported in alveolar 
macrophages and peripheral neutrophils from patients with COPD (115, 220). The 
increased production of ROS may be due to the mitochondrial ROS overproduction 
and altered xanthine oxidase activity. Increased mitochondrial ROS was reported in 
airway smooth muscle cells from patients with COPD (273), and products of xanthine 
oxidase activity were detected in bronchoalveolar fluid (BALF) from patients with 
COPD (202). Although the increased ROS may be mainly in the form of less potent 
radicals such as superoxide anion and hydrogen peroxide, they can be converted to 
more potent and destructive ROS such as peroxynitrite (ONOO
-
) by rapid reaction 
between superoxide radical and NO (261), and hypohalous acids (HOCl and HOBr) 
by MPO-catalyzed reactions between hydrogen peroxide and Cl
- 
or Br
- 
(224). MPO 
levels in neutrophils are reported to be elevated in patients with COPD (1). 
ROS generation is balanced by the activity of anti-oxidant defense in the normal 
body. The first anti-oxidant barrier against the noxious particles or gases is the 
epithelial lining fluid containing anti-oxidants such as vitamin C, vitamin E and uric 
acid (134). Reduced levels of vitamin C and vitamin E in the lung were associated 
with declining lung function in patient with COPD (134). Regarding cellular 
anti-oxidant activity, one of the most important reactions is the synthesis of 
glutathione (GSH), an anti-oxidant that depletes oxidants via conversion to oxidized 
glutathione (GSSG). Under acute oxidative stress, epithelial cells from healthy 
subjects presented elevated level of glutamate-cysteine ligase which is an enzyme 
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involved in GSH synthesis (228). Such anti-oxidant defense was impaired in 
bronchial epithelial cells and alveolar macrophages from patients with COPD, as 
indicated by lower expression of glutamate-cysteine ligase (228). Another 
anti-oxidant defense system is mediated through superoxide dismutase (SOD) which 
converts superoxide radicals into hydrogen peroxide (167). Hydrogen peroxide can be 
further converted to oxygen and water directly by catalase (53) or by reaction with 
GSH mediated by glutathione peroxidase (GPx) (232). As mentioned earlier, under 
excess ROS production, superoxide anions can react rapidly with NO to form 
peroxynitrite. Peroxynitrite can inhibit SOD, thus reducing the anti-oxidant defensive 
activity (261). The persistent high ROS burden and defective anti-oxidant defense 
lead to oxidative stress of the cells. 
 
1.1.4.2. Chronic airway inflammation 
Chronic and persistent airway inflammation is observed in patients with COPD, 
and higher grades of COPD severity is associated with higher severities of 
inflammation (108). Infiltrated inflammatory cells include neutrophils, macrophages, 
B-cells, lymphoid aggregates and T cells (107). In addition to the increased numbers 
in the lung, the function of inflammatory cells may also change in line with the 
pathogenesis of COPD (109).  
The number of macrophages increases in bronchial submucosa along with the 
severity of airflow limitation in patients with COPD (108). Macrophages can 
contribute to oxidative stress, destruction of structural cells and further progression of 
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inflammatory responses by releasing ROS, extracellular matrix proteins, leukotrienes, 
multiple cytokines, chemokines and matrix metalloproteinases (MMPs) (57). One 
primary function of macrophages in normal lungs is bacterial clearance through 
phagocytosis, which may be defective in patients with COPD (72). Ex vivo studies 
have demonstrated a defective phagocytositic ability against bacteria commonly 
detected in airways in both alveolar macrophages (29) and monocyte-derived 
macrophages (250) from patients with COPD. Moreover, the secretion of 
inflammatory mediators is elevated in alveolar macrophages from smokers and 
ex-smokers (101). 
Increased number of neutrophils in sputum has been reported to associate with 
higher severity of airflow obstruction and faster decline of lung function in patients 
with severe COPD (187). Neutrophils are distributed in various sites particularly in 
bronchial epithelium, bronchial glands (217) and in the airway smooth muscle (20). 
When recruited to the airways, neutrophils become activated and release ROS, 
inflammatory cytokines, neutrophil elastase, MMPs and MPO (240). In vitro data 
suggest that the phagocytic ability of neutrophils can be impaired by cigarette smoke 
extract (242). 
In general, infiltrating neutrophils and macrophages are considered to be the 
major players in the innate immune response in COPD. However, increased numbers 
of eosinophils have also been reported in sputum, BALF and the airway wall (140, 
142, 156). Levels of pro-eosinophil cytokines IL-4 and IL-5 are also reported to be 
increased in plasma cells of patients with COPD (298). The exact function of 
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recruited eosinophils and its contribution to the development of COPD remains 
unclear (57).  
There is also an adaptive immune response to the inflammatory responses in 
COPD. The number of dendritic cells has been reported to increase in epithelium and 
adventitia of small airways of patients with COPD compared with never-smokers and 
healthy smokers and correlated with the severity of airflow limitation (66). Dendritic 
cells can present both self-antigens from tissue destruction and foreign antigens to 
naive T cells, and numbers of both CD4+ and CD8+ T cells have been reported to 
increase in lungs of patients with COPD (175, 213, 216). CD8+ T cells from lungs of 
patients with COPD have been shown to release higher levels of inflammatory 
mediators including tumor necrosis factor (TNF)-α, interferon-γ and granulocyte 
macrophage-colony stimulating factor (GM-CSF). 
 
1.1.4.3. Protease and anti-protease imbalance 
Parenchymal destruction is one of the most significant pathological changes in 
the lungs of patients with COPD. The resulting loss of elastic recoil leads to the 
airflow limitation. Destruction of connective tissue, particularly lung elastin, by 
excess protease activity is believed to play an important role in this process (25). 
Active neutrophils can release serine proteases including neutrophil elastase, 
cathepsin G and proteinase 3 (25). Various cysteine protease cathepsin can also be 
released by different cells, including cathepsin S from airway smooth muscle, 
cathepsin B, K and L from alveolar macrophages and cathepsin W from CD8+ T cells 
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(25). Alveolar macrophages can provide another important protease family, MMPs, 
particularly MMP-9. The alveolar macrophages from healthy smokers express more 
MMP-9 than normal subject, while alveolar macrophages from patients of COPD 
express an even higher level (154, 214). 
The protease activities are balanced by anti-proteases in normal lungs. Serine 
protease activity can be counteracted by two major serine protease inhibitors in the 
lung, α1 antitrypsin and secretory leukoprotease inhibitor (SLPI). Genetic variability 
of α1 antitrypsin that leads to a deficiency in circulating levels is a risk factor for 
COPD. Cigarette smoking may lead to oxidized and impaired α1 antitrypsin activity, 
resulting in lack of counterbalance against the activity of neutrophil elastase (46). 
SLPI activity may also be reduced by oxidative stress (25). As for the other protease 
family MMPs, their activity can be counteracted by tissue inhibitors of MMPs (TIMP). 
Alveolar macrophages from normal subjects release increased amounts of TIMPs 
after pro-inflammatory stimulation, indicating a counterbalance to the release of 
MMPs. The increased release of TIMPs is reduced in the alveolar macrophages from 
COPD patients, which may lead to excess activity of MMPs (214).  
 
1.1.4.4. Apoptosis 
In addition to the excess protease activity, the parenchymal destruction may also 
be contributed to by increased cellular apoptosis in lung (67). Apoptosis and 
proliferation are well equilibrated in healthy tissue. Increased apoptosis in endothelial 
cells, alveolar epithelial cells, interstitial cells, neutrophils and lymphocytes has been 
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reported in tissue sections of the lung from patients with COPD compared to healthy 
subjects (223). Another study demonstrated that lung tissue from patients with COPD 
exhibited increased apoptosis of alveolar epithelial cells, endothelial cells and 
mesenchymal cells in association with an increased amount of the active subunit of 
caspase-3, a central mediator of apoptosis (116). Moreover, persistent apoptosis of 
alveolar epithelial cells and T-lymphocytes in bronchial bushings and bronchoalveolar 
lavage has been observed after smoking cessation, as indicated by comparison 
between ex-smokers with COPD, current smokers with COPD and healthy 
never-smokers (103). Increased apoptosis in alveolar cells in the absence of adequate 
compensation by proliferation leads to the gradual destruction of alveolar walls in the 
lung (67). Apoptosis of alveolar wall and endothelial cells are reported to induce 
emphysema even without infiltration of inflammatory cells in an animal model (67). 
The increased apoptosis in the lung may be driven by multiple mechanisms which 
are currently not well understood. Oxidative stress-induced attenuation of vascular 
endothelial growth factor (VEGF) activity may be a mechanism of the elevated 
apoptosis in COPD. It has been reported that increased apoptosis in epithelial and 
endothelial alveolar septal cells in patients with emphysema is associated with 
reduced expression of VEGF and VEGF receptor 2, which may lead to the endothelial 
septal death (127). The level of VEGF in induced sputum from patients with COPD 
has also been reported to decrease in severe COPD, in association with increased 
levels of oxidative stress (125). In animal models, apoptosis induced by inhibition in 
VEGF receptor (128, 199, 255) or VEGF (249) leads to emphysema even without 
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obvious inflammation. The relationship between oxidative stress and apoptosis may 
also be through mitochondrial dysfunction. Mitochondria are the major source of 
cellular ROS production of cells under oxidative stress (134). Airway smooth muscle 
cells (ASMCs) from patients with COPD have demonstrated increased mitochondrial 
ROS compared to healthy subjects (273). In general, mitochondrial dysfunction can 
be a potent driving force in inducing apoptosis through the mitochondrial pathways 
(90), but more evidence is required to reveal the exact relationship between 
mitochondrial damage and apoptosis in COPD. The inflammatory characteristic of 
COPD may also contribute to apoptosis. The phagocytic ability of alveolar 
macrophages against apoptotic airway epithelial cells is impaired in patients with 
COPD (90), leading to insufficient clearance of apoptotic airway epithelial cells. The 
recruitment of CD8+ cells into the lung may also induce an increase in apoptosis of 
structural cells, by secretion of cytotoxic mediators such as perforins, granzymes and 
TNF-α (26, 158). Indeed, increased infiltration of CD8+ T cell to alveolar walls is 
associated with increased apoptosis in the lung (166). 
Cell death, including apoptosis, is constantly counterbalanced by proliferation 
under normal physiological conditions (67). However, whether the proliferative 
activity is able to counterbalance increased apoptosis remains unclear (67). Increased 
proliferative activity has been reported in the alveolar wall of patients with 
emphysema (116, 287), which may indicate a compensatory mechanism to the 
increased apoptosis. However, another report demonstrated similar proliferation of the 
alveolar septal cells between patients with emphysema and healthy subjects with 
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increased apoptosis of alveolar epithelial cells in patients with end-stage emphysema 
(44). 
 
1.1.4.5. Ageing 
Age is a risk factor for COPD. On the one hand, age is associated with longer 
exposure history to noxious gas or particles, on the other hand, the process of ageing 
may also contribute to the pathogenesis of COPD (119). Lung function starts to 
decline approximately after the age of 30 as a result of normal ageing (198), but in 
patients with COPD the decline is accelerated (79, 163). The decline in lung function 
of ageing lungs may be explained by progressive distal airspace enlargement, which 
leads to loss of lung elastic recoil (120). Although the airspace enlargement is not as 
destructive as is the case in lungs of patients with COPD (262), the similarity of the 
functional and structural changes between ageing lungs and lungs of patients with 
COPD suggests a possible relationship between them. COPD is characterized by 
persistent oxidative stress, while oxidative stress-induced DNA damage is believed to 
play an important role in cellular senescence according to the free radical theory (99). 
Senescence of cells is associated with shortening of telomere length (TL) (218). 
Indeed, it has been reported that TL of circulating lymphocytes is shortened in 
smokers in a dose-dependent manner, but the effect was not amplified in smokers with 
COPD (178). Another study demonstrated TL shortening in circulating leucocytes 
from patients with COPD compared to healthy subjects of any age range (110, 219). 
TL of alveolar epithelial cells, endothelial cells (254) and fibroblasts (180) are also 
shortened in patients with emphysema compared with non-emphysematous subjects. 
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Whereas oxidative stress may drive an accelerated ageing process, the ageing 
process itself may also contribute to oxidative stress and inflammation, which is 
evident from multiple animal studies. Acute CS exposure of mice has been reported to 
induce a five-fold increase of GSH levels in BALF in two-month old mice, indicating 
an anti-oxidant response. In mice of increasing age, these effects gradually diminished, 
in association with increased inflammatory maker TNF-α and oxidative stress marker 
8-hydroxy-2-deoxyuanosine in BALF (88). Another study suggested that older mice 
had more neutrophils, inflammatory mediator keratinocyte-derived chemokine (KC, a 
mouse homolog of IL-8) and MIP-2 in lungs after 9 days of cigarette smoke (177). 
 
1.1.4.6. Bronchial epithelial cells and airway smooth muscle cells in COPD 
Bronchial epithelial cells are the first cellular defensive barrier against noxious 
gases and particles in lung. The epithelial injury caused by CS leads to the onset of 
oxidative stress and inflammation in the lung. The direct exposure to CS induces the 
intracellular release of endogenous molecules named danger-associated molecular 
patterns (DAMP) which can be identified by pattern-recognition receptors (PRR) e.g. 
Toll-like receptor 2 and 4 (190). This process activates epithelial cells to synthesize 
and secrete early inflammatory mediators such as TNF-α, interleukin (IL)-1β and IL-8 
(65). The release of these chemokine leads to recruitment of inflammatory cells such 
as macrophages and neutrophils. Bronchial epithelial cells can also facilitate the onset 
of the adaptive immune response in COPD. Dendritic cell migration, maturation and 
activation are reported to be regulated by bronchial epithelial cells by releasing 
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various chemokines such as macrophage inflammatory protein (MIP)-3α and 
chemokine ligand 20 (CCL20) (66, 201). In addition to the initiation of the 
inflammatory responses, bronchial epithelial cells also contribute to the persistent 
inflammation in COPD by releasing multiple cytokines and chemokines including 
IL-1β, TNF-α, IL-6, IL-8 and GM-CSF. For example, epithelial cells from smokers 
with COPD express higher levels of mRNA and protein of monocyte chemotactic 
protein 1 (MCP-1) and IL-8 compared to the cells from smokers without COPD (64). 
Bronchial epithelial cells also play an important role in the anti-oxidant system in the 
lung. As mentioned in previous sections, epithelial cells from patients with COPD 
demonstrated reduced ability to elevate GSH production in response to oxidative 
stress (228). In addition, bronchial epithelial cells also serve as a source of the 
anti-protease SLPI (25). 
Patients with COPD present with an increased mass of airway smooth muscle 
(ASM) in small airways (37, 59), correlating with declining lung function (57). The 
thickened airway smooth muscle layer contributes to a thicker airway wall, which 
plays an important role in the airflow obstruction of COPD (56). Due to its contractile 
properties, ASM is the major modulator of bronchomotor tone in the airway. 
Exaggerated constriction of the airways is a feature of patients with COPD, and 
relaxation of contracted ASM by bronchodilators is a major therapeutic intervention 
in the treatment of COPD (19). The role of ASM in the pathogenesis of COPD is not 
limited to its contractile properties. Similar to epithelial cells, ASM cells (ASMCs) 
also release inflammatory cytokines and chemokines including IL-6, IL-8, MCP-1, 
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MCP-2, MCP-3, growth-related oncogene (GRO)-α, IFN-γ-inducible protein (IP)-10 
and GM-CSF (56). In addition, increased levels of transforming growth factor-β 
(TGF-β) in patients with COPD can lead to reduced expression of catalase and 
manganese-SOD in ASMCs, resulting in reduced anti-oxidant activity (174).  
Unlike bronchial epithelial cells, ASMCs are usually not directly exposed to 
noxious particles or gases, although this may happen when the epithelial barrier is 
severely damaged by CS (102, 226). Therefore, the release of inflammatory mediators 
from ASMCs is most likely not the result of a direct response to CS, but rather 
induced by the effect of cytokines released by neighboring cells, e.g. epithelial cells. 
As mentioned earlier, CS causes direct injury to bronchial epithelial cells leading to 
release of inflammatory mediators. Amongst them, IL-1β and TNF-α can induce the 
release of IL-8 from ASMCs (121), and IFN-γ and TNF-α can induce the release of 
IP-10 from ASMCs (98). Moreover, bronchial epithelial cells may also contribute to 
the increased TGF-β levels in COPD. An in vitro study demonstrated that epithelial 
cells from smokers and patients with COPD secreted higher levels of TGF-β than the 
cells from normal subjects (248). As mentioned earlier, high levels of TGF-β can 
reduce the anti-oxidant activity in ASMCs. Therefore the secretory activities of 
cytokines and a defective anti-oxidant system in ASMCs may partly result from an 
interaction with injured epithelial cells. 
 
1.1.4.7. Mitochondria and COPD 
Mitochondria are double-membrane organelles with a unique structure and 
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important function. They are composed of an outer membrane, inner membrane 
inter-membrane space and matrix (11). The inner membrane is highly folded into 
cristae, and is impermeable to ions. Respiratory chain complex proteins reside on the 
inner membrane where they mediate electron transport chain and the subsequent 
accumulation of protons in the inter-membrane space (170). The proton gradient 
between the two sides of the inner membrane leads to the flux of proton back to 
matrix through adenosine triphosphate (ATP) synthase (Complex V) and drives the 
synthesis of ATP (170). The electrochemical gradient across the inner membrane is 
indicated by the mitochondrial membrane potential (ΔΨm) (170). The electron 
leakage from oxidative phosphorylation is believed to be a major source of ROS 
production in cells. It has been estimated that 0.2-2.0% of oxygen consumption by 
mitochondria results in formation of superoxide radicals (149, 165). Leakage of 
electrons from the electron transport chain takes place at Complex I towards the 
matrix and at Complex III towards both sides of the inner membrane (97, 149, 165). 
Leaked electron leads to partial reduction of oxygen. The resulting superoxide 
radicals can act as precursors for many other more active ROS, or they can be 
converted to hydrogen peroxide by SOD1 (superoxide dismutase 1) in the matrix or 
SOD2 (superoxide dismutase 2) in the inter-membrane space (97, 149, 165). 
Superoxide is believed to be short-lived while hydrogen peroxide is more stable and 
permeable to other part of mitochondria and cells (149, 170). The level of hydrogen 
peroxide has been estimated to be 100-fold higher than the level of superoxide 
radicals in mitochondria (43). In general, mitochondria are not rich in catalase, and 
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the reduction of hydrogen peroxide relies on the reaction with GSH catalyzed by 
glutathione peroxidase (149) (Figure 1.5). As the major source of ROS, mitochondria 
are also a target of ROS-mediated damage. Excess mitochondrial ROS may induce 
damage and mutations of mitochondrial DNA (170, 281). ROS may also induce 
carbonylation and dysfunction of various mitochondrial proteins, including the 
complex proteins leading to defective mitochondrial respiration, and the 
mitochondrial carrier proteins regulating molecular transport across the membrane, 
and the protein assembly of permeability transition (PT) pore which may trigger 
signals of apoptosis (170).  
ΔΨm indicates the electrochemical gradient across the inner membrane, which 
results from the activity of the election transport chain (170). As ROS is a byproduct 
of the electron transport chain, under the normal conditions where there is an 
ROS/anti-oxidant equilibrium, ΔΨm and ROS should be positively correlated. While 
this is supported by several studies (149, 165, 188), under conditions of cellular 
damage ΔΨm reduction is associated with increased ROS (9, 273). Reduction of ΔΨm 
may be a result of impaired proton transfer due to an interrupted electron transport 
chain, or be caused by opening of PT pores resulting in increased permeability. 
Mitochondria are highly dynamic organelles under constant cycles of fission and 
fusion (183). Fission refers to the splitting of mitochondria leading to short and less 
branched morphology while fusion is the merging of mitochondria leading to an 
elongated and a more branched network (149). These morphological dynamics are 
very important for normal function of the mitochondrial network in a cell. 
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Interruption of either the fusion or fission process causes dysfunction of mitochondria 
(183). This might be because the exchange of mitochondrial DNA in matrix during 
the fission and fusion can alleviate the effect of mutation (183).  
In addition to their role in energy supply and redox regulation in the cells, 
mitochondria play a central role in the regulation of apoptosis, senescence and 
autophagy (5, 11, 149, 170). Excess ROS may induce mitochondrial PT pores into a 
high-conductance state, leading to rising permeability for small molecules (83). This 
event is reflected by loss of ΔΨm. As the inner membrane is highly folded, the fluid 
influx lead to swelling of the inner membrane, resulting in further opening of 
mitochondrial PT pores and sometimes rupture of outer membrane (123). During this 
process cytochrome c is released from mitochondria, which triggers activation of 
caspase-9 and leads to apoptosis (90). In addition to the effects on PT pores, oxidative 
stress can also lead to peroxidation of cardiolipin, a lipid that immobilizes cytochrome 
c in the inner membrane, which further promotes the release of cytochrome c from 
mitochondria (124, 193).  
There is an increasing focus on the involvement of mitochondria in the 
pathogenesis of COPD (11). Most direct evidence has come from primary cells from 
the patients with COPD. It has been demonstrated that primary bronchial epithelial 
cells from ex-smokers with severe COPD exhibited swelling and fragmented 
mitochondrial morphology which is similar to that seen in CS medium (CSM)-treated 
immortalized bronchial epithelial cells (BEAS2-B) (105). Another study on ASMCs 
has been reported by Wiegman and colleagues with a more comprehensive evaluation 
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of mitochondrial function (273). In this study ASMCs from patients with COPD 
demonstrated elevated mitochondrial ROS levels, reduced ΔΨm, reduced amount of 
Complex I, III and V compared to healthy controls. Moreover, mitochondrial 
respiration was impaired in ASMCs with COPD as indicated by reduced basal and 
maximum respiration levels, and respiratory reserve capacity. Healthy smokers also 
demonstrated mitochondrial dysfunction compared to healthy controls, but the effects 
are less pronounced compared to patients with COPD. Several other studies also 
suggested mitochondria of respiratory striated muscle and skeletal muscles are 
damaged in patients with COPD (5). 
Mitochondrial damage is also observed in other COPD-related animal models or 
CSM-treated in vitro models. It has been reported that CS exposure can impair energy 
metabolism in mouse lung by switching glucose metabolism to the pentose phosphate 
pathway and reducing the substrate supply to mitochondria (4). In a chronic 
ozone-induced mouse model of COPD, elevation of mitochondrial ROS and reduction 
of ΔΨm is observed, which can be alleviated by the mitochondria-targeted 
anti-oxidant MitoQ (273). The alleviation of ozone-induced mitochondrial ROS leads 
to attenuation of ozone-induced airway hyper-responsiveness (AHR) and 
inflammation, indicating a potential strategy to target mitochondrial ROS for the 
treatment of COPD. Another study has demonstrated that wood smoke exposure to 
guinea pigs can induce impaired oxygen consumption activity and complex protein 
enzyme activity (89). CSM was also reported to alter the fission-fusion activity of 
mitochondria in vitro in both airway epithelial cells (105) and ASMCs (10), leading to 
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mitochondrial fragmentation and increased mitochondrial ROS. 
 
 
 
Figure 1. 5 Generation of mitochondrial ROS from electron transport chain. 
Leakage of electron from electron transport chain leads to generation of superoxide 
radicals, which can be converted to hydrogen peroxide by SOD. I-V: complex 
proteins; Q: coenzyme Q; Cyto c: cytochrome c; SOD: Superoxide dismutase, GPx: 
Glutathione peroxidase. The figure is plotted based on Li X et al, J Hematol Oncol 
(149). 
 
 
1.1.5. Current therapies 
  For patients with COPD who are current smokers, smoking cessation is the most 
effective approach that can influence the natural history of COPD. Smoking cessation 
can be facilitated by nicotine replacement therapies such as nicotine gum, inhaler, 
nasal spray, transdermal patch, sublingual tablet and lozenge, as well as supportive 
pharmacotherapy including varenicline, bupropion and nortriptyline (263). 
 Pharmacologic therapies for COPD include bronchodilators, corticosteroid and 
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phosphodiesterase-4 inhibitors (263). The choice of each medications or the 
combination of them is patient specific. Bronchodilators refer to the medications that 
induce the dilation of bronchi and bronchioles leading to increase in FEV1 (263). 
There are three classes of bronchodilators, β2-adrenorecepter agonist, anticholinergics 
and methylxanthine (82). The β2-adrenoreceptor agonists are further classified as 
short-acting β2 agonist (SABA) and long-acting β2-agonist (LABA), both working 
through induction of cellular cyclic adenosine monophosphate (cAMP). 
Bronchodilators are usually administrated through inhalation, and they are the central 
medication to manage the symptoms of COPD. Combination of different classes of 
bronchodilators may improve efficacy and reduce the side effects compared to a 
single class. Corticosteroid treatment is mainly adopted for the severe conditions. Oral 
corticosteroids aim to suppress the chronic inflammation, but they are generally 
associated with high risks of adverse effects (263). Inhaled corticosteroids in 
combination with bronchodilator may improve efficacy compared to single treatment, 
but the long-term safety and adverse effects of inhaled corticosteroids is largely 
unknown (263). Phosphodiesterase-4 inhibitors are a relatively new medication for 
COPD. They are able to reduce inflammation by inhibiting cAMP breakdown, and 
should be used with long-acting bronchodilators (263).  
 COPD is a complex, chronic disease resulting from long term interaction between 
genes and environmental stimuli (65). The pathogenesis of the disease is far from 
understood and the development of effective pharmacologic therapy has not been easy, 
especially for the control of chronic inflammation which is corticosteroid-resistant in 
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COPD (24). To date, the pharmacologic therapy is able to reduce COPD symptoms, 
exacerbations, and improve health status and exercise tolerance (263). However, none 
of current treatments is able to alleviate the progressive decline of lung function in 
COPD (263).  
 
1.2. Introduction to Stem Cells 
1.2.1. Definition and classification 
 Stem cells are cells that are able to self-renew and differentiate into other cell 
types (251). In contrast, somatic cells are usually able to self-renew but cannot 
differentiate, while progenitor cells are able to differentiate into somatic cells, but 
with poor ability of long-term self-renewal (251). Stem cells and progenitor cells act 
as sources of new somatic cells as a normal turnover or as a replenishment to 
increased somatic cell death after injury (251). 
 Stem cells can be classified as totipotent, pluripotent and multipotent according to 
their potency that is their capacity to differentiate (2, 251). Totipotent stem cells have 
the highest differentiation potential with capacity to develop into new individuals 
from a single cell. Although not able to form new individuals, pluripotent stem cells 
are capable of differentiating into cell types of all three germ layers (ectoderm, 
mesoderm and endoderm), which basically means they can generate almost any cell 
types except for extra-embryonic tissues such as trophectoderm (2, 251). Multipotent 
stem cells can form limited cell types, usually of one single lineage (2, 251). In 
general, the potency of stem cells gradually decreases along the development process 
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(2, 251). Totipotent stem cells only exist as zygotes and cells from very early embryos, 
while stem cells derived from blastocyst named embryonic stem cells (ESCs) 
represent the major form of pluripotent stem cells (2, 251). Stem cells in the adult 
body, or adult stem cells, are multipotent stem cells (2, 251). They are usually 
distributed in specific microenvironments called niches of the parent tissues and 
generate somatic cells of the same origin (2, 251). The progenitor cells have similar 
differentiation features as the adult stem cells. They also reside at niches of tissues 
and differentiate into specific cell types (85). 
 Utilising stem cells therapeutically is not a recent idea. Haematopoietic stem cells 
(HSC) have been used in bone marrow transplantation for treatment of leukaemia for 
more than 40 years (41). Other cells that have been tested in clinical trials include 
mesenchymal stem cells (MSC) and muscle satellite stem cells (251, 269). When it 
comes to stem cell-based therapy, the stem cells can be alternatively classified as 
endogenous stem cells which are the adult stem cells in their niches in the body, and 
exogenous stem cells which are the isolated and expanded adult stem cells ex vivo 
(251). 
 
1.2.2. Endogenous stem cells in lung 
The delineation of endogenous stem cells in individual organs is not an easy task. 
The most convincing approach is to examine the capacity of the cells to reconstitute 
the entire organ. For example, HSCs can rebuild the entire haematopoietic system 
after transplantation into irradiated animals (251). However the approach requires 
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destruction of organs which is rather difficult in most cases. An alternative approach 
is to genetically trace the lineage of cells in the organs, which can provide evidence of 
the differentiation of specific cell types into other cells. Intestinal stem cells (260) and 
skin stem cells (34) were identified through this approach. 
The lung is a complex organ with a very low turnover rate during normal 
homeostasis compared with intestine or skin tissues (106). The regenerative capacity 
of human lung is mostly demonstrated upon injury, such as pneumonia and severe 
respiratory infections (28, 42, 131, 138). Whether there is a defective regenerative 
function of endogenous lung stem cells in airway diseases is still unclear (268). In fact, 
the identity and roles of stem cells and progenitor cells in the lung remains unresolved 
due to the lack of markers for each cell type and lineage tracing approaches (268). 
Various putative airway and alveolar epithelial stem and progenitor cells are identified 
by mounting data from animal and human studies, including airway submucosal 
glands, keratin-14 expressing tracheal basal cells, Clara cells in association with 
neuroendocrine bodies or bronchoalveolar duct junction, and type 2 alveolar epithelial 
cells (AEC2s) (85). However, there is also controversial data from other studies and 
there is not yet uniform agreement on the identity of lung stem cells (268). 
 As COPD is associated with progressive destruction of the alveolar structure, the 
identification of stem cells in alveoli, and further investigation of their role in COPD, 
may provide valuable information on the disease. Alveoli are mainly composed of 
type 1 alveolar epithelial cells (AEC1s) and AEC2s. AEC2s which express high levels 
of surfactant protein C (SFTPC) can function as local stem cells (21). Lineage tracing 
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in mice are demonstrated that AEC2s can differentiate into AEC1s during homeostasis, 
and bleomycin-induced injury promoted such activity (21). The self-renewal ability of 
SFTPC+ AEC2s was also observed for at least one year. Moreover, when co-cultured 
with a mesenchymal population, the SFTPC+ AEC2s can differentiate into alveolar 
structures consisting both AEC2s and cells with AEC1 markers (21). In combination 
with the self-renewal property in vitro, these findings demonstrated the capacity of 
AEC2s for self-renewal and differentiation into other cells both in vivo and in vitro. 
 
1.2.3. Mesenchymal stem cells (MSCs) 
Mesenchymal stem cells (MSCs) are multipotent stem cells from stromal origin 
(269). Originally described as a fibroblastic-like population of bone marrow (BM) 
cells, MSCs now refer to similar cells found in a variety of tissues, including BM, 
adipose tissue, cord blood and placenta (269). MSCs can differentiate into 
chondrocyte, adipocyte, osteoblast or other lineages such as epithelial and endothelial 
cells (269). The general criteria to define MSCs include the cell marker profile, 
self-renewal property and the capacity of differentiating into osteoblasts, adipocytes 
and chondrocytes (251). Although MSCs isolated from different tissue share common 
features regarding these parameters, different gene expression, lineage tendencies and 
other properties have been demonstrated amongst them (15, 132). Moreover, 
individual MSC types may still present a heterogeneous group of cells of different 
subtypes (200). The functional and therapeutic differences between MSCs from 
different sources have been increasingly investigated (269). 
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Cells with features of MSCs have been isolated from adult mouse lungs, human 
nasal mucosa, and lungs of human neonates and lung transplant recipients (269). The 
functions of these cells in the lung remain unclear. They have been reported to play a 
potential role in fibrotic diseases and in the bronchiolitis obliterans following lung 
transplantation (14, 61, 210, 264).  
MSCs express very low levels of major histocompatibility complex (MHC) class 
I and class II molecules, which makes them highly immunologically-tolerant (80, 132, 
144, 269). Exogenous administration of allogeneic MSCs usually lead to low levels of 
immune rejections and does not require immunosuppression (251). MSCs are 
commonly used to develop exogenous stem cell-based therapy for lung diseases. 
There are numerous studies on this topic, which will be introduced in the later 
sections. 
 
1.2.4. Induced-pluripotent stem cells (iPSCs) 
As described earlier, in nature, cells demonstrate a unidirectional reduction in 
differentiation potency with development. Therefore, the access to pluripotent stem 
cells had relied on the isolation of ESCs until the discovery of induced-pluripotent 
stem cells (iPSCs) (247). iPSCs are pluripotent stem cells derived from somatic cells 
through transcriptional factor-induced reprogramming in vitro (e.g. through induction 
by Oct4, Sox2, Nanog and Lin28). Deriving iPSCs from somatic cells was first 
achieved by Takahashi and Yamanaka using mouse fibroblasts in 2006 (247). Human 
iPSCs were later generated also from fibroblasts in 2007 (246, 289). In theory, this 
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robust approach can generate iPSCs from any somatic cell type. 
Compared to the isolation of adult stem cells from the relevant tissue, the 
reprogramming of somatic cells is less restricted to the type of somatic tissue. 
Moreover, the high proliferation capacity of iPSCs reduces the amount of somatic 
tissue required. Therefore, iPSC provides an abundant supply of stem cells from each 
particular individual. However, the therapeutic application of iPSCs is limited by 
pluripotency. They are so potent that direct administration of iPSCs may lead to 
formation of teratomas (122).  
Although iPSCs may not be a very good candidate as a direct therapy for airway 
disease, they can serve as a great source to generate other cell types that may be 
effective in airway diseases. Indeed, the derivation of lung progenitor cells or 
epithelial cells from iPSCs has been reported by several studies (91, 111, 179, 278, 
279). AEC2 is the most common and prominent cell type derived from iPSCs, while 
AEC1 can also be generated. The iPSC-derived epithelial cells can be used in ex vivo 
tissue engineering of lung, providing cellular source to re-populate decellularized 
whole lung scaffolds (86, 159). However, information of their effects as direct source 
of cell-based therapy for airway disease is still lacking.  
 
1.2.5. iPSC-derived MSCs 
Given the numerous studies on the therapeutic potential of MSCs in airway 
disease models, deriving MSCs from iPSCs provides a promising strategy. This task 
was achieved by Lian and colleagues in 2010 (153) (Figure 1.6). The derivation was 
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through incubation of iPSCs in pro-MSC induction medium (detailed methodology 
can be found in Chapter 2). MSC-like cells were identified as CD24- and CD105+ 
cells. The resulting cell culture exhibited fibroblast-like morphology which is typical 
of MSCs. To acquire homogenous populations, single-cell derived colonies were 
generated from these cells. In addition to the fibroblast-like morphology, the derived 
cells demonstrated other features of MSC. Firstly, they presented an MSC-like surface 
marker profile (CD44+, CD49a+ CD49e+, CD73+, CD105+, CD166+, CD34−, 
CD45−, and CD133−). Secondly, the differentiation capacity was demonstrated by 
efficient adipogenesis, osteogenesis and chondrogenesis. Lastly, they were able to 
self-renew without loss of differentiation potential. In fact, they were far more 
expandable than BM-MSCs, with an ability to keep their differentiation capacity up to 
passage 40. As they fulfil all criteria of MSCs, these cells were named iPSC-derived 
MSCs (iPSC-MSCs). Compared to iPSCs, iPSC-MSCs demonstrated reduced 
expression of pluripotency-associated genes such as Oct4, Nanog and Sox2. When 
subcutaneously injected into combined immunodeficient (SCID) mice, iPSC induced 
teratoma while no teratoma was induced by iPSC-MSCs for up to four months. 
The in vitro generation of iPSC-MSCs from iPSCs brings potential opportunities 
to overcome several limitations of the adult MSCs as seen in BM-MSCs. The amount 
of BM-MSCs available from BM is limited which makes ex vivo expansion important 
(269). However, BM-MSCs become senescent after 20 doublings during ex vivo 
expansion with loss of differentiation potential (69). Their genetically stability in vitro 
also draws concerns as they may develop abnormal karyotypes during expansion 
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(148). The limited in vitro expansion capacity restricted the resource for cell therapy. 
In addition, one of the future directions of MSCs-based therapy is to genetically 
manipulate the cells. As MSCs can be recruited to injured tissue, by this approach 
they can express and release desired molecules at the site of the injured tissue (63, 
122). Such genetic manipulation also calls for high stability and expanding capacity 
of the MSCs. In contrast to BM-MSCs, iPSC-MSCs demonstrated normal karyotypes 
during expansion (153). They can be expanded for 120 doublings with stable surface 
marker profile for MSCs (153). Another limitation of BM-MSCs is that when isolated 
from aged subject or patients with ageing-related disorders, they may present reduced 
survival and differentiation ability (87, 100, 267, 294). In theory, as the safety of 
allogeneic MSCs has been well demonstrated, this issue can be avoided by selection 
of the donor. Nevertheless, availability of personalized MSCs is appealing for future 
development of MSCs-based therapy. iPSC-MSCs may hold hope as a way of  
overcoming the ageing-associated impairment of BM-MSCs. When generating 
iPSC-MSCs, somatic cells were firstly reprogrammed to an embryonic stem cell-like 
state, which may help to avoid the problem of senescence. According to the same 
study by Lian and Zhang et al., the telomerase activity of iPSC-MSCs was 10 times 
higher compared to BM-MSCs (153). 
As a relatively new type of MSCs, beneficial effects of iPSC-MSCs have already 
been demonstrated in rodent models of limb ischemia (153), allergic airway 
inflammation (244) and cardiomyopathy (293). 
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1.3. MSCs-based Therapy 
1.3.1. Efficacy of MSCs in animal models 
MSCs are the most studied candidates for the development of cell-based therapy 
against lung diseases. Efficacy of MSCs was demonstrated in a broad spectrum of 
animal models including acute lung injury and bacterial lung infection, COPD, 
asthma, bronchiolitis obliterans, bronchopulmoary dysplasia, fibrosing pulmonary 
injury, pulmonary hypertension, pulmonary ischemia re-perfusion injury, obstructive 
sleep apnea, radiation-induced lung injury, sepsis and burns (269). The studies of 
MSCs in COPD-related models are listed in Table 1.2. In general, these models can 
Figure 1. 6 Change of potency: from somatic cells to iPSC-MSCs. Inducing 
iPSCs from somatic cells provides great resource of stem cells. However, iPSCs are 
too potent for some applications, and differentiation of them into multipotent stem 
cells can generate cell types that may be more useful as treatment of diseases.  
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exhibit histological changes (primarily airspace enlargement) in the lung mimicking 
the lungs of patients with COPD, which are alleviated by MSCs from various sources 
including BM, adipose tissue, lung and amniotic fluid. The major approaches for 
inducing emphysema in animals are by administration of elastase and by chronic 
exposure to CS. Elastase can cause excess protease activity rapidly leading to direct 
destruction of alveolar structures, while CS exposure can induce inflammation very 
quickly but with the airspace enlargement developing much later (usually months 
after exposure). However, as cigarette smoking is the major risk factor of COPD, the 
CS-exposed model may be more relevant to the pathogenesis of COPD. CS-exposed 
animals have been demonstrated to develop inflammation, oxidative stress and excess 
protease activity both in lung and systemically (51, 52). The capacity of alleviating 
CS-induced inflammation is demonstrated in MSCs from BM (94, 112), amniotic 
fluid (151) and adipose tissue (222). Moreover, the MSCs from BM and adipose 
tissue also inhibited CS-induced apoptosis in the lung.
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Table 1.2 Studies of MSCs treatment in COPD-related animal models. 
 
Studies 
Experimental Model 
Route, and Timing of Treatment 
Source of MSCs Outcome Compared to Injury Effects 
Potential 
Mechanisms 
Shigemura 
2006(230) 
Rat: elastase. 
Direct topical application of ASC- 
seeded polyglycolic acid at lung 
volume reduction surgery. 
Rat adipose 
Plastic adherent 
• Improved histological repair HGF secretion 
Shigemura 
2006 (229) 
Rat: elastase. 
i.v. ASCs 1 week after elastase. 
Rat adipose 
Plastic adherent 
• Decreased apoptosis, improved 
histological repair  
• Improved gas exchange and exercise 
tolerance 
HGF secretion 
Yuhgetsu 
2006 (290) 
Rabbit: elastase.  
i.t. MSCs 24 hours after elastase. 
Rat BM - mononuclear 
cells from Ficoll gradient of 
total BM 
• Improved histology and lung function 
• Decreased BALF inflammation 
• Decreased tissue MMP2 and MMP9 
expression 
None specified 
(soluble mediators) 
Zhen 
2008 (295) 
Rat: papain. 
i.v. MSCs after papain (timing not 
specified). 
Rat BM 
Plasticadherentmononucelar 
cells from Percoll gradient 
• Decreased histological injury  
• Decreased alveolar cell apoptosis 
None specified 
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Zhen 
2010 (296) 
Rat: papain. 
i.v. MSCs 2 hours after papain 
Rat BM 
Plastic adherent 
mononucelar cells from 
Percoll gradient 
• Decreased histological injury  
• Partial restoration of VEGF 
expression in lung homogenates 
TNF-α–stimulated 
VEGF secretion by 
MSCs 
Katsha 
2011 (130) 
Mouse: i.t. elastase.  
i.t. MSCs 14 day after elastase. 
Mouse BM 
Plastic Adherent 
• Decreased histological injury  
• Decreased IL-1β  
• Transient increase in lung EGF, HGF, 
and SLPI 
None clarified 
(soluble mediators) 
Huh 
2011 (112) 
Rat: CS exposure for 6 months. 
Retrobulbar MSCs at the beginning 
of smoke cessation. 
Rat BM 
• Decreased histological injury  
• Increased numbers of small vessels 
and reduced RVSP 
• Increased proliferation of AEC2 cells 
and endothelial cells 
• Decreased apoptosis 
Soluble mediators 
Akt signaling 
suspected 
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Schweitzer 
2011 (222) 
Mouse: CS exposure for 4 months. 
i.v. ASCs every other week for 3rd 
and 4th months of CS exposure. 
Human or mouse adipose 
plastic adherent 
• Decreased histological injury and 
apoptosis (caspase activation) 
• Decreased BALF inflammation  
• Decreased CS-induced MAPK signal 
transduction  
• Decreased weight loss  
• Decreased BM suppression 
None specified 
Immunodeficient NOD-SCID 
mouse: VEGFR blockage induced 
emphysema. 
Human ASCs 3 days after VEGFR 
blockade 
Human adipose plastic 
adherent 
• Human ASCs decreased histological 
injury and caspase 3 activation 
following VEGFR blockade  
• Emboli if used > 5 × 105 MSCs or if > 
passage 3 
None specified 
Hoffman 
2011 (104) 
Mouse: i.t. elastase 
i.v. MSCs 6-7 weeks after elastase 
Mouse BM 
Lung-MSCs from primary 
explants cultures 
• Higher retention of lung MSCs 
• Decreased histological injury 
None specified 
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Ingenito 
2012 (117) 
Sheep: i.t. elastase (5 
doses/20weeks) 
Endoscopically transplanted in 
biological delivering scaffold 
Sheep lung 
• Increased lung tissue mass and 
perfusion 
• Increased histological cellularity, cell 
retention and extracellular matrix 
• Improved lung mechanics 
Paracrine effects. 
Increased epithelial 
proliferation in in 
vitro co-culture. 
Guan 
2013 (94) 
Rat: CS exposure for 11 weeks, 
sacrificed after 4 weeks cessation. 
i.t. MSCs on the first day of week 
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Rat BM 
• Decreased histological injury 
• Increased lung function 
• Decreased lung apoptosis 
• Decreased TNF-α, IL-1β, MCP-1, 
IL-6, MMP9 and MMP12 in lung 
• Increased VEGF, VEGF receptor-2 
and TGFβ-1 in lung 
Non specified 
Song 
2014 (237) 
Rats: CS exposure for 7 weeks, 
sacrificed after 4 weeks cessation. 
i.t. MSCs at week 8 
Rat BM 
• Increased histological injury 
• Increased lung function 
• Decreased inflammatory cells in BAL 
• Decreased levels of IL-1β, IL-6, 
TNF-α, MDA and increased TGFβ-1 in 
lung 
Non specified 
Tibboel 
2014 (252) 
Mouse: i.t. elastase 
i.t. or i.v. MSCs before or after 
elastase 
Mouse BM 
• Increased lung function only by i.v. 
injection prior elastase 
• No significant histological difference 
Non specified 
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Li X 
2014 (150) 
Rat: CS exposure for 56 days 
i.v. MSCs at day 29 and 43 
Human iPSC-MSCs • Decreased histological injury 
Mitochondrial 
transfer 
Li Y 
2014 (151) 
Rat: CS exposure for 12 weeks 
plus i.t. LPS at week 4 and 8. 
i.t. MSCs after CS exposureperiod 
Rat amniotic fluid 
• Decreased histological injury 
• Increased surfactant protein A and C 
• Decreased AEC2 apoptosis 
Differentiation into 
AEC2-like cells 
Anti-apoptotic 
mechanism 
unknown 
Gu 
2015 (93) 
Rat: CS exposure for 12 weeks 
sacrificed after 4 weeks cessation. 
i.t. MSCs started at week 7, 
twice/week for 5 weeks 
Rat BM 
• Decreased histological injury 
• Decreased inflammation 
• Decreased PGE-2 and IL-6 and 
increased IL-10 in BALF and serum 
• Decreased COX-2 and PGE2 in lung 
Inhibition of 
COX-2/PGE2 in 
alveolar 
macrophages by p38 
MAPK pathways 
 
Abbreviations: AEC2: Type 2 Alveolar epithelial cell; ASC: adipose stem cell; BALF: bronchoalveolar lavage fluid; BM: bone marrow; 
COX-2: cyclooxygenase-2; CS: cigarette smoke; EGF: epidermal growth factor; HGF: hepatocyte growth factor; IL: interleukin; iPSC-MCS: 
induced pluripotent stem cell-derived mesenchymal stem cells; i.t.: intratracheal; i.v.: intravenous; MAPK: mitogen-activated protein kinase; 
MCP-1: monocyte chemoattractant protein-1; MDA: malondialdehyde; MMP: matrix metalloproteinases; PGE2: prostaglandin E2; RVSP: 
right ventricle systolic pressure; SLPI: secretory leukoprotease inhibitor; TGF-β: transforming growth factor-β; TNF-α: tumor necrosis factor; 
VEGF(R): vascular endothelial growth factor (receptor). 
 
The list before (including) 2012 is adapted from two reviews by Weiss et al (269, 270); studies after 2012 are described from corresponding 
references. 
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1.3.2. Clinical trials 
The safety and efficacy of MSCs have been tested in acute myocardial infarction 
and several inflammatory and autoimmune diseases such as graft-versus-host disease 
(GVHD), autoimmune diabetes and Crohn‟s disease (269). The first licensed 
MSCs-based therapy has been approved in Canada, as a medication for GVHD (8, 
269). The intensive clinical study in these fields showed an important fact that MSCs 
may be well tolerated even by patients with very severe illness (8, 269). 
The mounting evidence supporting the efficacy of MSC in COPD-related animal 
models led to the initiation of the first multicenter, double-blind, placebo-controlled 
phase II clinical trial of a systemic-administrated BM-MSC preparation 
(PROCHYMAL, Osiris Therapeutic Inc, Columbia, MD, USA) for moderate or 
severe COPD (271). 62 patients participated in the clinical trial, during which they 
received 4 monthly infusions of BM-MSCs (100x10
6 
cells/infusion) or vehicle 
controls and were monitored in a subsequent 2-year period. End points included 
comprehensive safety evaluation, pulmonary function testing (PFT), and 
quality-of-life indicators including questionnaires, 6-minute walk test, and 
assessments of systemic inflammation. The trial proved the safety of BM-MSCs in 
patients with moderate or severe COPD. No pulmonary emboli formation or other 
infusional toxicity was observed for every single infusion among all the 4 infusions of 
all patients. No mortality or serious adverse effects were observed in the two-year 
follow-up. However, the administration of BM-MSCs did not improve the lung 
function of the patients compared to the placebo, as well as the quality of life 
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indicators such as 6-minute-walk evaluation and quality of life questionnaire. The 
only effect observed was on the systemic C-reactive protein (CRP) levels, which may 
indicate a modulation of systemic inflammation. Among the patients with high 
systemic CRP levels (above 4 mg/L) at the start of the trial, infusion of BM-MSCs 
significantly reduced the systemic CRP levels within the first month and the trend 
persisted for 2 years although the statistical significance was lost over time.  
A multicentre, open-label, dose-escalation, phase I clinical trial on treatment with 
BM-MSCs in moderate to severe acute respiratory distress syndrome (ARDS) in USA 
has been reported recently (276). Nine patients were included, and three dosages were 
tested (10
6
, 5x10
6
, 10x10
6 
cells/kg predicted body weight). The findings demonstrated 
safety of the single infusion into patients with ARDS, with no adverse effects or 
mortality attributable to the infusion. The trial has entered a phase II stage for 
examination of efficacy. Another placebo-controlled study demonstrated safety of 
adipose-derived MSCs infused in patients with ARDS (297). However, no significant 
efficacy was observed in this study. 
To date two non-randomized phase I clinical trials in patients with idiopathic 
pulmonary fibrosis have been performed. In the first placenta-derived MSCs were 
administrated intravenously (50) and in the second endobronchial infused adipose 
derived stromal cells-stromal vascular fraction were used (256). Both these phase I 
trials demonstrated good safety profile of MSCs in patients with idiopathic pulmonary 
fibrosis.  
Although the efficacy of MSCs in lung diseases has not been demonstrated in any 
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studies to date, the above studies proved strong evidence of the safety of MSCs 
infusions. There are many variables regarding the potential functions of MSCs, 
including dosage, preparation, and tissue source, and more investigation is required to 
define its clinical role. The lack of efficacy in the clinical trial in contrast with the 
numerous reports on the efficacy in animal models also calls for better pre-clinical 
models and more information about the mechanisms of action of MSCs. 
 
1.3.3. Mechanisms 
1.3.3.1. Engraftment and regeneration 
While intratracheal administration definitely leads to the delivery of MSCs to the 
lung, systemic-administrated MSCs have also been reported to localize in the lung 
vascular bed initially, and the number of localized cells can be enhanced by lung 
injury (269). The retention ability of systemic-administrated MSCs in lung varies in 
different studies. The effects of the MSC properties such as size, expression of 
specific integrins and proteoglycan patterns on the retention ability remain unclear. 
MSCs from different sources present different retention capacities. For example, 
MSCs from umbilical cord blood have been reported to be more easily cleared by the 
lung compared to BM-MSCs (185). In CS-exposed models, adipose stem cells have 
been reported to retain in lung tissue after 7 days or 21 days (222), while another 
study only detected 2-13 male BM cells per entire lung from 1 day to 1 month by 
fluorescent in situ hybridization (FISH) (112). Higher retention rate of iPSC-MSCs in 
the lung compared to BM-MSCs has also been reported 14 days after administration 
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(150).  
The capacity of BM-MSCs and adipose-MSCs to differentiate into cells 
expressing markers of alveolar or epithelial cells has been demonstrated in vitro (162, 
171, 243, 282), which represents an early motivation for research on MSCs-based 
therapy: to let the MSCs differentiate into progenitor or somatic cell types, replenish 
the damaged cells and thus regenerate the injured tissue. Indeed, early reports 
provided evidence of structural-engrafted HSCs, MSCs or endothelial progenitor cells 
differentiating into airway and alveolar cells or pulmonary vascular or interstitial cells 
(129, 270). However, later research suggested some major technical limitations of 
these early studies and current understanding regarding the issue is that the 
differentiation of MSCs into structural cells in the lung is rare and with unlikely 
physiological significance (270). 
Although the retention of MSCs does not lead to differentiation, it may induce 
other activities. The retention is possible to modulate paracrine function of MSCs, 
such as secretion of the anti-inflammatory cytokine tumor necrosis factor-stimulated 
gene-6 (TSG-6) (145). The retention may also facilitate the direct contact between 
MSCs and local cell types, which may induce the onset of other mechanism such as 
mitochondrial transfer. 
 
1.3.3.2. Immunoregulation 
Immunoregulation is a very significant function of MSCs. As mentioned above, 
treatment of the autoimmune disease GVHD using BM-MSCs has already been 
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approved for clinical use.  
The role of endogenous MSCs in immunoregulation is still largely unknown. 
Endogenous MSCs are found to reside perivascularly, and they may represent a 
portion of the pericytes (182). At this site they can interact with HSC and may affect 
immune responses. The immunoregulating capacity of exogenous MSCs has been 
widely reported in vitro. They have been demonstrated to inhibit various functions of 
immune cell such as dendritic cell differentiation, B cell proliferation, cytolytic 
potential of natural killer cell, and proliferation and activation of T cell (33, 235, 269, 
270). MSCs also facilitate the development of the M2 phenotype of macrophages, 
which is believed to be anti-inflammatory (81, 266, 286). In addition, MSCs are able 
to reduce the release of inflammatory mediators from these immune cells such as 
IFN-γ and promote secretion of anti-inflammatory cytokines such as IL-10. The full 
mechanism of the immunomodulation is unclear but the paracrine release of 
immunomodulating agents including of TGF-β1, HGF, prostaglandin E2 (PGE2), IL-10 
and nitric oxide from MSCs may play an important role in the process (2, 235, 270). 
  
1.3.3.3. Mitochondrial transfer 
Mitochondrial transfer was first observed in vitro in 2006 by Spees and 
colleagues (238). In their study they damaged mitochondrial DNA in a lung epithelial 
cell-line A549 by pre-treatment with ethidium bromide, leading to impaired aerobic 
respiration and proliferation. The mutated A549 cells only survive in a permissive 
medium containing uridine and pyruvate used to supplement anaerobic glycolysis. 
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However, after co-culture with BM-MSCs, these cells re-acquired the capacity to 
proliferate in normal medium, indicating restoration of aerobic respiration. 
Mitochondrial function was recovered as indicated by ATP levels, and mitochondrial 
transfer was identified from BM-MSCs to mutated A549 cells both by DNA 
measurement and microscopy. Following this study, mitochondrial transfer from 
BM-MSCs to other cell types including endothelial cells, cardiomyocytes and 
osteosarcoma cells in vitro has also been reported (55, 192, 204). 
In 2012, Islam and colleagues reported the first in vivo study demonstrating the 
occurrence and functional significance of mitochondrial transfer from exogenous 
BM-MSCs to host airway epithelial cells (118). In the study acute lung injury was 
induced by intratracheal infusion of lipopolysaccharide (LPS), followed by 
intratracheal infusion of BM-MSCs. They found BM-MSCs attached to the alveolar 
epithelia at connexin 43-containing gap junctions. Mitochondrial transfer was 
observed within 24 hours from BM-MSCs to alveolar epithelial cells, which is 
mediated by connexin 43-dependent generation of nanotubes and microvesicles. The 
mitochondrial transfer elevated alveolar ATP concentrations. The therapeutic efficacy 
of BM-MSCs on the acute lung injury, including reduction of alveolar leukocytosis 
and protein leak, elevation of surfactant secretion and reduction of mortality, were 
eliminated in BM-MSCs with mutated connexin 43 or dysfunctional mitochondria. 
Current understanding on the mechanisms of mitochondrial transfer is still very 
limited. Tunnelling nanotubes (TNTs) are identified as routes through which 
mitochondria move intracellularly in most in vitro studies. TNTs were first discovered 
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in vitro by Rustom and colleagues in 2004 as thin structures connecting single cells 
over long distance. TNTs are characterized with continuity of membrane connection 
between the two cells as well as continued cytoskeleton in the tubes (13). F-actin is 
found in most TNTs spanning along the entire length, and inhibition of F-actin 
polymerization lead to blockage of TNT formation (40). Machinery of intracellular 
movements of mitochondria in neuronal cells has been studied for many years. In 
neuronal cells, mitochondrial Rho GTPase 1 (Miro-1, also named Rhot-1), a 
calcium-sensitive adaptor protein, can bind mitochondria to kinesin motor protein-5 
(KIF5) with the aid of accessory proteins Milton/TRAK (155). Kinesin can then carry 
the mitochondria to move along microtubes (155). It has been proposed that this 
mechanism may also mediate the intercellular movement of mitochondria along the 
TNTs (Figure 1.7). A recent study demonstrated that over-expressing of Miro-1 in 
BM-MSCs can promote mitochondrial transfer to epithelial cells and enhance efficacy 
in vitro, while Miro-1 knock-down leads to lack of efficacy (6). Over-expression of 
Miro-1 also enhanced the efficacy to attenuate rotenone-induced lung injury and 
allergic airway inflammation in vivo. This finding provided a possible approach to 
selectively block mitochondrial transfer, which may be very helpful for future 
research about the role of mitochondrial transfer in MSCs action. Nevertheless, the 
mechanisms regulating TNT formation or the Miro-1-involved movement of 
mitochondria remain unclear. Further understanding on the topic may help address the 
important feature of mitochondria transfer such as the direction selectivity and 
enhanced activity upon injury.   
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Figure 1. 7 Proposed mechanism of mitochondrial transfer. BM-MSCs transfer 
mitochondria to damaged epithelial cells through tunneling nanotubes (TNTs). Miro-1 
loads mitochondria on KIF5 with aid of accessory protein Milton/Trak. KIF-5 moves 
along microtubes in the TNTs and thus transfers mitochondria between cells. The 
image showing the enlarged region is adapted from Sheng ZH et al, Nat Rev Neurosci 
(227). 
  
52 
 
1.4. Aims of Study 
The overall hypothesis for this thesis is that iPSC-MSCs are able to alleviate 
oxidative stress (CS or ozone)-induced lung damage (histological changes, 
hyper-responsiveness, inflammation, apoptosis and mitochondrial dysfunction) in 
vivo as well as mitochondrial dysfunction and apoptosis in bronchial epithelial cells 
and ASMCs in vitro, through multiple mechanisms including paracrine effect and 
mitochondrial transfer. 
 
Based on previous sections, the background of the study can be summarized as 
follows: 
1. COPD is a chronic and complex disease. It is a rising cause of death associated 
with huge social and economic burden. There are no current medications that can 
slow the progression of the disease. Cigarette smoking is the major cause of 
COPD. Age is also an important risk factor. 
2. Mitochondrial dysfunction may play an important role in the pathogenesis of 
COPD. Targeting mitochondria may be a novel strategy to develop new treatment 
for the disease. 
3. Efficacy of MSCs isolated from BM, adipose tissue and cord blood on 
CS-induced emphysema models has been demonstrated. BM-MSCs have been 
proven to be safe in clinical trials but without efficacy in COPD patients. 
4. iPSC-MSCs have several advantages over BM-MSCs including more abundant 
resource, high capacity of expanding without loss of differentiation potency and 
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potential to overcome ageing-associated impairment. 
5. The mechanisms of action of MSCs are not fully understood. Paracrine effects and 
mitochondrial transfer represents two possible mechanisms. 
 
Based on the above knowledge, my Ph.D study focuses on the effects of 
iPSC-MSCs on airway cells in a COPD or oxidative stress-related context. The aims 
of the study include: 
1. To compare effects of iPSC-MSCs and BM-MSCs on CS-induced damage in 
the rat lung in vivo and in human bronchial epithelial cells in vitro with an 
emphasis on apoptosis. Both mitochondrial transfer and paracrine effects 
were examined. 
2. To study the capacity of iPSC-MSCs to alleviate mitochondrial dysfunction in 
CS-treated human ASMCs in vitro and to examine the relevant contribution of 
mitochondrial transfer and paracrine effects to the efficacy. 
3. To investigate the capacity of iPSC-MSCs to alleviate oxidative 
stress-induced AHR, lung inflammation, mitochondrial dysfunction and 
apoptosis in an acute ozone-exposed mouse model.  
These studies should provide evidence to demonstrate the potential of 
iPSC-MSCs as a candidate for cell-based therapy for COPD. 
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Chapter 2 Material and Methods 
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2.1 Materials 
2.1.1 Reagents and chemicals 
 Chemicals, reagents and recombinant proteins were supplied by Thermo Fisher 
Scientific (Carlsbad, CA, USA), Sigma-Aldrich (St. Louis, MO, USA), Amresco 
(Solon, OH, USA), Bio-Rad Laboratories (Richmond, CA, USA), Cayman Chemical 
(Ann Arbor, MI, USA), Life Technologies (Eugene, OR, USA) and Roche (Mannheim, 
Germany). Cell culture reagents were purchased from Invitrogen (Thermo Fisher 
Scientific) and Sigma-Aldrich. Cigarettes including Camel (11 mg TAR and 0.8 mg 
nicotine, R.J. Reynolds, Winston-Salem, NC, USA) or Marlboro Red (10 mg TAR 
and 0.8 mg nicotine, Philip Morris International, New York City, NY, United States) 
were obtained from commercial retailers. 
 
2.1.2 Experimental animals 
 For the in vivo study performed in Hong Kong, the procedures of the project and 
the personnel involved were under licenses from Department of Health, Hong Kong 
SAR and approved by the Committee on the Use of Live Animals in Teaching and 
Research (CULATR) of the University of Hong Kong. Male Sprague-Dawley (SD) 
rats (weighted 170-200 g) were purchased from and kept in the Laboratory Animal 
Unit, the University of Hong Kong. 
 For the in vivo study performed at Imperial College London, the procedures of 
the project and the personnel involved were under a Project License and Personal 
Licenses from the British Home Office, United Kingdom, under the Animals 
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(Scientific Procedures) Act 1986. Male C57BL/6 mice (6 weeks old) were purchased 
from Harlan UK Ltd (Wyton, UK) and kept in Central Biomedical Services, Imperial 
College London.  
 The living environment of all animals was monitored and controlled with respect 
to temperature, humidity, and day/night cycle. The animals‟ general conditions were 
monitored daily. 
 
2.1.3 Human iPSC-MSCs 
 The iPSC-MSCs were kindly provided by Dr. Lian Q and Professor Tse HF from 
the Cardiology Division, Department of Medicine, LKS Faculty of Medicine, HKU. 
The protocol to generate iPSC-MSCs includes two steps: inducing iPSCs from 
somatic cells, and generating iPSC-MSCs from the iPSCs. Firstly, iMR90 fibroblast 
cells (CCL-186, American Type Culture Collection, Manassas, VA, USA) were 
transduced with human OCT4, SOX2, NANOG and LIN28 genes through lentiviral 
vectors (Plasmid 16577-80, Addgene, Cambridge, MA, USA) overnight. The 
transduction gene mixture was then replaced with human embryonic stem cell culture 
medium and cells transferred to inactivated mouse embryonic fibroblast (MEF) feeder. 
20 days later, cell colonies with human embryonic stem cell morphology were 
identified as iPSC-MSCs and propagated. The resulting iPSC lines were differentiated 
into iPSC-MSCs as previously described (153). iPSCs were harvested and placed on a 
gelatinized 10-cm dish containing knockout Dulbecco‟s modified Eagle medium 
(DMEM) (Invitrogen) supplemented with 10% serum replacement medium 
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(Invitrogen), 10 ng/mL basic fibroblast growth factor (bFGF) (Invitrogen), 10 ng/mL 
platelet-derived growth factor AB (Peprotech, Rocky Hill, NH, USA), and 10 ng/mL 
epidermal growth factor (EGF) (Peprotech) to induce differentiation. Cells were left 
to differentiate for 7 days after which they were harvested and incubated with 
CD24-phycoerythrin and CD105-FITC (BD PharMingen, San Diego, CA, USA). The 
CD24
-
CD105
+ 
population were separated by fluorescence-activated cell sorting 
(FACS). The CD24
-
CD105
+ 
cells were diluted and seeded in 96-well plates to select 
wells containing a single cell. Upon reaching 70% confluence, the single cell-derived 
clones were serially sub-cultured to confluence in a 175-cm
2
 tissue culture flask. They 
were then trypinised, aliquoted and frozen as stocks in liquid nitrogen for future 
experiments. 
 
2.1.4 Human bone marrow – derived MSCs (BM-MSCs) 
 Human BM-MSCs were obtained from a commercial supplier (Cat. No. PT-2501, 
Cambrex Bioscience, Rockland, ME, USA). Both iPSC-MSCs and BM-MSCs were 
cultured in DMEM (Invitrogen) supplemented with 10% fetal bovine serum 
(Invitrogen), 5 ng/mL bFGF (R&D Systems, Minneapolis, MN, USA), 10 ng/mL EGF 
(R&D Systems), 55 μM 2-mercaptoethanol (Invitrogen), 20 units/ml penicillin and 20 
μg/ml streptomycin. 
 
2.1.5 BEAS-2B cells 
 The BEAS-2B cells were virus-transformed immortalized human bronchial 
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epithelial cells from autopsy of non-cancerous individuals. The BEAS-2B cells in this 
study were from a commercial supplier (American Type Culture Collection, Rockville, 
MD, USA). They were cultured in keratinocyte serum free media K-SFM (Invitrogen) 
supplemented with 5 ng/ml EGF and 50 mg/ml bovine pituitary extract. Passages 
42-50 were used for experiments. 
 
2.1.6 Primary human airway smooth muscle cells (ASMCs) 
ASMCs were isolated from biopsies of bronchi or tracheas of healthy transplant 
donor lungs as previously described (174). Briefly, biopsies were cut into small pieces 
(<1 mm
2
) and placed in DMEM supplemented with 10% FBS, 4 mM L-glutamine, 20 
units/ml penicillin, 20 μg/ml streptomycin and 2.5 μg/ml amphotericin B. ASMCs 
were confirmed by the characteristic “hill and valley” morphology under light 
microscopy. Cells were sub-cultured to reach confluence in 175-cm
2
 tissue culture 
flasks and then frozen as stock. Passages 3 to 7 were used for experiments. When 
serum-free medium was required in the experiments, it was prepared as phenol-free 
DMEM supplemented with 1 mM sodium pyruvate, 4 mM L-glutamine, 1:100 
non-essential amino acids, 0.1% BSA, 20 units/ml penicillin, 20 μg/ml streptomycin 
and 2.5 μg/ml amphotericin B. 
All of the above cell types were maintained in a humidified incubator of 5% CO2 
and 37C and fed with medium every 2-3 days. 
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2.2 Methods 
2.2.1 MSCs treatment to cigarette smoke-exposed rats 
 Male Sprague-Dawley rats were exposed to 4% (v/v) CS for one hour daily for 56 
days (Figure 2.1) using a same protocol as described in a previous study (52). Briefly, 
a maximum of 8 rats were placed into a ventilated 20 liter-chamber. 800 ml of CS was 
injected into the chamber through a syringe to raise the initial CS concentration to 
4%.The filters of the cigarettes were removed beforehand. The chamber was then 
ventilated with a steady inflow of 4% CS at 1 L/min – a gas mixture of 100% CS (40 
ml/min) and normal air (960 ml/min) from two separate peristaltic pumps (Masterflex, 
Cole-Parmer Instruments Co, Niles, IL, USA) (Figure 2.2). The control group was 
exposed to sham air (SA) using the same protocol. The exposure was performed in a 
chemical fume hood at the same time of each day. At day 29 and day 43, CS-exposed 
rats were intravenously injected with plain PBS, 3x10
6
 human BM-MSCs or 3x10
6 
human iPSC-MSCs into tail vein (Figure 2.1). The SA group was injected with PBS. 
Daily check of general conditions showed no obvious adverse reactions towards the 
injections.  
Rats were sacrificed 24 hours after the last CS or air exposure by intraperitoneal 
injection of over-dosed pentobarbitone (100 mg/kg body weight). The larger lobe of 
left lungs was firstly inflated with 1 ml formalin and then fixed, dehydrated and 
paraffin embedded. The paraffin block was cut into 5 μm sections. The rest of the lung 
tissue was frozen and stored at -80℃. 
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Figure 2. 1 Schematic diagram of BM-/iPSC-MSCs treatments in a cigarette 
smoke (CS)-exposed rat model. Male Sprague-Dawley rats were exposed to 4% CS 
for 1 hour daily for 56 days. At Days 29 and 43, 3x10
6 
human iPSC-MSCs (n = 8) or 
BM-MSCs (n = 8) were injected intravenously through tail veins. A sham air (SA) 
group was included in which the rats were exposed to fresh air. At Day 57, the rats 
were sacrificed, and the larger lobe of the left lungs were fixed and sectioned for 
histological studies. 
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Figure 2. 2 The set-up of the ventilated smoking chamber. In the right chamber, the 
fresh air and CS were mixed in ratio of 96:4 to generate constant flow of 4% CS at 
1000 ml/min. In the left chamber, only fresh air was pumped. The whole set-up was 
placed in a chemical fume hood. 
 
 
 
2.2.2 Histology and morphometric analysis of rat lungs 
The paraffin sections were always deparaffinised and dehydrated before staining. 
The slides were incubated at 40℃ in an oven for one hour to melt the paraffin, 
followed by incubation twice in xylene for 15 minutes. A serial rehydration was then 
applied by incubation in 100%, 95%, 75% ethanol and double distilled water (ddH2O) 
successively, each for 10 minutes, twice.  
Mean linear intercept (Lm) was measured to evaluate airspace enlargement based 
on a modified method (62). Briefly, the paraffin sections from the largest lobes of rat 
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lungs were rehydrated and stained with hematoxylin and eosin. The slides were then 
mounted in a xylene-based mounting medium, observed using a brightfield 
microscope at 10x magnification and analysed using AxioVision (Zeiss, Germany). A 
100 μm-length interval was inserted in the field of a randomly selected region of the 
lung sections. The interval passed through several alveoli, resulting in multiple 
alveolar intercepts. Lm was calculated as 100 μm divided by the number of alveolar 
intercepts. 10 fields per section, 8 rats per group were analysed.  
Masson's trichrome staining was performed to measure the pulmonary fibrosis 
according to the standard protocol. The pulmonary fibrosis was assessed by 
semi-quantitative Ashcroft score, which gave each field a score ranging from 0 
(normal lung), 1 (minimal fibrous thickening of alveolar or bronchiolar walls), 3 
(moderate thickening of walls without obvious damage to lung architecture), 5 
(increased fibrosis with definite damage to lung structure and formation of fibrous 
bands or small fibrous masses), 7 (severe distortion of structure and large fibrous 
areas) to 8 (total fibrous obliteration of the field) (12). Scores from 5 fields per section, 
total 6 rats, were assessed under 20x magnification. 
 
2.2.3 iPSC-MSCs treatment to ozone-exposed mice 
Male C57BL/6 mice were put into a chamber ventilated with gas mixture of 
normal air and ozone produced by an ozone generator (model 500 Ozoniser, Sander, 
Wuppertal, Germany). The concentration of ozone in the chamber was monitored by 
an ozone detector and maintained at 3 ppm by tuning the ozone generator (Figure 2.3). 
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Control groups were exposed to normal air. The exposure lasted for 3 hours.  
iPSC-MSCs or PBS were administrated to mice by intravenous injection through 
tail vein. The administration was performed either 24 hours prior or 6 hours after the 
exposure (Figure 2.4). There were 5 groups of mice in total: Air, Air with iPSC-MSCs 
administrated 24 hours prior (-24 hr), Ozone, Ozone with iPSC-MSCs administrated 
24 hours prior-exposure (-24 hr) and Ozone with iPSC-MSCs administrated 6 hour 
post-exposure (+6 hr). The Mice from all groups were anaesthetised for AHR 
measurements 21 hours after the exposure. They were sacrificed immediately after the 
AHR measurements by intraperitoneal injection of over-dosed pentobarbitone (100 
mg/kg body weight). Bronchoalveolar lavage (BAL) was collected before the 
collection of the lungs. The right lobes were frozen for mitochondria extraction while 
left lobes were inflated with and fixed in paraformaldehyde. The larger lobe of the 
fixed lungs were later embedded into paraffin blocks and sectioned into 5 
μm-sections.  
 
Figure 2. 3 The set-up of the ventilated chamber for ozone exposure. Ozone 
generated from an ozone generator and normal air from an air pump was ventilated 
into the chamber. The ozone concentration was constantly monitored by an ozone 
detector and maintained at 3 ppm by tuning the ozone generator. 
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Figure 2. 4 Schematic diagram of iPSC-MSCs treatments in an ozone-exposed 
mouse model. Male C57BL/6 mice were exposed to ozone (3 ppm) for 3 hours. 
Control groups were exposed to fresh air. 10
6 
iPSC-MSCs were intravenously injected 
into the tail vein either 24 hours prior to the ozone exposure, or 6 hours after the 
exposure. Airway hyper-responsiveness (AHR) was measured 21 hours after the 
exposure. The mice were then sacrificed and BAL and lung tissues collected.  
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2.2.4 Measurement of airways hyper-responsiveness (AHR) of mice 
The AHR was measured as previously described (272). Before the measurement 
of AHR, mice were anaesthetised by intraperitoneal injection of 
ketamine/xylazine/saline mixture. The trachea was then opened and inserted with a 
catheter through which the mouse was ventilated (MiniVent type 845, Hugo Sach 
Electronic, Germany) at 250 breaths/minute and a tidal volume of 250 μl. The animal 
was continuously monitored in a whole body plethysmograph with a 
pneumotachograph connected to a transducer (EMMS, Hants, UK). Another 
transducer was connected to an esophageal catheter to evaluate the intrapleural 
pressure. The transpulmonary pressure was assessed based on the pressure 
measurements from the two transducers. Increasing concentrations (4-256 mg/ml) of 
acetylcholine in PBS were then administered into airway via a nebulizer (Aeroneb 
Lab Micropump Nebulizer, EMMS) and the pulmonary resistance (RL) was recorded 
for 3 minute periods during each dose. Baseline RL was defined as the RL with 
nebulised PBS. A concentration-response curve was plotted for each animal and the 
concentration of acetylcholine that induced 100% elevation of RL from baseline was 
derived (PC100). The value of -log PC100 was taken as a measurement of AHR. 
 
2.2.5 Measurement of cells and cytokines in BAL of mice 
Bronchoalveolar lavage (BAL) was collected by rinsing the lungs three times 
with 0.8 ml cold PBS through an endotracheal tube. After centrifugation at 3000 rpm, 
4°C for 5 min, the supernatant was collected as BAL fluid (BALF) while the cell 
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pellets were resuspended in 200 μl PBS and counted on a haemocytometer for total 
cell number. BAL cell samples were centrifuged again onto glass slides by a cytospin 
device at 30g for 6 minutes (Shandon Cytospin 4; Thermo Electron Corporation, 
Waltham, MA, US). The resulting cell slides were air-dried overnight and stained 
using Diff-Quick kit (Reagena, Toivala, Finland) according to manufacturer‟s 
instructions. Differential count of white blood cells (neutrophil, macrophage, 
lymphocyte and eosinophil) was performed under an optical microscope (Olympus 
BH2, Olympus). 
The cytokine levels in BALF of mice were determined using a MAGPIX 
Luminex multiplexing analyser (Merck Millipore, Darmstadt, Germany), which 
simultaneously measured levels of multiple analytes, including MCP-1, Eotaxin, IL-6, 
IL-5 and macrophage inflammatory proteins (MIP)-1α.  
 
2.2.6 Isolation of intact mitochondria from mouse lungs 
Intact mitochondria were isolated from mouse lungs using a Mitochondria 
Isolation Kit for Tissue (Thermo Fisher Scientific) and Dounce tissue grinder set 
(Sigma) following the manufacturer‟s instructions. In brief, approximately 20 mg of 
lung tissue was washed with PBS supplemented with EDTA-free protease inhibitors 
(Roche). The tissue was homogenized in corresponding reagent with 5 strokes of 
Dounce A followed by 20 strokes of Dounce B. The homogenates were centrifuged 
firstly at 700xg for 10 minutes at 4°C, to sediment large organelle fractions containing 
nucleus, plasma membrane, endoplasmic reticulum, Golgi and so on. The 
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supernatants were centrifuged again at 12,000xg for 5 minutes. The supernatants and 
pellets were collected as cytosolic fractions and mitochondrial fractions, respectively.  
 
2.2.7 Generation of cigarette smoke medium (CSM)  
 CSM was prepared as previously described (143). Briefly, cigarette smoke from 
two filter-removed cigarettes was bubbled into 20 ml of serum free medium. The 
medium was then filtered through a 0.22 μm filter. The optical density (OD) at 
wavelength 320 nm was measured.  
For the study with BEAS-2B cells which was performed at Hong Kong university, 
the cigarettes smoke was from Camel cigarettes (11 mg TAR and 0.8 mg nicotine), 
and pumped into serum free medium manually by syringe. 100% CSM was generated 
by adjusting the OD at 320 nm with serum free medium to 3.5. 
For the study of ASMCs which was performed at Imperial College London, the 
cigarette smoke was from Marlboro Red cigarettes (10 mg TAR and 0.8 mg nicotine) 
and pumped into serum free medium through a peristaltic pump, which resulted in a 
lower OD read-out than the manual method. Thus the 100% CSM was generated by 
adjusting the OD at 320 nm with serum free medium to 1.1. The advantage of 
peristaltic pump is a very consistent output for each batch of CSM. 
After preparation, the 100% CSM was aliquoted and stored at -80℃. 
 
2.2.8 Co-culture of BEAS-2B cells with MSCs. 
 BEAS-2B cells were pre-stained with CellTrace Violet (Invitrogen) which 
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fluorescently labelled the cells for several generations while iPSC-MSCs or 
BM-MSCs were pre-stained with MitoTracker Green (Invitrogen), which specifically 
stained the mitochondria in the cells. In brief, BEAS-2B cells were harvested, counted, 
incubated with 5 µM Celltrace Violet for 20 minutes, while MSCs were harvested, 
counted and incubated with 200 nM Mitotracker Green for 30 minutes. They were 
centrifuged at 1000 rpm for 5 min and incubated in complete medium for 10 min after 
the staining to wash away the remaining dye. After another centrifugation, they were 
re-suspended in 1:1 mixed medium and co-cultured at a 1:1 ratio in a 24-well plate. 
Approximately 5 hours later, when the cells attached to the plates, 100% CSM was 
added into the medium to make the final concentration 2%. After 24 hours, cells were 
visualized by motorized inverted microscope (IX81-ZDC2; Olympus, Shinjuku, 
Tokyo City, Tokyo, Japan) or analyzed by flow cytometry with a BD FACS Aria I 
Cell Sorter (BD Biosciences, Oxford, UK).  
 
2.2.9 Determination of ATP content in BEAS-2B cells following co-culture 
BEAS-2B cells in the co-culture were sorted as CellTrace positive cells by a BD 
FACS Aria I Cell Sorter. ATP was extracted with boiling distilled water according to a 
one-step method previously described (284). The ATP content was measured by a 
luciferase-catalysed luminescent assay using an ATP Determination Kit (Invitrogen) 
according to the manufacturer‟s instruction.  
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2.2.10 BM-MSC and iPSC-MSC conditioned medium treatment of CSM-treated 
BEAS-2B cells  
The conditioned medium (CdM) was prepared as previously described (294). 
Briefly, BM-MSCs and iPSC-MSCs were re-fed with DMEM without serum and 
supplements. After 24 hr, the medium was collected and concentrated via 
centrifugation through ultrafiltration conical tubes (Amicon Ultra-15 with membranes 
selective for 5 kDa). The final concentration was adjusted to 20 times that of the 
collected CdM.  
Alternatively, to investigate the effects of stem cell factor (SCF), SCF was 
depleted from iPSC-MSCs-CdM as previously described (139). Briefly, 0.5 μg of 
anti-SCF (AF-255-NA; R&D) or normal human IgG control antibody (1-001-A; R&D) 
were mixed with protein G-agarose beads in PBS at 4°C for 1 hour with intermittent 
shaking. After centrifugation, beads were washed three times and used for 
immunedepletion of SCF. iPSC-MSCs-CdM was incubated with protein G-agarose 
beads immobilized with anti-SCF antibodies or human IgG control antibody for 1 
hour at 4°C. The beads with immune complexes attached were precipitated by 
centrifugation. The supernatants collected were either SCF-depleted 
iPSC-MSCs-CdM or control iPSC-MSCs-CdM.  
The BEAS-2B cells were cultured on top of coverslips in 24-well plates. The 
medium was replaced by keratinocyte medium with no supplements 24 hr before the 
treatment. They were then treated with 2% (v/v) CSM. BM-MSCs-CdM or 
iPSC-MSCs-CdM containing 3 μg of total protein was added at the same time. After 
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24 hours, the supernatant was removed and the cells fixed for immunohistochemical 
tests or terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling 
(TUNEL) assay. To investigate role of SCF, the cells were treated with either 
SCF-depleted iPSC-MSCs-CdM or recombinant SCF (255-SC, R&D) with 2% CSM. 
 
2.2.11 Immunohistochemistry 
To detect expression and localization of various proteins in lung sections and cell 
culture, standard immunohistochemistry procedures were applied. Briefly, lung 
sections were serially rehydrated and antigen retrieved by boiling for 5 minutes at 
120C in Sodium Citrate Buffer (10 mM sodium citrate, 0.05% Tween 20, pH 6.0). 
They were then blocked by 5% bovine serum albumin (BSA) for 30 minutes at room 
temperature followed by overnight incubation in primary antibodies at 4C. The 
primary antibodies included human nuclear antigen (HNA) (MAB1281, Chemicon), 
human/rat clara cell secretory protein 10 (CC10) (SC-9772, Santa Cruz, CA, USA), 
human/rat/mouse Ki-67 (ab15580, Abcam, Cambridge, UK), human/rat Complex I 
(SC-271387, Santa Cruz), human COX4 (SC-133478, Santa Cruz), rat/mouse CD68 
(SC-7084, Santa Cruz), mouse/rat/human C-kit (SC-1494, Santa Cruz). After 3 washs 
with PBS, the sections were incubated in secondary antibodies including horseradish 
peroxidase-conjugated or fluorescent-conjugated anti-mouse IgG, anti-rat IgG and 
anti-rabbit IgG for 1 hour at room temperature. For HRP-conjugated secondary 
antibodies, the targets were recognized by an intense brown colour after developing 
with 3,3'-diaminobenzidine (DAB) substrate solution. For fluorescent-conjugated 
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secondary antibodies, the sections were mounted with mounting medium (ProLong 
Gold antifade reagent with DAPI, Invitrogen) containing 
4,6-diamidino-2-phenylindole (DAPI) to visualize nuclei. At least five fields per 
section were randomly captured under a conventional fluorescent microscope 
(IX81-ZDC2; Olympus) at the desired magnification and analyzed using AxioVision 
(Zeiss, Oberkochen, Germany). 
 For cell culture, the cells were seeded and treated on coverslips in 24-well dishes. 
They were fixed with 4% paraformaldehyde in PBS for 15 min, blocked with 5% 
BSA for 30 min and permeabilized with 0.1% Triton-100 in PBS for 3 min, all at 
room temperature. The cells were incubated in primary antibodies including C-kit 
(SC-1494, Santa Cruz) and cytochrome c (SC-13156, Santa Cruz) at room 
temperature for 1 hr and then in fluorescent-conjugated secondary antibodies. The 
coverslips were taken out from the wells, flipped and put on a drop of mounting 
medium containing DAPI on glass slides. Images of 5 fields for each slide were 
captured randomly by a motorized inverted microscope (Olympus) and analyzed 
using AxioVision (Zeiss). The ratio of positively stained cells in the total cell 
population was calculated as the rate of cytochrome c translocation, apoptosis or 
proliferation. 
 
2.2.12 Terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling 
(TUNEL) assay 
TUNEL assay detects cell apoptosis by labelling the terminal end of nucleic acids 
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which increase in abundance in cells only if the DNA becomes fragmented. Apoptosis 
of BEAS-2B cells and mouse lung sections were determined via TUNEL assay using 
the In Situ Cell Death Detection Kit, POD (Roche Applied Science, Mannheim, 
Germany).  
For analysis of the lung sections, they were rehydrated as per the 
immunohistochemistry protocol, and heated in citrate buffer in a microwave oven for 
5 minutes. They were then washed with PBS and incubated with TUNEL reaction 
mixture for 1 hour. Nucleus of apoptotic cells were stained green by the reaction. 
For the BEAS-2B cells, they were fixed with 4% paraformaldehyde in PBS, 
blocked with 3% H2O2 in methanol, permeabilized with 0.1% Triton-100 in 0.1% 
sodium citrate and washed with PBS. TUNEL reaction mixture was then applied for a 
one-hour incubation at 37 ℃. 
All samples were mounted in mounting medium containing DAPI. Images of 5 
fields for each slide were captured randomly by a motorized inverted microscope 
(Olympus) and analysed using AxioVision (Zeiss). 
 
2.2.13 Total protein extraction from cell culture 
 To extract total protein from cultured cells, cells in 6-well plates were first 
washed with ice-cold PBS and then frozen at -80℃. The cells were then scraped with 
approximately 50 μl/well T-PER Cell Protein Extraction Reagent (Thermo Fisher 
Scientific) supplemented with protease/phosphatase inhibitor cocktail (Thermo Fisher 
Scientific) and 100 mM PMSF. The cell/reagent mixture were vortexed, put on ice for 
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30 min and centrifuged at 16000xg at 4℃ for 30 minutes. The supernatant was 
collected as cell lysates and stored at -80℃. Protein concentrations were determined 
by Bradford protein assay using bovine BSA as standard. 
 
2.2.14 Western blot 
Cell lysates containing the comparable amounts of total protein (20-40 μg) were 
denatured and reduced by boiling at 95℃ for 5 minutes in Laemmli buffer with 
sodium dodecyl sulfate (SDS) and 2-mercaptoethanol. The proteins in the samples 
were separated by size by running through an SDS–polyacrylamide gel. They were 
transferred onto a polyvinylidene fluoride (PVDF) membrane (Bio-Rad Laboratories) 
which was then blocked in 5% skimmed milk in Tris-buffered saline (pH 7.4) with 0.1% 
Tween-20. The membranes were incubated with diluted anti-C-kit (1:500) (SC-1494, 
Santa Cruz) or anti-β-actin (1:5000) antibodies at 4°C overnight, washed three times, 
and then incubated with horseradish peroxide-conjugated anti-goat antibody (1:2000) 
or anti-mouse antibody (1:2000) (Dako, Danmark) for 1 h at room temperature. After 
three further washes and a one-minute incubation with enhanced chemiluminescence 
(ECL), the membranes were exposed to x-ray films (Fujifilm, Tokyo, Japan) on which 
the target proteins were developed as dark bands. 
 
2.2.15 Enzyme-linked immunosorbent assay (ELISA) 
The concentration of SCF in CdM was measured by Human SCF DuoSet ELISA 
Kit (R&D) according to manufacturer‟s instructions. In general, samples and serially 
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diluted standards were added into 96-well plates coated with capture antibody. After 
adequate washing, the captured target proteins were further incubated with detecting 
antibody and streptavidin conjugated with horseradish peroxidase (HRP), 
consecutively. HRP catalysed a colorimetric reaction of tetramethylbenzidine (TMB) 
substrates. The reaction was stopped by adding 2 N H2SO4, and the OD was measured 
at wavelength 450/570 nm in a microplate reader (FLUOstar Optima, BMG Labtech). 
A standard curve was generated according to OD values of the standards, and SCF 
levels of CdM were calculated from the standard curve. 
 
2.2.16 Treatment of CSM or H2O2 to ASMCs or iPSC-MSCs 
ASMCs were cultured in 6-well plates or 96-well plates. On reaching 90% 
confluence, the medium was replaced with serum-free medium for 24 hours. The cells 
were then treated with different concentrations of H2O2 (50, 100 and 200 μM) or CSM 
(10, 25, 50 and 75%) for 2, 4 and 24 hours. A cessation group was also included, in 
which after 4 hours of treatment H2O2 or CSM was replaced with fresh serum-free 
medium for the next 20 hours. The iPSC-MSCs were similarly treated for 4 hours and 
24 hours. The cell viability, mitochondria membrane potential and mitochondrial ROS 
levels were measured by methylthiazolyldiphenyl-tetrazoliumbromide (MTT) assay, 
JC-1 (5,5‟,6,6‟-tetrachloro-1,1‟,3,3‟-tetraethylbenzimidazolylcarbocyanineiodide) and 
MitoSOX staining, respectively.  
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2.2.17 Cell viability assay 
MTT assay is a commonly used cell viability assay. In brief, MTT 
(Sigma-Aldrich) was dissolved in 37 ℃ serum free medium at 1 mg/ml. ASMCs or 
iPSC-MSCs cultured in 96-well plates were incubated with 100 μl MTT solution at 
37 ℃ after treatments. After 15 min, the cells were checked every 5 minutes using 
microscope to observe formation of purple color within. When the color is visible but 
not too intense, the MTT solution was replaced with 50 μl DMSO. After shaking for 5 
minutes, the OD at wavelength 550 nm was measured.  
 
2.2.18 Measurement of mitochondrial ROS 
Mitochondrial ROS levels were assessed by staining with MitoSOX Red 
Mitochondrial Superoxide Indicator (Invitrogen). 50 μg MitoSOX powder was 
dissolved in 13 μl DMSO to make a 5 mM stock solution and further diluted to 5 μM 
with relevant buffers to make working solutions. 
For the in vitro study of ASMCs, cells in 6-well plates were washed with 
modified Hank‟s Balanced Salt Solution (HBSS) (containing Ca/Mg) (Sigma-Aldrich), 
and incubated with 5 μM MitoSOX diluted in modified HBSS for 30 minutes. The 
cells were then washed with HBSS (Sigma-Aldrich) and incubated with 500 µl/well 
accutase solution (Sigma-Aldrich) for up to 5 min at 37 °C and 5% CO2. One ml/well 
DMEM with 4 mM L-glutamine and 10% FBS was then added to the detached cells. 
After centrifugation and resuspension in HBSS, the intensity of red fluorescence was 
measured at 510/580 nm by a FACSCanto II flow cytometer (BD Biosciences).  
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For the in vivo study of ozone-exposed mice, the intact mitochondria were 
isolated from lungs, and then incubated with 5 μM MitoSOX in 96-well plates for 30 
minutes at 37°C. The intensity of red fluorescence was measured at 510/580 nm using 
a fluorescence plate reader. 
 
2.2.19 Mitochondrial membrane potential 
Mitochondrial membrane potential (ΔΨm) was determined by staining with JC-1 
dye (Invitrogen).  The dye exists as monomers with green fluorescence, but when 
they enter live mitochondria they form J-aggregates which exhibit red fluorescence. 
The accumulation of the dye in mitochondria is potential-dependent, making the ratio 
of red to green fluorescence as an indicator of ΔΨm. ASMCs or intact mitochondria 
from mouse lungs were incubated with 2 µM of JC-1 for 30 minutes at 37°C. The 
fluorescent signal was determined either using a FACSCanto II flow cytometer (BD 
Biosciences) for the living cells, or a fluorescence plate reader (Synergy HT Biotek, 
Winooski, VT, USA) for the isolated mouse mitochondria. The green fluorescence 
from JC-1 monomers was measured at excitation/emission ratios of 485/535 nm and 
the red fluorescence from J-aggregates at 560/595 nm. 
 
2.2.20 Annexin V staining 
The apoptosis of ASMCs/iPSC-MSCs co-culture was detected by Annexin V 
staining through flow cytometry. Annexin V detects apoptosis by binding to the 
externalized phosphatidylserine in apoptotic cells. Briefly, cells were harvested and 
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resuspended at a density of 10
6
 cells/ml in assay buffer. 5 μl of FITC-conjugated 
Annexin V (Invitrogen) was added into 100 μl of cell suspension. After 15 
minutes-incubation at room temperature, the intensity of Annexin V was measured by 
a FACSCanto II flow cytometer (BD Biosciences).  
 
2.2.21 Direct co-culture of ASMCs and iPSC-MSCs 
To study the effects of direct interaction between ASMCs and iPSC-MSCs on 
mitochondrial ROS, ΔΨm and apoptosis, ASMCs and iPSC-MSCs were co-cultured 
in using two different procedures, one as a prophylactic study and the other as 
therapeutic (Figure 2.5).  
For the prophylactic study, the ASMCs and iPSC-MSCs were cultured in T150 
flasks separately before the experiments. The ASMCs were trypsinized, resuspended 
and counted. They were washed with HBSS by centrifugation and resuspension, 
followed by 20 minutes-incubation with CellTrace Violet (1:1000 in HBSS, 1 ml/10
6
 
cells). After centrifugation, they were incubated with complete medium for 10 
minutes to wash and neutralize the dye. Meanwhile, the iPSC-MSCs were trypsinized, 
resuspended and counted. The two cell types were mixed and seeded in 6-well plates 
at a density of 10
5
 ASMCs plus 1.5x10
5 
iPSC-MSCs per well. Single cell culture 
groups were included as comparison, in which only 10
5
 ASMCs or 1.5x10
5 
iPSC-MSCs were seeded into each well. After 20 hours, the medium was replaced 
with 10% or 25% CSM for 4 hours. The mitochondrial ROS, ΔΨm and apoptosis 
were then assessed by MitoSOX, JC-1 and Annexin V staining through flow 
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cytometry.  
For the therapeutic study, 10
5
 ASMCs were first seeded in each well of 6-well 
plates. 20 hours later, they were incubated with CellTrace Violet for 20 minutes 
followed by treatment with 10% or 25% CSM for 4 hours. The CSM were then 
removed and 1.5x10
5 
iPSC-MSCs were added into each well. After another 24 hours, 
the mitochondrial ROS, mitochondrial membrane potential and apoptosis were 
measured through flow cytometry. 
 
2.2.22 Detection of mitochondrial transfer in co-culture of ASMCs and 
iPSC-MSCs 
To detect mitochondrial transfer in the co-culture of ASMCs and iPSC-MSCs, 
ASMCs pre-stained with CellTrace Violet and iPSC-MSCs pre-stained with 
MitoTracker Red (for fluorescent microscope) or MitoTracker Green (for flow 
cytometry) were mixed and seeded into 6-well plates at a density of 10
5
 ASMCs plus 
1.5x10
5 
iPSC-MSCs per well. 20 hours later, they were treated with 10% or 25% 
CSM and analyzed by flow cytometry. The percentage of ASMCs that were 
MitoTracker positive was subsequently calculated. For fluorescent microscopy, the 
cells were fixed in 3.7% formaldehyde (Sigma-Aldrich) for 10 minutes, permeabilized 
in 0.1% Triton X-100 (Sigma-Aldrich) for 5 minutes and stained by Alexa Fluor 488 
phalloidin (Invitrogen) in PBS with 1% BSA. Phalloidin is a probe that labels 
filamentous actin selectively. The cells were then visualized by a motorized inverted 
fluorescent microscope. 
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A 
B 
Figure 2. 5 Protocols of direct co-culture of iPSC-MSCs and ASMCs. (A) 
Prophylactic co-culture with iPSC-MSCs. 1.5x 10
5
 ASMCs were pre-stained with 
CellTrace Violet and seeded in 6-well plates either with or without 10
5
 
iPSC-MSCs. 20 hours later they were treated with CSM for 4 hours. MitoSOX , 
JC-1 and Annexin V staining were applied to measure mitochondrial ROS, ΔΨm 
and apoptosis. (B) Therapeutic co-culture with iPSC-MSCs. 1.5x 10
5 
ASMCs were 
labeled with CellTrace Violet and treated with CSM for 4 hours. CSM was 
removed and either 10
5
 iPSC-MSCs or serum free medium was added. After 20 
hours of co-culture, the mitochondrial ROS and membrane potential were 
measured. 
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2.2.23 iPSC-MSCs-conditioned medium treatment to ASMCs 
The iPSC-MSCs-CdM was prepared as described above. The ASMCs were 
pretreated with 20-fold diluted iPSC-MSCs-CdM for 4 hours. The CSM were then 
added on top of the iPSC-MSCs-CdM to make 10% or 25% CSM. Serum free 
medium was added to the control group or 10% CSM group to keep the total volume 
of each well the same. 4 hours later, the mitochondrial ROS, ΔΨm and apoptosis were 
measured.  
 
2.2.24 Transwell co-culture between ASMCs and iPSC-MSCs 
To study the effects of paracrine crosstalk between ASMCs and iPSC-MSCs, they 
were co-cultured in a transwell co-culture system. In brief, 10
5
 ASMCs were seeded 
in 6-well plates while 1.5x10
5 
iPSC-MSCs were seeded in a cell-culture insert with 
pores sized 0.4 μm (Falcon, Corning, NY, USA). They were incubated overnight and 
then combined. Single-culture groups were included with empty inserts or empty 
wells. After 20 hours‟ co-culture, they were treated with 10% or 25% CSM for 4 
hours, and assessed for the mitochondrial ROS, ΔΨm and apoptosis.  
 
2.2.25 Statistical analysis 
 Numerical data are presented as mean±standard error of mean (SEM). The 
statistical analysis was performed using software Prism 5.0 (Graphpad, San Diego, 
CA, USA). Differences between groups were evaluated by student t-test or one-way 
ANOVA followed by Newman-Keuls test when appropriate. Significant difference 
was defined as when p-value < 0.05. The number of animals required for the study 
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was determined by power calculations (78) using data from previous studies 
conducted in the department. In particular, for CS-exposed rats, the Lm were 
31.28±1.75 μm vs. 19.79±0.81 μm for CS and SA groups (n=9) in a previous report 
(52). Based on this change, the maximal number of animals to attain statistical 
significance of p<0.01 with a 95% probability equated to 6. Considering possible loss 
of animals during experimental period, n=8 was chosen for the rat experiments. For 
the ozone-exposed mice, -logPC100 was reported to be 1.059±0.127 vs. 2.088±0.136 
for ozone and air groups (n=8) respectively (275). Based on these data, the maximal 
number of animals to attain statistical significance of p<0.01 with a 95% probability 
equated to 5. n=5-6 was chosen for the mouse study. 
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Chapter 3. iPSC-MSCs Attenuate CS-induced 
Damage in Airway Epithelial Cells through 
Mitochondrial Transfer and Paracrine Effect 
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3.1. Introduction 
Cigarette smoke (CS) is the primary cause of chronic obstructive pulmonary 
disease (COPD) (23, 39). In the first part of this study a rat model of chronic exposure 
to CS was used to study the effects of BM-MSCs and iPSC-MSCs on CS-induced 
alterations of lung regarding emphysema, fibrosis, inflammation, apoptosis and 
proliferation. Male SD rats were exposed to 4% CS for 1 hour/day for 56 consecutive 
days. 3x10
6
 of BM-MSCs or iPSC-MSCs were intravenously administrated at day 29 
and 43. A control group exposed to sham air (SA) was included. 
Despite numerous reports of MSCs‟ effectiveness in diverse disease models, the 
mechanism of MSCs‟ action remains unresolved (270). A major breakthrough was the 
report of mitochondrial transfer from BM-MSCs to pulmonary alveoli which 
protected mice against acute lung injury (118). In this study I hypothesized that a 
similar phenomenon also existed in the CS-exposed model. The results demonstrated 
mitochondrial transfer in vivo from BM-MSCs or iPSC-MSCs to the local cells of 
CS-exposed lung tissue. The in vivo findings were followed by in vitro studies on 
such activity in a co-culture of MSCs and bronchial epithelial cells (BEAS-2B) 
treated with CSM. The mitochondrial transfer was determined through fluorescent 
microscope and flow cytometry, and the effect on ATP depletion was also examined.  
Although mitochondrial transfer may be a potent way to rescue damaged cells, 
such action requires direct cell contact and is therefore restricted to small regions 
around the MSCs. On the other hand, MSCs have been reported to induce paracrine 
effects via release of various immunomodulators, such as TGF-β1, hepatic growth 
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factor, prostaglandin E2, interleukin (IL)-10 and nitric oxide (2, 235, 270). The 
paracrine effect can be effective in a large radius from MSCs as it does not rely on 
direct cell-cell contact. Therefore I further investigated the effects of the paracrine 
factors released from MSCs in an in vitro model using bronchial epithelial cells. In 
particular, the role of stem cell factor (SCF) secreted from MSCs, a growth factor that 
can mediate cell survival, migration, and proliferation was examined (146). BEAS-2B 
cells were treated with conditioned medium (CdM) from BM-MSCs or iPSC-MSCs to 
test a general paracrine effect on apoptosis and proliferation. SCF was then depleted 
from CdM for a more specific investigation on the role of SCF in the CdM. 
 The aims of the study include: 
1. To examine the effect of iPSC-MSCs on CS-induced lung damage in a chronic 
CS-exposed rat model compared with BM-MSCs. 
2. To determine whether there is mitochondrial transfer from iPSC-MSCs to 
CS-damaged airway epithelial cells both in vivo and in vitro. 
3. To investigate the involvement of paracrine regulation on the protective effects of 
iPSC-MSCs on CSM-induced apoptosis in bronchial epithelial cells by using 
conditioned medium (CdM), and to specifically determine the role of a potential 
functional molecule, namely stem cell factor (SCF). 
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3.2. Effects of iPSC-MSCs on CS-induced lung damage in 
rats. 
3.2.1. iPSC-MSCs attenuated CS-induced airspace enlargement, fibrosis and 
inflammation in rat lung  
Emphysema is one of the major characteristics of COPD. In this study, airspace 
enlargement in the CS-exposed rat lung was assessed by histological examination 
after haematoxylin and eosin staining. CS exposure caused obvious alveolar 
destruction (Figure 3.1A), leading to a much longer mean linear intercept (Lm) (60 ± 
4.6 μm) compared to the SA group (31.0±2.3 μm, p<0.001) (Figure 3.1B). The 
airspace enlargement was attenuated by the BM-MSCs treatment (Figure 3.1A), with 
a significantly reduced Lm compared with the CS group (48.0±4.0 μm, p<0.01) 
(Figure 3.1B). Treatment with iPSC-MSCs also attenuated alveolar wall destruction 
(Figure 3.1A), leading to significant reduction in Lm compared to the CS group 
(40.0±2 μm, p<0.05). Moreover, the treatment with iPSC-MSCs was more effective 
than BM-MSCs, as indicated by a shorter Lm value (p < 0.05) (Figure 3.1B). 
 CS also induced airway fibrosis compared to the SA group, as shown by the 
Masson's Trichrome staining (Figure 3.2) (5±0.13% vs. 0.98±0.09%, p < 0.05). 
Fibrosis was reduced by both BM-MSCs (3.85±0.17%, p < 0.05) and iPSC-MSCs 
treatment (2.37±0.12%, p < 0.05), and iPSC-MSCs demonstrated superior effect 
compared to BM-MSCs (p < 0.05) (Figure 3.2). 
The inflammation induced by CS in lung tissues was illustrated by 
immunohistochemistry staining against CD68, a transmembrane glycoprotein highly 
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expressed by monocytes and tissue macrophages (26) (Figure 3.3A). CS exposure 
significantly elevated the number of CD68-positive cells compared to SA group 
(21.3±1.9 vs. 2.0±0.41%; p<0.01) (Figure 3.3B). Both treatments of iPSC-MSCs and 
BM-MSCs significantly reduced the number of CD68-positive cells compared to the 
CS group (4.3±0.8% for iPSC-MSCs and 12.3±1.3% for BM-MSCs respectively; 
p<0.01) with a superior effect seen iPSC-MSCs (p<0.01) (Figure 3.3B).   
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Figure 3.1 Human iPSC-MSCs and BM-MSCs alleviated CS-induced airspace 
enlargement in rats. (A) Histological assessment of lung sections stained with 
haematoxylin and eosin at 10x magnification. Scale bar = 100 μm. (B) Morphometric 
analysis of mean linear intercept (Lm) (n=8). *p<0.05 compared with SA group; 
#
p<0.05 compared with CS group;
 †
p<0.05 compared with BM-MSCs group.  
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Figure 3.2 BM-MSCs and iPSC-MSCs attenuated CS-induced lung fibrosis in 
rats. (A) Masson's trichrome staining of lung sections. Blue staining indicates site of 
fibrosis. 40x magnification. Scale bar = 50 μm. (B) Percentage of bronchioles with 
fibrosis (n=8). *p<0.05 compared to SA group; 
#
p<0.05 compared to CS group;
 
†
p<0.05 compared to BM-MSCs group. 
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Figure 3.3 BM-MSCs and iPSC-MSCs ameliorated CS-induced inflammation in 
rat lungs. (A) Illustration of monocytes/macrophages as CD68 positive cells with 
brown staining. (B) Number of CD68 positive cells in lung sections (n=6-8). 
**p<0.01 compared to SA group; 
##
p<0.01 compared to CS group; 
††
p<0.01 compared 
to BM-MSCs group. 
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3.2.2. iPSC-MSCs attenuated CS-induced apoptosis/proliferation imbalance in 
rat lung epithelium. 
To illustrate apoptosis in the epithelium, lung sections were co-stained with the 
TUNEL assay which labels apoptotic cells, and Clara cell 10-kDa protein (CC-10) 
which is a marker of epithelium (Figure 3.4A). CS exposure induced increased 
apoptosis in lung epithelium (5.2±0.7% vs. 0.4±0.2%; p<0.01), which was attenuated 
by both BM-MSCs (3.4±0.5%; p<0.01 in comparison to CS group) and iPSC-MSCs 
(2.0±0.6%; p<0.01 in comparison to CS group) (Figure 3.4B). The treatment of 
iPSC-MSCs was more effective than BM-MSCs group (p<0.01) (Figure 3.4B). 
CS exposure also led to reduction of proliferation in the epithelium, which was 
shown by co-staining against CC-10 and Ki-67, a marker of cell proliferation (221) 
(Figure 3.4A). CS exposure significantly reduced the number of proliferating cells in 
the epithelium (5.5±0.5% vs. 25.8±2.8%; p<0.01), which was improved by the 
treatment with either BM-MSCs (11.2±0.8%; p<0.01 in comparison to CS group) or 
iPSC-MSCs (15.2±2.3%; p<0.01 in comparison to CS group) (Figure 3.4B). The 
iPSC-MSCs group demonstrated higher proliferation activity than the BM-MSCs 
group (p<0.01) (Figure 3.4B). 
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3.2.3. Mitochondrial transfer from MSCs to adjacent lung cells 
The epithelium in the rat lung was stained with CC-10, and mitochondria in both 
MSCs and host cells were labeled with an antibody against human/rat Complex I. 
Meanwhile, human mitochondria were detected by staining using a human specific 
Cox-4 antibody (Figure 3.5A&B). For both BM-MSCs and iPSC-MSCs treatments, 
human mitochondria were detected inside some of the CC-10-expressing cells 
(Figure 3.5A&B), indicating events of mitochondrial adoption by the bronchial 
epithelium from the foreign human MSCs. With the same number of cells injected, 
rats treated with iPSC-MSCs demonstrated a higher number of cells receiving 
MSC-derived mitochondria than those treated with BM-MSCs (number/40x field: 
8.4 ± 1.6 vs. 4.6 ± 0.9, p< 0.05; Figure 3.5C).  
 
  
92 
 
 
Figure 3.4 BM-MSCs and iPSC-MSCs attenuated CS-induced increase in 
apoptosis and reduction of proliferation in rat lung epithelium. (A) Apoptotic 
cells in airway epithelium. Red (CC-10): airway epithelium; green (TUNEL): 
apoptotic cells; blue (DAPI): nuclei. (B) Proliferative cells in airway epithelium. 
Green (CC-10): airway epithelium, Red (Ki-67): proliferative cells; Blue (DAPI): 
nuclei. (C) Number of apoptotic cells in airway epithelium (n=6-8). (D) Number of 
proliferating cells in airway epithelium. **p<0.01 compared to SA;
 ##
p<0.01 
compared to CS; 
††
p<0.01 compared to BM-MSCs.  
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Figure 3.5 Mitochondria transfer from MSCs to lung epithelium in rats. Lung 
sections treated with (A) BM-MSCs and (B) iPSC-MSCs were co-stained against 
CC-10 (red) marking lung epithelium, human/rat Complex I (green) labeling 
human/rat mitochondria and human Cox-4 (violet) detecting human mitochondria 
specifically. Co-localization of three signals indicates receiving of human 
mitochondria by lung epithelium of rats. Scale bar = 50 μm. (C) Number of cells 
receiving foreign mitochondria in 40x fields. *p<0.05 compared between iPSC-MSCs 
and BM-MSCs groups. 
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3.3. Mitochondrial Transfer from MSCs to BEAS-2B cells in 
vitro 
3.3.1. Mitochondrial transfer from MSCs to BEAS-2B cells 
Mitochondrial transfer was further investigated in an in vitro co-culture model in 
the context of CSM treatment. According to a previous report, treatment of 2% CSM 
for 24 hours induces a significant inflammatory response and oxidative stress without 
loss of viability in human bronchial epithelial BEAS-2B cells (143). This condition 
was adopted in the co-culture study. BEAS-2B cells were pre-labeled with CellTrace 
Violet while mitochondria of BM-MSCs or iPSC-MSCs were pre-labeled with 
MitoTracker Green. BEAS-2B cells were then co-cultured with either BM-MSCs or 
iPSC-MSCs in a 1:1 ratio and treated with 2% CSM for 24 hours. The 
MitoTracker-labeled mitochondria which originated from the MSCs were observed in 
neighboring BEAS-2B cells, indicating that mitochondria transferred from MSCs to 
BEAS-2B cells within 24 hours (Figure 3.6A&B). Moreover, formation of tunneling 
nanotube (TNT)-like structures between the MSCs and BEAS-2B cells was identified 
after 24 hours (Figure 3.6A&B). The formation of TNTs was reported to be blocked 
by Cytochalasin B at nanomolar concentrations without affecting endocytosis and 
phagocytosis (40). In this study, when 300 nM of cytochalasin B was added to the 
co-culture together with the CSM, the formation of TNTs was highly inhibited and 
few MSCs-derived mitochondria were observed in BEAS-2B cells (Figure 3.6 C&D), 
indicating that that mitochondrial transfer may be mediated through TNTs. 
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Figure 3.6 Mitochondrial transfer from BM-MSCs and iPSC-MSCs to BEAS-2B 
cells in co-culture. (A) BM-MSCs or (B) iPSC-MSCs pre-stained with MitoTracker 
Green and BEAS-2B cells pre-labeled by CellTrace Violet were co-cultured in a 1:1 
ratio and treated with 2% CSM for 24 hours. The observation of MitoTracker Green 
in the BEAS-2B cells (Blue) indicated the adoption of MSCs-derived mitochondria by 
BEAS-2B cells. Connection between the cells through TNT-like structures was 
observed. Treatment of Cytochalasin B suppressed the formation of TNT-like 
structures and mitochondrial transfer in both (C) BM-MSCs and (D) iPSC-MSCs 
group. Scale bar = 20 μm. B2B: BEAS-2B cells; DIC: differential interference 
contrast. A representative image from three independent experiments is shown. 
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3.3.2. CSM promoted mitochondrial transfer from MSCs to BEAS-2B cells 
In addition to fluorescent microscopy, mitochondrial transfer in the co-culture 
was further evidenced by flow cytometry at different time-points. The percentage of 
CellTrace/MitoTracker double positive cells in the whole CellTrace positive 
population was defined as the transfer rate (Figure 3.7A). There were three findings 
from this experiment. First, the transfer rate gradually increased along the co-culture 
period in both BM-MSCs and iPSC-MSCs groups. Second, after 24 hours, the 
iPSC-MSCs group demonstrated a higher transfer rate compared with the BM-MSCs 
group (38.8±2% vs. 27.8±1.6%, p<0.05), suggesting a higher potential for 
mitochondrial transfer between iPSC-MSCs and BEAS-2B cells. Lastly, at the 24 
hour time-point, CSM treatment significantly increased the transfer rate compared to 
the untreated group, both for the BM-MSCs co-culture (27.8±1.6% vs. 14.4±1%, p< 
0.05) and iPSC-MSCs co-culture (38.8±2% vs. 18±1.9%, p<0.05), suggesting that 
mitochondrial transfer is promoted in the presence of CSM.  
 
3.3.3. Co-culture with iPSC-MSCs elevated ATP levels in BEAS-2B cells 
Given the observation of mitochondrial transfer in the co-culture, the effect of 
co-culture with BM-MSCs and iPSC-MSCs on intracellular ATP levels in BEAS-2B 
cells was investigated. BEAS-2B cells were identified from the co-culture followed 
by determination of intracellular ATP levels. The 2% CSM treatment for 24 hours 
significantly reduced the intracellular ATP level (percentage of control: 76.5 ±3.5% vs. 
100 ±10.1%, p<0.05) (Figure 3.8). The drop of ATP level was restored by co-culture 
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with iPSC-MSCs (percentage of control: 97.8 ±9.1% vs. 76.5 ±3.5% for iPSC-MSCs 
and CSM group respectively, p<0.05), but not the BM-MSCs (percentage of control: 
80.7 ± 7.1%) (Figure 3.8). 
 
 
Figure 3.7 CSM promoted mitochondrial transfer. (A) Representative flow 
cytometry outcome of single culture of MSCs (left), BEAS-2B cells (middle) and 
co-culture (right). BM-MSCs or iPSC-MSCs pre-labeled with MitoTracker Green and 
BEAS-2B cells pre-labeled with CellTrace Violet were co-cultured at a 1:1 ratio in 
the presence of 2% CSM. (B) Effects of time, CSM and cell type on mitochondrial 
transfer rate (n=3).Transfer rate was defined as the percentage of BEAS-2B cells 
containing MSCs-derived mitochondria in the total BEAS-2B population. W/O stands 
for CSM untreated group while other groups were treated with 2% CSM for 24 hours. 
*p<0.05 represents statistical difference as indicated. 
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Figure 3.8 iPSC-MSCs restored intracellular ATP levels of BEAS-2B cells.  
BEAS-2B cells were co-cultured with MSCs with 2% CSM for 24 hours before sorted 
out through flow cytometry and determination of intracellular ATP levels (n=3). 
*p<0.05 compared to control group; 
#
p<0.05 compared to CSM group; 
†
p<0.05 
compared to BM-MSCs group. 
 
 
3.4. iPSC-MSCs Attenuated CSM-induced Apoptosis and 
Proliferation Imbalance in BEAS-2B Cells by Paracrine 
Effect 
3.4.1. iPSC-MSCs-CdM attenuates CSM-induced apoptosis in BEAS-2B cells 
Conditioned medium (CdM) from BM-MSCs and iPSC-MSCs contains paracrine 
factors released from the MSCs accumulated over 24 hours. Thus the effects of 
MSCs-CdM on BEAS-2B cells were investigated in order to study the paracrine effect. 
BEAS-2B cells were treated with 2% CSM and CdM for 24 hr. The release of 
cytochrome c from mitochondria and its translocation to nucleus (Figure 3.9A) is a 
major event in triggering the onset of apoptosis (184, 211). CSM elevated the 
percentage of cells with cytochrome c translocation compared to the untreated group 
99 
 
(73.4±6.8%vs. 1.88±1%; p<0.01), which was attenuated by both BM-MSCs-CdM 
(41.2±6.3%; p<0.01 in comparison to CSM group) and iPSC-MSCs-CdM (16.6±5%; 
p<0.01 in comparison to CSM group) (Figure 3.9D). iPSC-MSCs-CdM exhibited a 
superior effect compared with to BM-MSCs-CdM (p<0.01) (Fig. 3.9D). In addition, 
cellular apoptosis was identified by TUNEL staining (Figure 3.9B). CSM elevated the 
percentage of apoptotic cells (16.2±2% vs. 1.4±0.4%; p<0.01), which was attenuated 
by both BM-MSCs-CdM (9.3±0.7%; p<0.01 in comparison to CSM group) and 
iPSC-MSCs-CdM (5.5±0.5%; p<0.01 in comparison to CSM group) (Figure 3.9E). 
There were fewer apoptotic cells in the iPSC-MSCs-CdM group compared to 
BM-MSCs-CdM group (p<0.01), suggesting a better anti-apoptotic activity of 
iPSC-MSCs-CdM.  
While apoptosis was enhanced, the percentage of proliferating cells was reduced 
by the 2% CSM (3.4±0.5% vs. 19.2±0.8%; p<0.01) as determined by staining against 
Ki-67 (Figure 3.9C&F). This reduction was improved by both BM-MSCs-CdM 
(8.2±0.6%; p<0.01 in comparison to CSM group) and iPSC-MSCs-CdM (13.4±0.5%; 
p<0.01 in comparison to CSM group) (Figure 3.9F), in which iPSC-MSCs-CdM 
demonstrated a more potent effect (p<0.1) (Figure 3.9F), indicating a higher ability to 
promote cell proliferation.  
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Figure 3.9 CdM from BM-MSCs and iPSC-MSCs ameliorated CSM-induced 
apoptosis/proliferation imbalance in BEAS-2B cells. BEAS-2B cells were treated 
with 2% CSM and BM-MSCs-CdM or iPSC-MSCs-CdM for 24hr. (A) Cytochrome c 
translocation in BEAS-2B cells. Green: cytochrome c; blue: DAPI. Cells with 
cytochrome c translocation to nuclei are marked by red arrows. (B) Apoptotic 
BEAS-2B cells as stained by TUNEL. Green: TUNEL; blue: DAPI. (C) Proliferative 
BEAS-2B cells as marked by Ki-67. Red: Ki-67; blue: DAPI. (D) Percentage of 
BEAS-2B cells with cytochrome c translocation (n=3). (E) Percentage of apoptotic 
BEAS-2B cells (n=3). (F) Percentage of proliferative BEAS-2B cells. **p<0.01 
compared to control group;
 ##
p<0.01 compared to CSM group; 
††
p<0.01 compared to 
BM-MSCs-CdM group.  
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3.4.2. Effects of iPSC-MSCs-CdM on apoptosis and proliferation of BEAS-2B 
cells were SCF-dependent 
Given the superior effects of iPSC-MSCs-CdM over BM-MSCs-CdM regarding 
apoptosis and proliferation, the active components responsible for such effects were 
further investigated. In particular, the role of SCF was examined in my model. 
First of all, the levels of SCF in CdM were measured, showing that 
iPSC-MSCs-CdM contains a much higher level of SCF than BM-MSCs-CdM 
(518±57 vs. 113±13 pg/mg protein; p<0.01) (Figure 3.10A). The expression of SCF 
receptor, C-kit, by BEAS-2B cells was confirmed by both immunohistochemistry 
staining and Western blotting (Figure 3.10B) which showed that the level of C-kit was 
not changed by CSM treatment (Figure 3.10B).  
To investigate the role of SCF, SCF-deprived iPSC-MSCs-CdM was generated by 
incubation with immobilized anti-SCF antibody. Effects of iPSC-MSCs-CdM, 
SCF-deprived iPSC-MSCs-CdM and recombinant SCF were evaluated on BEAS-2B 
cells treated with 2% CSM for 24 hours. All three treatments attenuated CSM-induced 
morphological change (Figure 3.11A), cytochrome c translocation (22.0±2.1%, 
42.4±2.5% and 41.8±1.9% respectively, p<0.01 in comparison to CSM group, 
74.8±2.9%) (Figure 3.11BE), apoptosis (5.6±0.5%, 10.4±0.5% and 10.2±1.0% 
respectively, p<0.01 in comparison to CSM group, 20±1.7%) (Figure 3.11CF) and 
reduction of proliferation (15.4±0.5%, 11.0±0.5% and 11.0±0.9% respectively, p<0.01 
in comparison to the CSM group, 5.8±0.4%) (Figure 3.11DG). Compared to the 
normal iPSC-MSCs-CdM treatment, depletion of SCF in the CdM resulted in 
102 
 
significantly weakened activity, as shown by more cytochrome c translocation 
(p<0.01), more apoptosis (p<0.01) and less proliferation (p<0.01). This finding, in 
combination with the result that recombinant SCF was able to induce considerable 
effects by itself, indicated that SCF contributed to the activity of iPSC-MSCs-CdM. 
Similarly, the recombinant SCF were less effective than iPSC-MSCs-CdM regarding 
cytochrome c translocation (p<0.01), apoptosis (p<0.01) and proliferation (p<0.01). 
Given that the deprived iPSC-MSCs-CdM still retained some capacity to restore all 
three parameters, this finding indicated that in addition to SCF, there were other 
components promoting similar effects. In summary, the data suggested that the action 
of iPSC-MSCs-CdM to alleviate CSM-induced apoptosis/ proliferation imbalance was 
partly through SCF. 
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Figure 3.10 Secretion of SCF by BM-MSCs and iPSC-MSCs and expression of 
C-kit by BEAS-2B cells. (A) SCF levels in CdM from BM-MSCs or iPSC-MSCs as 
measured by ELISA (n=3). (B) Expression of C-kit in BEAS-2B cells.  C-kit 
expression was identified by immunohistostaining (i) with or (ii) without 2% CSM 
treatment for 24 hours, and by (iii) Western blotting. Red: C-kit; blue: DAPI. 
**p<0.01 compared to BM-MSCs-CdM. 
  
A 
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Figure 3.11 The anti-apoptotic and pro-proliferation activity of 
iPSC-MSCs-CdM was partly through SCF. Immobilized anti-SCF antibody was 
used to scavenge SCF from iPSC-MSCs-CdM. BEAS-2B cells were treated with 2% 
CSM and iPSC-MSCs-CdM for 24 hours before fixation and TUNEL staining or 
immunostaining against cytochrome c and Ki-67 (n=3). (A) The morphological 
change of the BEAS-2B cells. DIC: differential interference contrast. (B) Cytochrome 
c translocation in BEAS-2B cells. Green: cytochrome c; blue: DAPI. Cells with 
cytochrome c translocation to nuclei are marked by red arrows. (C) Apoptotic 
BEAS-2B cells as stained by TUNEL. Green: TUNEL; blue: DAPI. (D) Proliferative 
BEAS-2B cells as marked by Ki-67. Red: Ki-67; blue: DAPI. (E) The percentage of 
BEAS-2B cells with cytochrome c translocation to nuclei (n=3). (F) The apoptotic 
rate of BEAS-2B cells (n=3). (G) Percentage of proliferative BEAS-2B cells (n=3). 
**p<0.01 compared to control group;
 ##
p<0.01 compared to CSM group; 
††
p<0.01 
compared to normal iPSC-MSCs-CdM group.  
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3.5. Discussion 
This study elucidated that iPSC-MSCs are more effective than BM-MSCs in 
attenuating CS-induced alterations in rat lungs. The higher efficacy may be explained 
by a higher activity of mitochondrial transfer, which was evidenced in vivo and 
further confirmed by in vitro co-culture study. Meanwhile, the higher efficacy may 
also be attributed to more potent paracrine effects, partly through SCF. 
MSCs isolated from BM (94, 112), amniotic fluid (151) and adipose tissue (222) 
have been reported to attenuate CS-induced emphysema in murine models. These 
MSCs are isolated directly from adult tissue, hence relevant patient tissues such as 
bone marrow and adipose tissue need to be obtained to collect them. The technique to 
differentiate iPSCs into MSCs provides a different source of MSCs, which has several 
advantages over classic MSCs. Firstly, large quantities of iPSC-MSCs can be 
generated from a small number of somatic cells which can be of a number cell types 
such as fibroblasts. In other words, the supply of iPSC-MSCs is unlimited and 
personalised. Secondly, iPSC-MSCs have a strong capacity of proliferation and 
differentiation, with differentiation potential maintained for over 120 population 
doublings (152), while normal MSCs may reach senescence after 20 doublings (69). 
Thirdly, impaired survival and differentiation ability may be associated with MSCs 
isolated from aged subject or patients with ageing-related disorders (87, 100, 267, 
294). However, iPSC-MSCs may hold hope to overcome these issues because when 
deriving iPSC-MSCs, somatic cells are firstly reprogrammed to an embryonic stem 
cell-like state, which may provide the cells with a rejuvenated phenotype. Therefore 
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iPSC-MSCs are valuable candidates for the development of cell therapy against 
COPD whose prevalence, morbidity, and mortality are all highly associated with age 
(38, 126, 137). Regarding airway disease models, iPSC-MSCs have been reported to 
attenuate allergic airway inflammation in mice (244). 
The first part of this study evaluated a general effect of iPSC-MSCs on 
CS-induced lung alterations in rats. The parameters included emphysema, fibrosis, 
inflammation, apoptosis and proliferation. My results show that, iPSC-MSCs 
demonstrated a better effect regarding each of the parameters in comparison to those 
elicited in response to treatment with BM-MSCs. In fact, as far as iPSC-MSCs can 
produce comparable effects to BM-MSCs, due to iPSC-MSCs‟ advantages regarding 
the resource and ageing issue, they would at the outset be a better candidate than the 
BM-MSCs. The superior efficacy over BM-MSCs further defined iPSC-MSCs as a 
promising candidate. Moreover, for the BM-MSCs, a placebo-controlled, randomized 
clinical trial in COPD subjects has already been reported (271). The trial observed no 
toxicity caused by the treatment. However, there were also no effects regarding both 
pulmonary function and indicators of quality-of-life. It did reveal some potential 
anti-inflammatory activity though, as the treatment decreased C-reactive protein (CRP) 
levels at an early stage. There were some limitations of the study including the 
determination of doses, but it still pointed out to the possibility that BM-MSCs might 
not work in the clinical setting, despite the clear efficacy demonstrated in animal 
models. From our study, iPSC-MSCs are much more effective than BM-MSCs in the 
rat model. Therefore the possible failure of BM-MSCs in the clinical context will not 
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necessarily indicate a failure of iPSC-MSCs. Instead, it will call for improved MSCs 
therapies, which makes study of iPSC-MSCs even more worthwhile and important. 
However, on the other hand, the clinical study also revealed the difference between 
animal models and diseased subjects, thus the effects of iPSC-MSCs in the clinical 
context are not predictable. 
Despite numerous reports of MSCs‟ effectiveness in diverse disease models, the 
mechanism of MSCs‟ action remains unresolved (270). A major breakthrough is the 
report of that in vivo mitochondrial transfer from BM-MSCs into pulmonary alveoli 
protect the lung against lipopolysaccharide-induced acute lung injury (118), 
illustrating a new mechanism of MSCs‟ action. However, mitochondrial transfer in the 
context of CS-induced lung damage was unknown. This study demonstrated that 
BM-MSCs and iPSC-MSCs could effectively transfer mitochondria to CS-damaged 
lung epithelial cells, similar to sending in a “Trojan horse”. This is one of the very 
early demonstrations of such activity following the first report in the acute lung injury 
model mentioned above. Although the signaling that drives the MSCs to transfer 
mitochondria for rescue of lung epithelial cell was unknown, in vitro formation of 
TNTs was observed between MSCs and bronchial epithelial cells. The interruption of 
TNT formation by cytochalasin B almost completely blocked mitochondrial transfer, 
suggesting that mitochondria might be transferred via TNTs in vitro. Such 
TNT-mediated mitochondrial transfer between MSCs and damaged lung epithelial 
cells might be an important mechanism through which the exhausted epithelial 
cellular bioenergetics can be restored and damaged lung epithelium be rejuvenated. 
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Bronchial epithelial cells were chosen for the in vitro study because they act as 
the first barrier against CS exposure. The inflammation and oxidative stress in COPD 
was initiated by the bronchial epithelial cells‟ response to CS-exposure such as 
expression of cell injury–associated endogenous molecules and secretion of 
inflammatory mediators including TNF-α and IL-8 (190). Mitochondria are mostly 
known as the powerhouse of the cell. In patients with COPD, decreased energy 
metabolism is associated with declining lung function (285). Given the observation of 
mitochondrial transfer from MSCs to bronchial epithelial cells, the effect of MSCs on 
the cellular bioenergetics was studied by measuring the ATP level. The CSM 
treatment reduced ATP levels of bronchial epithelial cells, which was alleviated by 
co-culture with iPSC-MSCs, indicating improvement in bioenergetics. Such activity 
was coupled with CSM-induced enhancement of mitochondrial transfer from 
iPSC-MSCs to bronchial epithelial cells, which may be the source of the restored 
bioenergetics. Moreover, iPSC-MSCs have demonstrated a more active role in 
mitochondrial transfer in both in vivo and in vitro experiments, which may contribute 
to the higher efficacy of iPSC-MSCs in attenuating CS-induced lung alterations. 
The limitation of mitochondrial transfer is its working radius. Relying on direct 
contact between iPSC-MSCs and pulmonary cells, the primary effects of 
mitochondrial transfer might be only effective within a limited distance from the 
iPSC-MSCs. Although the retention of the iPSC-MSCs were identified even two 
weeks after injection based on our previous study (150), it is unlikely that all the cells 
in the lungs would have the opportunity to directly adopt mitochondria from them. 
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The full activity of the MSCs may be better explained with a complementary 
mechanism that overcomes the restriction imposed by the distance between cells, 
namely, the paracrine effect. The paracrine effect of MSCs has been documented in 
various studies, with different active factors identified, such as vascular endothelial 
growth factor, TGF-β1, hepatic growth factor, bFGFr and platelet derived growth 
factor (2, 235, 270). In this study the potential of paracrine effects was demonstrated 
by treating bronchial epithelial cells with CdM in vitro. The treatment of CSM led to 
increased apoptosis and reduced proliferation in bronchial epithelial cells in vitro, 
resulting in an imbalance between apoptosis and proliferation. CdM restored the 
imbalance by reducing the apoptotic rate and promoting proliferation. The 
iPSC-MSCs-CdM was superior than BM-MSC-CdM regarding all the observed 
effects. From the in vivo data discussed earlier, iPSC-MSCs have shown superior 
effects than BM-MSCs in attenuating apoptosis and promoting proliferation in rat 
lung epithelium. The in vivo and in vitro findings together suggested a better 
anti-apoptotic and pro-proliferation capacity of iPSC-MSCs through paracrine action. 
There are two reasons for studying the effects on apoptosis. Firstly, most studies 
on paracrine effects have focused on the immunoregulatory role (e.g. suppression of 
inflammation) of MSCs, which is therefore well demonstrated by previous reports (2, 
235, 270). In contrast, the modulation of apoptosis by the CdM is less well 
investigated. Secondly, there is mounting data suggesting that the gradual alveolar 
destruction in COPD pathogenesis may be partly driven by imbalance between 
apoptosis and proliferation (67), although classically it is explained by the imbalance 
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of protease and anti-protease activity (68, 76, 77, 189). Apoptosis and proliferation are 
well equilibrated in healthy tissue. The induction of apoptosis by CS has been 
reported in various cell types of lung, such as endothelial cells, alveolar epithelial 
cells, fibroblasts and immune cells (16, 103, 116, 127, 166, 223). Excess apoptosis in 
alveolar cells without compensation from proliferation led to the gradual destruction 
of alveolar walls in lung (67). Apoptosis of alveolar wall and endothelial cells was 
reported to induce emphysema even without infiltration of inflammatory cells in an 
animal model (67). Therefore the anti-apoptotic and pro-proliferation potential might 
identify a key capacity of iPSC-MSCs as a promising candidate for cell therapy 
development against COPD. 
Given the effects of CdM on apoptosis and inflammation, the active component 
of CdM was the next research question. SCF, a dimeric protein, triggers 
homodimerization and autophosphorylation of its receptor c-Kit upon binding, which 
further activates diverse pathways involving cell survival, migration, and proliferation 
(146). In addition to its ability to induce proliferation, SCF/c-Kit may also affect 
apoptosis through down-stream activation of the serine/threonine kinase Akt (35). Akt 
subsequently phosphorylates and inhibits pro-apoptotic protein Bad which regulates 
the cytochrome c release from the mitochondria through Bcl-2/Bax signalling (35, 
265, 283). Despite of a lack of understanding regarding the mechanism, the SCF/c-Kit 
signalling has been proved essential to maintain normal alveolar structure in mouse 
lung. Deficiency in SCF/c-Kit signalling was reported to cause spontaneous alveolar 
destruction, increased ex vivo lung compliance and enlarged residual volume in mice 
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(157). Given its important role in proliferation/apoptosis regulation and maintaining 
alveolar structure, this study targeted SCF as a potential active component in CdM. 
SCF alone was able to attenuate CSM-induced cytochrome c translocation, apoptosis 
and reduction in proliferation, indicating its anti-apoptotic and pro-proliferative 
activity. Meanwhile, SCF depletion led to a weakened ability of iPSC-MSCs-CdM to 
attenuate CSM-induced cytochrome c translocation, apoptosis and reduction in 
proliferation, indicating that SCF played an important role in the action of 
iPSC-MSCs-CdM. However, the data also showed that SCF alone was less effective 
than iPSC-MSCs-CdM, and that SCF depletion only weakened but did not eliminate 
the efficacy of iPSC-MSCs-CdM, suggesting that the action of iPSC-MSC-CdM was 
only partly dependent on SCF. Moreover, iPSC-MSCs secreted much higher levels of 
SCF than BM-MSCs, which may explain its superior anti-apoptotic and 
pro-proliferation effects through paracrine action. 
From the above discussion, this study has demonstrated two possible mechanisms 
through which the iPSC-MSCs protect lung epithelial cells against CS-induced 
damage. However, the relative importance of each mechanism was not evaluated in 
the study. As mitochondrial transfer was limited by distance, the total therapeutic 
effects of the treatment strongly rely on the number of MSCs retained in the lung 
tissue. However, the ability of the MSCs to be retained in the lung varies between 
different reports. From our previous study in the CS-exposed model, clusters of MSCs 
were identified even two weeks after injection. Similarly, adipose stem cells have 
been reported to be retained in lung tissue in CS-exposed model after 7 days or 21 
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days (222). However, in another study using BM cells in CS-exposed female rats, 
fluorescent in situ hybridization (FISH) only found 2-13 male BM cells per entire 
lung from 1 day to 1 month (112). The factors that determine this retention ability 
remain unknown, and such factors would also be key to give mitochondrial transfer 
higher importance in therapeutic action of MSCs. The paracrine effect, on the other 
hand, may be more effective when the retained MSCs are less abundant, as the effects 
might be initiated by low level secretion of relevant paracrine factors but amplified by 
signalling pathways in the responding cells. The MSCs in the circulation might also 
possess systemic effects through release of molecules into the circulation. However, 
regarding acute responses, the direct delivery of mitochondria seemed to be a more 
straightforward and immediate rescue, which may be why the mitochondrial transfer 
has been identified as such an important mechanism in the context of acute lung 
injury models where bioenergetics is rapidly impaired. 
There are nonetheless several limitations of this study, and more future research 
questions can be raised from current findings.  
First of all, for the general advantages discussed earlier, although the iPSC-MSCs 
may be able to overcome the age-related impairment of normal MSCs, its phenotype 
when derived from patients with genetic mutations/inherited diseases remains unclear. 
About 1-3% of COPD patients are associated with a genetic alteration which leads to 
deficiency of serine protease α-1 antitrypsin (241). There are also other genes 
suspected to be associated, such as TGF-β1 (47). 
The mitochondrial transfer was proposed as an important mechanism, but the 
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TNT may also facilitate the transfer of other organelles, proteins and compounds. For 
example, whether the ATP was directly transferred from MSCs to bronchial epithelial 
cells was not determined. In addition, other mechanisms for the transfer of material 
between cells may also play important roles, such as gap junction and microvesicles. 
Lastly, despite the identification of mitochondrial transfer via TNTs in vitro, the route 
of mitochondrial transfer in vivo was not demonstrated and requires further 
investigation. 
Regarding the paracrine effects, the CdM was collected from normal culture of 
BM-MSCs or iPSC-MSCs without any interactions with BEAS-2B cells. However, it 
is possible that CSM can induce BEAS-2B cells to release cytokines, which may act 
on MSCs and modulate secretory functions of MSCs. A trans-well co-culture with 
both cells in the same system may overcome this limitation in vitro.  
SCF has been identified to contribute to the anti-apoptosis and pro-proliferation 
action of iPSC-MSCs-CdM, but the depletion of SCF did not eliminate the effects. 
Therefore more active molecules remain to be determined.  
In summary, this study demonstrated that iPSC-MSCs attenuate CS-induced lung 
damage and observed evidence of mitochondrial transfer from iPSC-MSCs to lung 
epithelial cells. The higher activity to transfer mitochondria to CS-damaged bronchial 
epithelial cells in vitro and in vivo, in line with the higher anti-apoptosis and 
pro-proliferation capacity by paracrine effect partly due to more abundant SCF 
secretion, together explained the superior effects of iPSC-MSCs over BM-MSCs. This 
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study defines iPSC-MSCs as a promising candidate for the development of cellular 
therapy against COPD. 
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Chapter 4. iPSC-MSCs attenuated 
CSM-induced Mitochondrial Dysfunction in 
Human Airway Smooth Muscle Cells 
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4.1. Introduction 
There is an increasing interest in the role of mitochondria in the pathogenesis of 
airway diseases. Mitochondria, most well-known as the powerhouse of the cells, also 
play crucial roles in other cellular functions in addition to bioenergetic regulation, 
such as calcium metabolism, reactive oxygen species (ROS) modulation and onset of 
apoptosis (45, 90, 95, 212). As the site of oxidative phosphorylation, mitochondria are 
an important intracellular source of ROS. Defective oxidative phosphorylation may 
lead to overwhelming generation of ROS in mitochondria. Increased external and 
internal ROS production, without sufficient protection from anti-oxidants, leads to 
cellular oxidative stress, which is a key player in the pathogenesis of COPD (57). The 
effectiveness of MSCs has been demonstrated in multiple airway disease models 
including emphysema and allergic airway inflammation, but the underlining 
mechanisms remain unresolved (270). Given that mitochondria are a potential 
therapeutic target for airway diseases, investigating the effects of MSCs on oxidative 
stress-induced mitochondrial damage in airway cells may be of value. In this study I 
hypothesized that interaction with iPSC-MSCs can attenuate cigarette smoke medium 
(CSM)-induced mitochondrial damage in ASMCs. 
Recently, mitochondrial dysfunction has been reported in airway smooth muscle 
cells (ASMCs) isolated from patients with COPD (273), indicating that mitochondria 
may be a promising therapeutic target for COPD. Airway smooth muscle plays an 
important role in airway remodelling and inflammation (56). In addition to their 
contractile properties, ASMCs are also involved in airway inflammation by releasing 
117 
 
pro-inflammatory cytokines (10). The first part of this chapter aims to evaluate 
changes in mitochondrial function in normal ASMCs in response to oxidative stress. 
Cigarette smoke (CS), the primary cause of COPD, is a significant source of oxidants. 
Cigarette smoke extract was reported to alter the morphology of mitochondria in vitro 
in both airway epithelial cells (105) and ASMCs (10), leading to mitochondrial 
fragmentation. Therefore CSM was used in this study to induce mitochondrial damage. 
In addition, H2O2 was used as a direct source of oxidants. Mitochondrial ROS levels 
and ΔΨm were examined to evaluate changes in mitochondrial function.  
Mitochondria play a key role in the regulation of cell fate. The depolarization of 
mitochondria is regarded as an early event triggering mitochondrial apoptosis (90). 
Therefore, in the second part of this chapter I investigated the effects of co-culture 
with iPSC-MSCs on CSM-induced mitochondrial dysfunction and apoptosis in 
ASMCs. 
Paracrine regulation by MSCs is a widely reported mechanism through which 
MSCs can suppress inflammation (2, 235, 270) or attenuate apoptosis, as suggested in 
the previous chapter. The third part of this chapter aims to determine whether the 
effects of iPSC-MSCs on CSM-induced mitochondrial alterations were through 
secretion of paracrine factors. To investigate this, the effects of 
iPSC-MSCs-conditioned medium (iPSC-MSCs-CdM) on CSM-induced 
mitochondrial alterations were firstly examined. The contents of the 
iPSC-MSCs-CdM represented the paracrine factors secreted by iPSC-MSCs under 
normal conditions. However, in a real interaction, ASMCs may affect the iPSC-MSCs 
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and modulate the latter‟s synthetic and secretory functions. CSM may also affect the 
paracrine effects of iPSC-MSCs as well as the interaction between iPSC-MSCs and 
ASMCs. Therefore a study using a trans-well co-culture system was carried out in 
which the two cell types are separated by a membrane that is permeable to the 
paracrine factors but prevents direct cell-cell contact. 
Another recently reported mechanism of the action of MSCs is through 
mitochondrial transfer from MSCs to recipient cells, which was firstly described in 
vivo in an acute lung injury rodent model (118). In the previous chapter, mitochondrial 
transfer from iPSC-MSCs to airway epithelial cells was observed in CS-exposed rat 
lungs and CSM-treated bronchial epithelial cells. However, the effect of 
mitochondrial transfer on markers of mitochondrial damage was not studied. In the 
final part of this chapter, I studied mitochondrial transfer between ASMCs and 
iPSC-MSCs using fluorescent microscopy and flow cytometry. 
The aims of this chapter were: 
1. To evaluate oxidative stress-induced mitochondrial dysfunction in human primary 
ASMCs 
2. To examine the capacity of iPSC-MSCs to reduce CSM-induced mitochondrial 
dysfunction and apoptosis in ASMCs 
3. To evaluate the relative contributions of paracrine effects and cell-cell contact in 
the protective effects of iPSC-MSC‟s on mitochondrial dysfunction and apoptosis 
in ASMCs 
4. To investigate mitochondrial transfer from iPSC-MSCs to ASMCs 
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4.2. Oxidative Stress-induced Mitochondrial Dysfunction in 
ASMCs and iPSC-MSCs 
4.2.1. Oxidative stress reduced the viability of ASMCs 
Normal ASMCs isolated from bronchi or tracheas of healthy transplant donor 
lungs were treated with H2O2 (50, 100 and 200 μM) or CSM (10, 25, 50 and 75%) for 
2, 4 and 24 hours. In the 4/20 hour group cells were stimulated for 4 hours and then 
incubated with serum-free medium for 20 hours. Cell viability was measured by MTT 
assay. H2O2 led to a concentration-dependent reduction in viability at each time point 
(Maximum reduction at 200 μM, fold-change vs. controls: 2 hours, 0.70±0.05, 
p<0.001; 4 hours, 0.62 ±0.02, p<0.001; 24 hours, 0.62 ±0.06, p<0.01; 4/24 hours, 0.59 
±0.06, p<0.001) (Figure 4.1A). A similar effect was observed at all time points.  
CSM also caused loss of viability in a concentration-dependent manner at 2 hours, 
4 hours and 24 hours (Maximum effects at 75% CSM, fold-change vs. controls: 2 
hours, 0.88±0.04, p<0.01; 4 hours, 0.81±0.07, p<0.01; 24 hours, 0.57±0.13, p<0.05) 
(Figure 4.1B). However, no significant reduction in viability was observed in the 4/20 
hours group (fold to control, 75% CSM: 0.93±0.15). Moreover, the 75% CSM 
treatment led to a significantly lower viability at 24 hours compared with the viability 
at 2 hours (p<0.05) or 4 hours (p<0.05), indicating that the effect of 75% CSM was 
time-dependent.  
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MTT assay is based on NAD(P)H-dependent reductive reactions catalyzed by 
oxidoreductases in cells (30-32). Mitochondria are one of the major carriers of such 
enzymes, thus the reduction of MTT readout may be a reflection of mitochondrial 
dysfunction. 
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Figure 4. 1 Effects of H2O2 and CSM on the viability of ASMCs. Viability of 
ASMC was measured by MTT assay after treatment with (A) H2O2 (50, 100 and 
200 μM) or (B) CSM (10, 25, 50 and 75%) for 2 hours, 4 hours or 24 hours. In the 
4/20 hr group ASMCs were stimulated for 4 hours and then incubated with 
serum-free medium for 20 hours. *p<0.05, **p<0.01 and ***p<0.001 compare 
corresponding groups with relevant control groups; #p<0.05 compares groups as 
indicated. 
121 
 
4.2.2. Oxidative stress induced mitochondrial ROS in ASMCs 
Mitochondrial ROS levels were measured by staining with MitoSOX, a dye that 
targets the mitochondria of live cells and emits red fluorescence when oxidized by 
superoxide. H2O2 treatment increased the mitochondrial ROS levels in a 
concentration-dependent manner at 2 hours (Maximum induction at 200 μM, fold to 
control, 1.61±0.16, p<0.05 vs. control) and 4 hours (Maximum induction at 200 μM, 
fold to control, 1.75±0.15, p<0.01vs. control). After 24 hours only 200 μM H2O2 
increased mitochondrial ROS levels (fold to controls: 24 hours, 1.6±0.25, p<0.05 vs. 
control) (Figure 4.2A). Treatment for 24 hours did not show a more potent induction 
of mitochondrial ROS than the 2 hour or 4 hour treatments. The induction of 
mitochondrial ROS persisted up to 20 hours after the removal of H2O2 (Maximum 
induction at 200 μM, fold to control, 1.56±0.22, p<0.01 vs. control). 
Mitochondrial ROS was highly induced by CSM treatment in a 
concentration-dependent manner (Max induction at 75% CSM, fold to controls: 2 
hours, 8.54±1.99, p<0.001; 4 hours, 8.70±1.17, p<0.001; 24 hours, 11.98±2.85, 
p<0.001; p-value compared to control of each time point) (Figure 4.2B). The increase 
in mitochondrial ROS persisted up to 20 hour after the removal of CSM (Max 
induction at 75% CSM, 8.74±2.87, p<0.001). 
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Figure 4. 2 H2O2 and CSM induced mitochondrial ROS in ASMCs. 
Mitochondrial ROS in ASMCS was measured by staining with MitoSOX after 
treatment with (A) H2O2 (50, 100 and 200 μM) or (B) CSM (10, 25, 50 and 75%) 
for 2, 4 or 24 hours. In the 4/20 hr group ASMCs were stimulated for 4 hours and 
then incubated with serum-free medium for 20 hours. *p<0.05, **p<0.01 and 
***p<0.001 compare corresponding groups with relevant control groups; 
#p<0.05 compares groups as indicated. 
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4.2.3. Oxidative stress induced reduction of ΔΨm in ASMCs 
Maintenance of the mitochondrial membrane potential (ΔΨm) is very important 
for the normal function of mitochondria. Mitochondrial depolarization can lead to an 
interruption in the action of the respiratory chain and triggers apoptosis (90). In this 
study ΔΨm was measured by staining with JC-1. A decreased ratio of red/green 
fluorescence indicates loss of ΔΨm.  
The ΔΨm was reduced by H2O2 treatment in a concentration-dependent manner at 
each time point (Maximum effects at 200 μM, fold to controls: 2 hours, 0.88±0.02, 
p<0.05; 4 hours, 0.89±0.01, p<0.05; 24 hours, 0.70±0.10, p<0.01; p-value compared 
to control of each time point) (Figure 4.3A). The reduction of ΔΨm was observed 
even 20 hours after the removal of H2O2 (Maximum effects at 200 μM, fold to 
controls: 0.64±0.09, p<0.01). 
There was a trend showing a decrease in ΔΨm after 2 hours treatment with CSM, 
which did not reach statistical significance. Significant reduction in ΔΨm was 
observed in a concentration-dependent manner at the 4 hour and 24 hour time points 
(Maximum effects at 75% CSM, fold to controls: 4 hours, 0.62±0.04, p<0.001; 24 
hours, 0.39±0.07, p<0.001) (Figure 4.3B). Moreover, 75% CSM treatment led to 
significantly lower ΔΨm at 24 hours compared to the 2 hours (p<0.001) and 4 hours 
(p<0.001) time points. The reduction of ΔΨm was still evident even 20 hours after the 
removal of CSM (Maximum effects at 75% CSM, fold to controls: 0.67±0.07, 
p<0.01) 
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Figure 4. 3 H2O2 and CSM reduced ΔΨm in ASMCs. ΔΨm in ASMCS was 
measured by staining with JC-1 after treatment with (A) H2O2 (50, 100 and 200 
μM) or (B) CSM (10, 25, 50 and 75%) for 2, 4 or 24 hours. In the 4/20 hr group 
ASMCs were stimulated for 4 hours and then incubated with serum-free medium 
for 20 hours. *p<0.05, **p<0.01 and ***p<0.001 compare corresponding groups 
with relevant control groups; #p<0.05, ##p<0.01, ###p<0.001 compare groups as 
indicated.  
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4.2.4. Oxidative stress reduced cell viability of iPSC-MSCs 
To examine the effects of oxidative stress on iPSC-MSCs, iPSC-MSCs were 
treated with H2O2 (50, 100 and 200 μM) or CSM (10, 25, 50 and 75%) for 4 and 24 
hours. The effects were compared with those observed in ASMCs. 
H2O2 reduced the viability of iPSC-MSCs in a concentration-dependent manner 
after 4 and 24 hours (Max effect at 200 μM, fold to controls: 4 hours, 0.43 ±0.14, 
p<0.05; 24 hours, 0.44 ±0.05, p<0.001; p-value compared to control of each time 
point), in line with the effects seen in ASMCs (Figure 4.4A). 
CSM also reduced the viability of iPSC-MSCs in a concentration-dependent 
manner after 4 and 24 hours. At 4 hours, significant reduction was observed with 50% 
CSM (fold to controls: 0.60 ±0.12, p<0.05 vs. control) and 75% CSM (fold to controls: 
0.49 ±0.09, p<0.01 vs. controls; Figure 4.4B). At 24 hours, significant reduction was 
observed with 25% CSM (fold to controls: 0.76 ±0.09, p<0.05 vs. control), 50% CSM 
(0.18 ±0.02, p<0.001 vs. control) and 75% CSM (0.16±0.02, p<0.001 vs. control). 
The viability of iPSC-MSCs was significantly lower than ASMCs (p<0.05 at each 
treatment and time point), indicating that iPSC-MSCs are more sensitive to high 
concentrations of CSM than ASMCs with respect to their viability. 
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Figure 4. 4 Effects of H2O2 and CSM on viability of iPSC-MSCs. Changes in the 
viability of iPSC-MSCs were measured by MTT assay after treatment with (A) H2O2 
or (B) CSM for 4 hours and 24 hours. Changes in the viability of ASMCs were shown 
for comparison. *p<0.05, **p<0.01 and ***p<0.001 compare corresponding groups 
with relevant control groups; #p<0.05 compares groups as indicated. 
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4.2.5. Oxidative stress induced mitochondrial ROS in iPSC-MSCs 
H2O2 increased the mitochondrial ROS levels in iPSC-MSCs in a 
concentration-dependent manner at both 4 and 24 hours (Maximum effect at 200 μM, 
fold to controls: 4 hours, 4.12±1.73, p<0.05; 24 hours, 4.46±0.81, p<0.05; p-value 
compared to control of each time point) (Figure 4.5A). The increase in mitochondrial 
ROS levels induced by CSM (200 μM) after 24 hours was greater in iPSC-MSCs 
compared to ASMCs (p<0.01.) 
CSM also induced mitochondrial ROS in iPSC-MSCs, in a 
concentration-dependent manner after 4 and 24 hours (Maximum effect at 75% CSM, 
fold to controls: 4 hours, 6.36±1.94, p<0.05; 24 hours, 10.33±3.29, p<0.001; p-value 
compared to control of each time point) (Figure 4.5B). No significant difference was 
observed between the response of iPSC-MSCs and ASMCs. 
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Figure 4. 5 Effects of H2O2 and CSM on mitochondrial ROS of iPSC-MSCs. 
Mitochondrial ROS levels of iPSC-MSCs were measured by MitoSOX staining after 
treatment with (A) H2O2 or (B) CSM for 4 and 24 hours. Changes in the mitochondrial 
ROS levels of ASMCs were shown for comparison. *p<0.05, **p<0.01 and 
***p<0.001 compare corresponding groups with relevant control groups; ##p<0.01 
compares groups as indicated. 
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4.2.6. Oxidative stress induced reduction of ΔΨm in iPSC-MSCs 
H2O2 reduced the ΔΨm in iPSC-MSCs in a concentration-dependent manner at 
both 4 hours and 24 hours (Maximum effect at 200 μM, fold to controls: 4 hours, 
0.80±0.09, p<0.05; 24 hours, 0.41±0.09, p<0.001; p-value compared to control of 
each time point) (Figure 4.6A). The reduction in ΔΨm by H2O2 (200 μM) was 
stronger in iPSC-MSCs compared to ASMCs but it did not reach statistical 
significance. 
CSM also reduced the ΔΨm in iPSC-MSCs in a concentration-dependent manner 
at both 4 and 24 hours (Maximum effect at 75% CSM, fold to controls: 4 hours, 
0.23±0.06, p<0.001; 24 hours, 0.21±0.01, p<0.001; p-value compared to control of 
each time point) (Figure 4.6B). The reduction in ΔΨm was significantly stronger in 
iPSC-MSCs compared with ASMCs after treatment with 50% and 75% CSM for 4 
hours or with any concentration of CSM for 24 hours. 
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Figure 4. 6 Effects of H2O2 and CSM on ΔΨm of iPSC-MSCs. The ΔΨm of 
iPSC-MSCs was measured by JC-1 assay after treatment with H2O2 (A) or CSM (B) 
for 4 hours and 24 hours. Changes in the ΔΨm of ASMCs were shown for 
comparison. *p<0.05, **p<0.01 and ***p<0.001 compare corresponding groups 
with relevant control groups; #p<0.05, ##p<0.01 compare groups as indicated. 
A 
4hr H2O2 24hr H2O2 
0.0
0.5
1.0
1.5
[H2O2]Ctrl 50 M 100 M 200 M
ASMC (n=6) iPSC-MSC (n=5)
*
***
**


m
(F
o
ld
 c
h
a
n
g
e
 t
o
 c
o
n
tr
o
l)
0.0
0.5
1.0
1.5
ASMC (n=5) iPSC-MSC (n=5)
CSM%
***
****
**
***
***
# ##
Ctrl 10% 25% 50% 75%


m
(F
o
ld
 c
h
a
n
g
e
 t
o
 c
o
n
tr
o
l)
0.0
0.5
1.0
1.5
ASMC (n=5) iPSC-MSC (n=5)
CSM%
***
***
**
***
***
***
# ## # #
Ctrl 10% 25% 50% 75%


m
(F
o
ld
 c
h
a
n
g
e
 t
o
 c
o
n
tr
o
l)
4hr CSM 24hr CSM 
B 
0.0
0.5
1.0
1.5
[H2O2]Ctrl 50 M 100 M 200 M
ASMC (n=6) iPSC-MSC (n=5)
** *


m
(F
o
ld
 c
h
a
n
g
e
 t
o
 c
o
n
tr
o
l)
131 
 
4.3. Direct Co-culture with iPSC-MSCs Attenuated 
CSM-induced Mitochondrial Dysfunction and Apoptosis in 
ASMCs 
In order to determine whether iPSC-MSCs are capable of preventing 
CSM-induced mitochondrial dysfunction in ASMCs, in a prophylactic protocol 
iPSC-MSCs were directly co-cultured with CellTrace-labeled ASMCs for 20 hours 
and then treated with CSM (10 and 25%) for 4 hours. As a control, single cultures of 
ASMCs were stained with Cell Trace, incubated for 20 hrs and then treated with CSM 
for 4 hours (Figure 2.5 A). In a therapeutic protocol, CellTrace-labeled ASMCs were 
treated with CSM (10 and 25%) for 4 hours before iPSC-MSCs were added to the 
culture and incubated for a further 20 hours. As a control, single cultures of ASMCs 
were stained with Cell Trace, treated with CSM for 4 hours and then incubated in the 
absence of stimulation for 20 hrs (Figure 2.5B).  
 
4.3.1. iPSC-MSCs prevented and reversed CSM-induced mitochondrial ROS in 
ASMCs 
The two cell types in the co-cultures were distinguished by the CellTrace staining 
using flow cytometry (Figure 4.7A). The mitochondrial ROS levels were measured in 
the gated ASMC (CellTrace-positive) population and compared with the ASMCs in 
the single-culture (Figure 4.7B). 10% CSM significantly increased the levels of 
mitochondrial ROS in ASMCs in the single culture (fold to control: 3.26±0.33, 
p<0.01 in comparison to control), which was prevented by co-culture with 
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iPSC-MSCs (fold to control: 2.12±0.17, p<0.05 in comparison to single-culture). 25% 
CSM further increased the level of mitochondrial ROS in single-culture compared to 
10% CSM (fold to control: 6.71±0.75, p<0.001), which was also reduced by 
iPSC-MSCs (fold to control: 4.01±0.44, p<0.05 in comparison to single-culture). 
However, a concentration-dependent increase of mitochondrial ROS levels of ASMCs 
in the co-culture was still observed, indicating the effects of CSM were only 
alleviated but not eliminated. 
In addition, a therapeutic protocol was also performed, in which the CSM was 
removed from the ASMCs and replaced by either serum free medium or iPSC-MSCs 
(Figure 4.7C). Under these conditions only 25% CSM led to a significant increase in 
mitochondrial ROS (fold to control: 3.42±0.46, p<0.01 in comparison to control). A 
small but significant reduction in mitochondrial ROS was observed in the co-culture 
group compared to the single culture group treated with 25% CSM (fold to control: 
2.70±0.48, p<0.05), indicating therapeutic recovery from CSM-induced mitochondrial 
ROS by iPSC-MSCs. Again the concentration-dependent elevation of mitochondrial 
ROS was still evident among the co-culture groups, indicating the effects of CSM 
were not eliminated.  
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Figure 4. 7 Effects of direct co-culture with iPSC-MSCs on mitochondrial 
ROS in ASMCs. (A) Flow cytometry histograms showing CellTrace positive 
and negative populations corresponding to ASMCs and iPSC-MSCs, 
respectively. (B) Prophylactic effects of iPSC-MSCs on CSM-induced 
mitochondrial ROS in ASMCs. iPSC-MSCs were co-cultured with 
CellTrace-labeled ASMCs for 20 hours and then treated with CSM (10 and 
25%) for 4 hours. Single ASMCs cultures were used as controls. Mitochondrial 
ROS levels were determined using MitoSOX staining. (C) Therapeutic effects 
of iPSC-MSCs on CSM-induced mitochondrial ROS in ASMCs.  
CellTrace-labeled ASMCs were treated with CSM (10 and 25%) for 4 hours. 
CSM was then removed and iPSC-MSCs were loaded. Single ASMCs cultures 
were used as controls. *p<0.05, **p<0.01, ***p<0.001 compare groups as 
indicated.  
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4.3.2. iPSC-MSCs prevented but did not reverse CSM-induced reduction in ΔΨm 
in ASMCs 
In the prophylactic protocol, CSM induced reduction of ΔΨm at both 10% (fold 
to control: 0.80±0.04, p<0.01) and 25% concentration (fold to control: 0.52±0.07, 
p<0.001). 25% CSM led to lower ΔΨm than 10% CSM (p<0.001). Co-culture with 
iPSC-MSCs improved the ΔΨm under both 10% CSM treatment (fold to control: 
0.95±0.04, p<0.01) and 25% CSM treatment (fold to control: 0.78±0.10, p=0.059) 
(Figure 4.8A). CSM still led to a trend showing a reduction in ΔΨm in ASMCs in the 
co-culture, but the difference was not statistically-significant. 
In the therapeutic protocol, after recovery for 20 hours, single-cultures of ASMCs 
still showed significantly reduced ΔΨm in both 10% CSM-treated group (fold to 
control: 0.84±0.07, p<0.01) and 25% CSM-treated group (fold to control: 0.75±0.59, 
p<0.001) (Figure 4.8B). There is a trend showing an increase in mitochondrial 
potential in the co-culture groups compared to the single culture at both 10% (fold to 
control: 0.94±0.04) and 25% CSM treatments (fold to control: 0.87±0.11), which did 
not reach statistical significance. 
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Figure 4. 8 Effects of direct co-culture with iPSC-MSCs on ΔΨm in ASMCs. 
(A) Prophylactic effects of iPSC-MSCs on CSM-induced reduction in ΔΨm in 
ASMCs. iPSC-MSCs were co-cultured with CellTrace-labeled ASMCs for 20 
hours and then treated with CSM (10 and 25%) for 4 hours. Single ASMCs 
cultures were used as controls. ΔΨm was determined using JC-1 staining. (B) 
Therapeutic effects of iPSC-MSCs on CSM-induced reduction in ΔΨm in ASMCs. 
CellTrace-labeled ASMCs were treated with CSM (10 and 25%) for 4 hours. CSM 
was then removed and iPSC-MSCs were loaded. Single ASMCs cultures were used 
as controls. *p<0.05, **p<0.01, ***p<0.001 compares groups as indicated.  
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4.3.3. iPSC-MSCs prevented CSM-induced apoptosis of ASMCs 
Based on the observations of a protective role of iPSC-MSCs against 
CSM-induced mitochondrial dysfunction in ASMCs, further investigations were 
carried out on whether such mitochondrial improvement led to improved function of 
the cells. In particular apoptosis, as a possible outcome of severe mitochondrial 
damage, was investigated in the co-culture using the prophylactic protocol (Figure 
4.9). Results from Annexin V staining confirmed induction of apoptosis by CSM in 
single-cultured ASMCs at 25% CSM (46.6±1.3% vs. 17.4±2.9%, p<0.001) and 50% 
CSM (86.8±3.8% vs. 17.4±2.9%, p<0.001). In the absence of stimulation, the 
iPSC-MSCs-treated ASMCs demonstrated higher percentage of apoptosis than those 
in the single-culture (30.7±1.4% vs. 17.4±2.9%, p<0.05), which indicates that 
introducing iPSC-MSCs to the system may induce stress to the ASMCs at baseline. 
However, iPSC-MSCs led to a significant reduction in apoptosis induced by 25% 
(34.7±1.5% vs. 46.6±1.3%, p<0.05) and 50% CSM (49.5±4.2% vs. 86.8±3.8%, 
p<0.001), indicating that interaction with iPSC-MSCs can protect ASMCs from 
CSM-induced mitochondrial dysfunction and apoptosis. 
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Figure 4. 9 Prophylactic effects of iPSC-MSCs on CSM-induced apoptosis 
in ASMCs. iPSC-MSCs were co-cultured with CellTrace-labeled ASMCs for 
20 hours and then treated with CSM (10 and 25%) for 4 hours. Single ASMCs 
cultures were used as controls. Apoptosis was detected by Annexin V staining. 
*p<0.05, **p<0.01, ***p<0.001 compare groups as indicated. 
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4.4. Paracrine Effects are only Partly Involved in the 
Protective Effects of iPSC-MSCs on CSM-induced 
Mitochondrial Dysfunction and Apoptosis in ASMCs 
4.4.1. Effects of conditioned medium from iPSC-MSCs on CSM-induced 
mitochondrial dysfunction in ASMCs 
In order to examine the role of paracrine effects in the protective effects of 
iPSC-MSCs on CSM-induced mitochondrial damage in ASMCs, the effects of 
conditioned medium from iPSC-MSCs (iPSC-MSCs-CdM) on CSM-induced 
mitochondrial damage in ASMCs were investigated. CdM was a concentrate of all 
paracrine factors released over a 24 hour period from confluent cultures of 
iPSC-MSCs. The ASMCs were pre-treated with iPSC-MSCs-CdM for 4 hours 
followed by CSM treatment for a further 4 hours in the presence of CdM. The 
evaluation of mitochondrial ROS revealed very similar results with the direct 
co-culture system (Figure 4.10A). CSM treatments increased mitochondrial ROS in a 
concentration-dependent manner in both untreated ASMCs (fold to controls: 10% 
CSM, 2.96±0.34, p<0.05; 25% CSM, 7.76±0.06, p<0.001; p-value compared to 
relevant controls) and ASMCs treated with iPSC-MSCs-CdM (fold to controls: 10% 
CSM, 2.56±0.29, p<0.01; 25% CSM, 5.81±0.49, p<0.001; p-value compared to 
relevant controls). However, compared to untreated ASMCs, ASMCs treated with 
iPSC-MSCs-CdM demonstrated significantly lower levels of mitochondrial ROS in 
both 10% CSM group (p<0.05) and 25% CSM group (p<0.05). 
The reduction of mitochondrial ROS by iPSC-MSCs-CdM was not associated 
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with prevention of ΔΨm reduction. CSM treatments reduced ΔΨm in the untreated 
ASMCs (fold to controls: 10% CSM, 0.84±0.03, p<0.01; 25% CSM, 0.59±0.05, 
p<0.001; p-value compared to relevant controls) as well as in the ASMCs treated with 
iPSC-MSCs-CdM (fold to controls: 10% CSM, 0.87±0.02, p<0.05; 25% CSM, 
0.59±0.05, p<0.001; p-value compared to relevant controls; Figure 4.10B). The effect 
of CSM on ΔΨm was similar in untreated and iPSC-MSCs-CdM-treated ASMCs. 
These findings suggest that paracrine factors are only partly involved in the capacity 
of iPSC-MSCs to protect ASMCs from CSM-induced mitochondrial damage 
 
4.4.2. Effect of iPSC-MSCs-CdM on CSM-induce apoptosis of ASMCs 
The effect of iPSC-MSCs-CdM on CSM-induced ASMC apoptosis was also 
determined. CSM increased the percentage of apoptotic ASMCs in a 
concentration-dependent manner (Maximum induction by 50% CSM: 64.8±9.2% vs. 
12.6±1.4%, p<0.001; p-value compared to control). Within the iPSC-MSCs-CdM 
treated groups, a similar induction was observed (Maximum induction by 50% CSM: 
67.8±9.0% vs. 13.8±1.3%, p<0.001; p-value compared to control) (Figure 4.11). 
Treatment with iPSC-MSCs-CdM did not affect the baseline or CSM-induced 
apoptosis.  
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Figure 4. 10 Effects of iPSC-MSCs-CdM on mitochondrial ROS and 
ΔΨm in ASMCs. ASMCs were pre-treated with iPSC-MSCs-CdM for 4 
hours before stimulating with CSM for 4 hours. (A) Mitochondrial ROS 
was determined by MitoSOX staining and (B) ΔΨm by JC-1 staining. 
*p<0.05, **p<0.01, ***p<0.001 compare groups as indicated. 
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Figure 4. 11 Effects of iPSC-MSCs-CdM on CSM-induced apoptosis in 
ASMCs. ASMCs were pre-treated with iPSC-MSCs-CdM for 4 hours before 
stimulating with CSM for 4 hours. Apoptosis was determined by Annexin V 
staining. **p<0.01, ***p<0.001 compare groups as indicated. 
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4.4.3. Effects of trans-well co-culture with iPSC-MSCs on CSM-induced 
mitochondrial alterations in ASMCs 
To better replicate the crosstalk between the ASMCs and iPSC-MSCs through 
paracrine effects, trans-well co-culture was performed using cell culture inserts with 
0.4 μm pores. ASMCs in 6-well plates were incubated with either blank inserts or 
inserts containing iPSC-MSCs for 20 hours before being treated with CSM (10 or 
25%) for 4 hours (Figure 4.12A). Mitochondrial ROS levels were increased by 10% 
CSM (fold to control: 3.55±0.59, p<0.01) and 25% CSM (fold to control: 8.35±0.83, 
p<0.001) in the ASMCs treated with blank inserts. In the trans-well co-culture group, 
mitochondrial ROS levels in ASMCs were also elevated by 10% CSM (fold to control:  
3.12±0.57, p<0.05) and 25% CSM (fold to control: 7.15±0.84, p<0.001), but the 
mitochondrial ROS induced by 25% CSM was significant reduced compared to the 
blank insert group (p<0.05) (Figure 4.12B). 
Significant reduction of ΔΨm was induced by 25% CSM at both blank insert 
group (fold to control: 0.39±0.06, p<0.01) and iPSC-MSCs-treated group (fold to 
control: 0.49±0.12, p<0.01). No significant difference was observed between the 
iPSC-MSCs treatment and blank insert (Figure 4.12C). These results are in line with 
the findings from the iPSC-MSCs-CdM experiment. 
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Figure 4. 12 Effects of co-culture with iPSC-MSCs using the trans-well 
system on mitochondrial ROS and ΔΨm in ASMCs. (A) Illustration of the 
trans-well setup. Inserts with or without iPSC-MSCs were placed into the wells of 
6-well tissue culture plates, containing ASMCs, for 20 hours. The whole system 
was treated with CSM for 4 hours. In the ASMCs mitochondrial ROS was 
determined by (B) MitoSOX staining and (C) ΔΨm by JC-1 staining. *p<0.05, 
**p<0.01, ***p<0.001 compare groups as indicated. 
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4.4.4. Effect of trans-well co-culture with iPSC-MSCs on CSM-induced apoptosis 
in ASMCs 
The effect of co-culture using a trans-well system on ASMC apoptosis was also 
examined. 25% CSM induced a significant increase in ASMC apoptosis in both the 
blank insert group (48.6±10.9% vs. 11.7±2.6%, p<0.05) and the iPSC-MSC-treated 
group (54.6±8.3% vs. 16.7±3.3%, p<0.01) (Figure 4.13). No difference was observed 
in the iPSC-MSCs-treated group in comparison with the blank group. 
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Figure 4. 13 Effects of trans-well co-culture with iPSC-MSCs on apoptosis in 
ASMCs. Inserts with or without iPSC-MSCs were placed into the wells of 6-well 
tissue culture plates, containing ASMCs, for 20 hours. The whole system was treated 
with CSM for 4 hours. In the ASMCs apoptosis was determined by Annexin V 
staining.*p<0.05, **p<0.01 compares corresponding groups with relevant controls. 
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4.5. Mitochondrial Transfer from iPSC-MSCs to ASMCs 
4.5.1. Mitochondrial transfer from iPSC-MSCs to ASMCs 
A possible mechanism underlining the protective effects of iPSC-MSCs against 
CSM-induced mitochondrial dysfunction in ASMCs is mitochondrial transfer. To 
investigate whether mitochondrial transfer from iPSC-MSCs to ASMCs takes place, 
ASMCs were pre-stained with CellTrace Violet while iPSC-MSCs were pre-stained 
with MitoTracker Red, a mitochondrial-targeted fluorescent dye. They were 
co-cultured for 20 hours followed by 4 hours stimulation with 25% CSM. The cells 
were fixed and stained with phalloidin which selectively labels F-actin. Using 
fluorescent microscopy, iPSC-MSCs-derived MitoTracker-labeled mitochondria were 
observed in CellTrace-labeled ASMCs, indicating transfer of mitochondria from 
iPSC-MSCs to ASMCs (Figure 4.14). In addition, tunneling nanotube (TNT)-like 
structures, containing iPSC-MSC mitochondria, were observed connecting 
iPSC-MSCs and ASMCs. Actin filaments were identified in the TNTs by phalloidin 
staining confirming a connection between the cytoskeleton systems of iPSC-MSCs 
and ASMCs, which may provide a path through which the mitochondria are 
transferred. 
 
4.5.2. CSM increased mitochondrial transfer from iPSC-MSCs to ASMCs 
Mitochondrial transfer was quantified by determining the percentage of 
MitoTracker-positive cells in the ASMC population using flow cytometry.  
Mitochondrial transfer was detected after co-culture for 24 hours without CSM 
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stimulation or after stimulation with 10% or 25% CSM during the last 4 hours of the 
co-culture period. 10% CSM enhanced mitochondrial transfer, as shown by a 
significant elevation of the transfer rate (48.9±6.8% vs. 18.8±4.1%, p<0.05). 25% 
CSM further increased the transfer rate compared to 10% CSM (75.5±8.5% vs. 
48.9±6.8%, p<0.05), suggesting that CSM promoted mitochondrial transfer from 
iPSC-MSCs to ASMCs in a concentration-dependent manner (Figure 4.15). 
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Figure 4. 14 Mitochondrial transfer from iPSC-MSCs to ASMCs. ASMCs were 
pre-stained with CellTrace and iPSC-MSCs with MitoTracker. Cells were co-cultured 
for 20 hours and then treated with 25% CSM for 4 hours. Phalloidin staining was 
applied after fixation. The presence of MitoTracker-labeled mitochondria was 
observed in CellTrace-labeled cells, indicating transfer of iPSC-MSC-derived 
mitochondria to ASMCs. Tunneling nanotube–like structures between iPSC-MSCs 
and ASMCs can be observed. Scale bar=25 μm.  
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Figure 4. 15 Effect of CSM on the rate of mitochondrial transfer from 
iPSC-MSCs to ASMCs. ASMCs were pre-stained with CellTrace and 
iPSC-MSCs with MitoTracker. Cells were co-cultured for 20 hours and then 
treated with 25% CSM for 4 hours. (A) Mitochondrial transfer from 
iPSC-MSCs (MitoTracker-positive) to ASMCs (CellTrace-positive) was 
determined by flow cytometry. The ASMC population is indicated by the gate 
in the plots of co-culture. (B) The rate of mitochondrial transfer was evaluated 
by the percentage of MitoTracker-positive ASMCs in total ASMC population. 
*p<0.05, ***p<0.001 compare groups as indicated. 
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4.6. Discussion 
This study demonstrated increased mitochondrial ROS and reduced ΔΨm in 
healthy ASMCs, in response to H2O2 or CSM. Direct contact with iPSC-MSCs 
protected the ASMCs from CSM-induced mitochondrial ROS and reduction of ΔΨm, 
which may explain the attenuation of CSM-induced apoptosis. When the interaction 
between the two cell types was restricted to paracrine effects, only CSM-induced 
mitochondrial ROS but not CSM-induced ΔΨm loss and apoptosis in ASMCs were 
ameliorated, indicating that the paracrine effects can only partly explain the protective 
effects of iPSC-MSCs. Under direct interaction, mitochondria were transferred from 
iPSC-MSCs to ASMCs, which was enhanced by CSM treatment. Formation of TNTs 
between iPSC-MSCs and ASMCs was observed in the co-culture. The prophylactic 
effects of iPSC-MSCs on CSM-induced mitochondrial damage in ASMCs were lost 
when the co-culture was carried out using a trans-well system. As the trans-well 
inserts would block nanotube formation, whilst allowing only paracrine 
communication, this suggests an important role of mitochondrial transfer in the 
protective effects of iPSC-MSCs. These findings highlight that the full protective 
capacity of iPSC-MSCs may rely on direct contact with target cells through which 
mitochondrial transfer can take place. This study suggested that iPSC-MSCs may be 
promising candidates for cell-based treatments targeting mitochondrial damage in 
patients with COPD. 
Targeting mitochondrial damage provides a new promising strategy for 
developing treatments for COPD. Mitochondrial dysfunction was recently 
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demonstrated in ASMCs from patients with COPD, as characterized by reduced ATP 
levels, mitochondrial complex protein expression and ΔΨm, as well as increased 
mitochondrial ROS (273). The study also demonstrated mitochondrial damage, as 
reflected by the same parameters, in an ozone-induced mouse model of airway 
inflammation and hyper-responsiveness. Mitochondrial damage as well as airway 
inflammation and hyper-responsiveness were attenuated by the mitochondrial- 
targeted antioxidant MitoQ (273). In an earlier report, swelling and fragmented 
mitochondria with depleted cristae were observed in airway epithelial cells from 
patients with stage 4 COPD (105). In the present study, oxidative stress-induced 
mitochondrial damage was identified by increased mitochondrial ROS and loss of 
ΔΨm in ASMCs, which provided a model in which to study the effects of 
iPSC-MSCs. 
CS, the major cause of COPD, contains numerous oxidants. One puff of cigarette 
smoke contains approximately 10
15 
oxidants in the gas phase and 10
18
 oxidants in the 
tar phase, together with 3000 ppm of nitrite oxide (57, 58). Acute exposure to CS is 
reported to impair energy metabolism and mitochondrial protein expression in mouse 
lungs, leading to switch of glucose metabolism to pentose phosphate pathway and 
reduction of substrate supply to mitochondrial respiration (4). Cigarette smoke 
medium was reported to alter the morphology of mitochondria in vitro, in both airway 
epithelial cells (105) and ASMCs (10), inducing mitochondrial fragmentation in both 
cell types and mitochondrial ROS elevation in ASMCs. However, the effect on ΔΨm 
was not examined in these studies. In the present study CSM was demonstrated to 
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induce mitochondrial ROS, ΔΨm loss and apoptosis in normal ASMCs from healthy 
subjects. Although inhalation of CS primarily affects the epithelium, CS-derived 
chemicals could also affect airway smooth muscle directly via the circulation (205) or 
indirectly through inducing the production of epithelial cell-derived inflammatory 
mediators such as IL-1β, IFN-γ and TNF-α which affect ASMC function (70, 231). 
Moreover, chronic exposure to CS can lead to a defective epithelial barrier function 
(102, 226), which may result in a direct exposure of CS to ASMCs. Hence the in vitro 
model of CSM-induced ASMC dysfunction is physiologically relevant. On the other 
hand, it is to my interest to establish a model of oxidative stress-induced 
mitochondrial damage, through which mitochondrial-targeted therapeutic approaches 
can be tested. The concentrations of CSM chosen for the co-culture experiments were 
based on the findings of concentration response experiments performed on single 
cultures of ASMCs, as it would be impossible to determine physiologically-relevant 
concentrations of cigarette smoke constituents. CSM-induced apoptosis was observed 
in association with mitochondrial dysfunction. Induction of apoptosis by CS has also 
been demonstrated in other cell types in the lung including endothelial cells, alveolar 
epithelial cells, fibroblasts and immune cells (16, 103, 116, 127, 166, 223). The 
anti-apoptotic role of iPSC-MSCs demonstrated in the ASMC model may also be 
important in other cell types in the lung. 
MSCs have been reported to attenuate lung emphysema and allergic airway 
inflammation in murine models (94, 150, 151, 244). Although MSCs are considered 
as putative cell-based therapies for COPD, their potential mechanisms of their action 
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remain unclear. It is possible that their effects are at least partly mediated by 
improving mitochondrial function in COPD lungs. Indeed, MSCs have been shown to 
rescue defective mitochondria and impaired bioenergetics of mitochondria in an 
animal model of lipopolysaccharide-induced acute lung injury (118), as well as in an 
in vitro model of mitochondrial DNA mutation (238). In my study, the effects of 
iPSC-MSCs on CSM-induced mitochondrial damage in ASMCs were examined. 
Using a prophylactic protocol, I have shown that interaction with iPSC-MSCs 
prevents CSM-induced mitochondrial ROS and reduction in ΔΨm in ASMCs. 
CSM-induced apoptosis in ASMCs was also attenuated by iPSC-MSCs, which may 
be a result of improved mitochondrial function. Using the therapeutic protocol, I 
observed significant attenuation of CSM-induced mitochondrial ROS but not reversal 
of CSM-induced ΔΨm reduction. The therapeutic effects of iPSC-MSCs appear to be 
less pronounced, possibly due to the partial recovery of mitochondrial function in 
absence of CSM stimulation, or the progression of mitochondrial damage to an 
irreversible stage. Therefore the prophylactic protocol was chosen for later 
experiments. These findings support the hypothesis that iPSC-MSCs can attenuate 
CSM-induced mitochondrial damage, suggesting their potential capacity to repair 
mitochondrial dysfunction in patients with COPD.  
MSCs have been reported to induce paracrine effects by releasing 
immunoregulatory cytokines such as VEGF, TGF-β1, HGF, bFGF and platelet derived 
growth factor (2, 235, 270). In the previous chapter iPSC-MSCs-CdM was found to 
attenuate CSM-induced apoptosis in bronchial epithelial cells in vitro. However, in 
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the present study, iPSC-MSCs-CdM was only able to ameliorate CSM-induced 
mitochondrial ROS in ASMCs without any effectiveness on ΔΨm or apoptosis. As 
iPSC-MSCs were not in close proximity to ASMCs or exposed to CSM treatment 
before the collection of CdM, the lack of effect may indicate that the protective effects 
of iPSC-MSCs on ASMCs may be induced by the CSM or mediators produced by the 
ASMCs themselves. However, in a trans-well co-culture system where there is 
paracrine crosstalk between the two cell types, just as in the direct co-culture system, 
the iPSC-MSCs prevented CSM-induced mitochondrial ROS production but not the 
reduction of ΔΨm or apoptosis in ASMCs.  
Therefore, the protective role of iPSC-MSCs against CSM-induced mitochondrial 
depolarization and apoptosis in ASMCs seems to be dependent on the direct contact 
between the two cell types, which may also involve mitochondrial transfer. 
Mitochondrial transfer was firstly identified in co-cultures of BM-MSCs and lung 
epithelial cells with defective mitochondria (238). Since then, mitochondrial transfer 
from BM-MSCs to epithelial cells, endothelial cells, cardiomyocytes and 
osteosarcoma cells has been demonstrated (55, 192, 204, 238). Mitochondrial transfer 
from MSCs to epithelial cells was also observed in vivo in rodent models of acute 
lung injury (118) and CS-induced emphysema (150). In this study mitochondrial 
transfer from iPSC-MSCs to ASMCs was demonstrated. Moreover, CSM significantly 
enhanced the transfer in a concentration-dependent manner. A previous study reported 
that CS exposure can lead to a reduction in the supply of substrates to the electron 
transport chain, leading to increased mitochondrial workload to maintain normal 
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energy supply (4). The transfer of healthy mitochondria may alleviate such burden 
and thus relieve the mitochondrial stress as indicated by the reversal of mitochondrial 
depolarization. In this study the formation of TNTs connecting the cytoskeleton 
systems of the two cells were evident by staining the actin filaments. TNTs are highly 
sensitive nanotubular structures between cells which can facilitate the selective 
transfer of membrane vesicles and organelles (215). TNTs have been reported to 
mediate mitochondrial transfer from BM-MSCs to epithelial cells, from endothelial 
cells to cancer cells and from vascular smooth muscle cells to MSCs (196, 238, 258). 
ASMCs are also reported to form TNTs with CD4+ T cells in vitro, leading to 
enhanced T cell survival (7). The formation of TNTs between iPSC-MSCs and 
ASMCs may provide a path through which mitochondria can be transferred, but the 
mechanisms underlining the regulation of TNT formation by the two cell types or by 
CSM remain unknown. The mechanism by which cells regulate mitochondrial 
transfer through the TNTs is also unclear. A recent study demonstrated that 
mitochondria are carried by a mitochondrial Rho-GTPase, Miro1, which can move 
along the actin filament in the TNTs between two cell types (6). Possible mechanisms 
of regulation of Miro1 by CS should be further investigated in the future. 
Despite the evidence indicating iPSC-MSC-mediated protection of ASMCs from 
CSM-induced mitochondrial damage, some of my findings need to be considered 
carefully. Firstly, although MSCs have been reported to rescue injured cells in various 
models of inflammation and oxidative stress, their own response to oxidative stress is 
often neglected. In this study I have demonstrated that iPSC-MSCs are not more 
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resistant to oxidative stress than ASMCs. Therefore caution is required in the 
development of MSC-based therapies as MSCs may also show mitochondrial damage 
under oxidative stress. Secondly, in the absence of CSM treatment, the co-culture with 
iPSC-MSCs increased the apoptosis of ASMCs suggesting that iPSC-MSCs may 
induce stress in the target cells at baseline. Such data imply that the safety of 
iPSC-MSCs should be carefully examined if they are to be used therapeutically in 
man. 
There are several limitations to this study and therefore further work is required 
to better understand the protective effects of iPSC-MSCs and the mechanisms 
mediating these effects. Firstly, the ASMCs used in my study were isolated from 
healthy subjects. A better understanding of the therapeutic potential of iPSC-MSCs in 
COPD would result from a study of ASMCs from COPD patients, in which 
mitochondria are known to be already impaired (273). Secondly, although the 
paracrine effects were not shown to mediate the full protective effect of iPSC-MSCs, 
protection from CSM-induced mitochondrial ROS was still evident. The molecules 
mediating these effects require further investigation. Thirdly, the formation of TNTs 
may also facilitate the exchange of other cellular content, which may also protect the 
ASMCs from mitochondrial damage. Lastly, the mechanism of CSM‟s effect on 
promotion of mitochondrial transfer need to be further addressed.  
In summary, this study demonstrated that the capacity of iPSC-MSCs to attenuate 
CSM-induced mitochondrial damage in ASMCs relies highly on direct cell-cell 
contact. Mitochondrial transfer through the TNTs may play an important role in this 
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process. I elucidated the potential of iPSC-MSCs to target mitochondrial dysfunction 
in patients with COPD, thus further highlighting iPSC-MSCs as a promising 
candidate for development of cell-based therapies in COPD. 
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Chapter 5. Effects of iPSC-MSCs on 
Ozone-induced Airway 
Hyper-responsiveness, Lung Inflammation, 
Apoptosis and Mitochondrial Dysfunction 
in Mice 
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5.1. Introduction 
Ozone (O3) is a potent oxidizing pollutant. High concentration of ozone in the 
environment have been reported to be associated with worsening of symptoms in 
patients with COPD and asthma (18, 74, 84, 173, 197, 239, 257). In mouse models, 
exposure to ozone is reported to induce airway oxidative stress, airway 
hyper-responsiveness (AHR) and inflammation (54, 253, 272, 274, 275). Repeated 
exposure to ozone can destroy alveolar structures in mice, finally leading to 
emphysema (203, 253).  
Beneficial effects of iPSC-MSCs have been reported in rodent models of allergic 
airway inflammation and CS-exposed emphysema (150, 244). However, their effects 
on AHR have not been investigated yet. In this study, a previously reported mouse 
model of acute ozone-exposure was used (274, 275) in order to examine the effects of 
iPSC-MSCs on oxidative stress-induced AHR and airway inflammation.  
Although in the last chapter the capacity of iPSC-MSCs to prevent oxidative 
stress-induced mitochondrial dysfunction in ASMCs was demonstrated in vitro, the 
capacity of iPSC-MSCs to modulate oxidative stress-induced mitochondrial 
dysfunction in the lung in vivo remains unknown. Mitochondrial dysfunction in lung 
tissue has been documented in the ozone-exposed mouse model (273). Therefore the 
other aim of the study was to examine the effects of iPSC-MSCs on oxidative 
stress-induced mitochondrial dysfunction in the ozone-exposed mouse model. The 
hypothesis of the study is that intravenous administration of iPSC-MSCs can 
prophylactically prevent and/or therapeutically reverse ozone-induced AHR, airway 
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inflammation, apoptosis and mitochondrial dysfunction in the lung.  
The aims of this chapter were: 
1. To evaluate the effects of iPSC-MSCs on AHR and lung inflammation in an acute 
ozone-exposed mouse model. 
2. To examine effects of iPSC-MSCs on mitochondrial dysfunction and apoptosis in 
the lung, in an acute ozone-exposed mouse model. 
 
5.2. Results 
5.2.1. iPSC-MSCs prevented ozone-induced AHR 
Male C57BL/6 mice were exposed to normal air or ozone (3 ppm) for 3 hours. 
1x10
6
 iPSC-MSCs or PBS were administrated to mice through intravenous injection 
either 24 hours prior or 6 hours after the exposure. There were 5 groups of mice in 
total: the Air/saline (n=5), the Air with iPSC-MSCs administrated 24 hours 
prior-exposure (Air/-24hr) (n=5), the Ozone/saline (n=6), the Ozone with iPSC-MSCs 
administrated 24 hours prior-exposure (Ozone/-24hr) (n=6) and the Ozone with 
iPSC-MSCs administrated 6 hour post-exposure (Ozone/+6hr) (n=6). 
Pulmonary resistance (RL) to increasing concentration of acetylcholine was 
measured 24 hours after exposure (Figure 5.1A). The injection of iPSC-MSCs 24 
hours prior to air exposure did not show significant effect on AHR compared to the 
Air/saline group, as indicated by -log PC100 (2.01±0.06 vs. 2.15±0.06, p>0.05) Figure 
5.1B). Ozone/saline group demonstrated significantly increased AHR compared with 
Air/saline group, as indicated by significantly reduced -log PC100 (1.68±0.06 vs. 
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2.15±0.06, p<0.01). The treatment of iPSC-MSCs 24 hours prior-exposure 
significantly reduced ozone-induced AHR as compared with Ozone/saline group (-log 
PC100: 1.99±0.08 vs.1.68±0.06, p<0.05). The Ozone/+6hr group, on the other hand, 
did not exhibit a difference in AHR compared to the Ozone group (-log PC100: 
1.75±0.07 vs.1.68±0.06, p>0.05). The data suggest that intravenously injected 
iPSC-MSCs can prevent rather than reverse ozone-induced AHR in mice. 
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Figure 5. 1 Effect of iPSC-MSCs on ozone-induced AHR. Mice were exposed to 
ozone (3 ppm) or air for 3 hours. iPSC-MSCs were intravenously injected 24 hrs 
before or 6 hours post exposure. (A) RL in response to increasing concentration of 
acetylcholine. (B) -log PC100 derived from plot. **p<0.01 compared to air/saline; 
†
p<0.05 compared to ozone/saline.  
  
161 
 
5.2.2. Effect of iPSC-MSCs on ozone-induced infiltration of inflammatory cells in 
the lung 
The total cell number in bronchoalveolar lavage (BAL) was determined as 
indication of inflammatory cell infiltration in the lung (Figure 5.2A). The 
Ozone/saline group demonstrated significantly higher total cell numbers in the BAL 
compared to the Air/saline group (51.5±6.7x10
5
 vs. 13.8±4.8x10
5
, p<0.01). The 
Ozone/-24hr group also demonstrated higher total cell numbers in the BAL compared 
to Air/-24hr group (31.9±4.3x10
5
 vs. 12.4±2.1x10
5
, p<0.01). However, the total cell 
numbers in Ozone/-24hr group was significantly lower compared to Ozone/saline 
group (p<0.05). The Ozone/+6hr group did not show any significant difference in 
total cell numbers compared to the Ozone/Saline group.  
Diff-Quik staining was performed on the BAL cells after cytospin. The numbers 
of neutrophils, macrophages, eosinophils and lymphocytes were determined. In the 
saline groups, ozone exposure significantly increased the neutrophil number in the 
BAL compared to air exposure (20.6±3.5x10
5
 vs. 0.44±0.20x10
5
, p<0.05). Treatment 
with iPSC-MSCs 24 hours before the ozone exposure significantly reduced the 
neutrophil number compared to the ozone/saline group (7.6±1.3x10
5
 vs. 20.6±3.5x10
5
, 
p<0.01), but the level was still higher than the air/-24hr group (7.6±1.3x10
5
 vs. 
0.26±0.07x10
5
, p<0.05). The Ozone/+6hr group did not show any significant 
difference compared to Ozone/Saline group. Macrophage number was also elevated in 
Ozone/saline group compared to Air/saline (21.6±1.7x10
5
 vs. 1.58±0.67x10
5
, p<0.01). 
There was a trend of decrease in Ozone/-24hr compared to Ozone/saline but not 
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reaching significance (14.6±2.8x10
5
 vs. 21.6±1.7x10
5
). The Ozone/+6hr group did not 
show trend of difference compared to Ozone/Saline group (21.2±3.1x10
5
 vs. 
21.6±1.7x10
5
). Similarly, eosinophil number in the BAL was increased in 
Ozone/saline group compared with Air/saline (2.58±0.63x10
5
 vs. 0.16±0.09x10
5
, 
p<0.01). There was a trend of decreased eosinophil number in Ozone/-24hr group 
compared with Ozone/saline though not reaching significance (0.98±0.27x10
5
 vs. 
2.58±0.63x10
5
). Similar trend existed in Ozone/+6hr group as compared with 
Ozone/Saline group, also not reaching significance (1.31±0.52x10
5
 vs. 
2.58±0.63x10
5
). As for number of lymphocytes, the induction by ozone is significant 
(5.76±1.21x10
5
 vs. 1.06±0.41x10
5
, p<0.05). There were trends of decrease in both 
Ozone/-24hr (4.44±0.86x10
5
) and Ozone/+6hr groups (4.13±1.21x10
5
), neither of 
which reached significance. 
The results suggested that iPSC-MSCs were able to prevent but not reverse 
ozone-induced recruitment of inflammatory cells into mouse lung. 
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Figure 5. 2 Effects of iPSC-MSCs on total and differential cell counts in BAL 
from ozone-exposed mice. BAL was collected 24 hours after ozone exposure. (A) 
The number of total cells was determined. (B) Differential counts of cells in BAL. 
BAL cells were subjected to a cytospin protocol and stained by Diff-Quik. 
Neutrophils, macrophages, eosinophils and lymphocytes were identified, based on 
their color and morphology, and counted.  *p<0.05, **p<0.01 compared to air/saline; 
#p<0.05, ##p<0.01 compared to air/-24hr, 
†
p<0.05, 
††
p<0.01 compared to 
ozone/saline. 
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5.2.3. Effect of iPSC-MSCs on cytokine contents of BALF 
The BAL fluid (BALF) was collected as the non-cellular compartment of the 
BAL. Levels of the inflammatory mediators MCP-1, eotaxin, IL-6, IL-5 and MIP-1α 
in BALF were measured by MAGPIX Luminex multiplexing analyzer. Compared 
with the Air/saline group, ozone exposure significantly elevated the levels of MCP-1 
(181.5±13.3 pg/ml vs. 151.9±1.6 pg/ml, p<0.05), eotaxin (48.6±2.2 pg/ml vs. 
30.2±2.7 pg/ml, p<0.01), IL-6 (76.1±9.8 pg/ml vs. 37.4±2.7 pg/ml, p<0.01), IL-5 
(11.9±2.6 pg/ml vs. 1.9±0.07 pg/ml, p<0.05) and MIP-1α (9.2±1.6 pg/ml vs. 2.2±0.1 
pg/ml, p<0.05). Prophylactic administration of iPSC-MSCs significantly reduced IL-6 
(45.1±3.2 pg/ml, p<0.05) and IL-5 (4.66±0.60 pg/ml, p<0.01) levels compared with 
the Ozone/saline group. Trends of reduction in eotaxin (40.8±2.3 pg/ml, p=0.053) and 
MIP-1α (5.4±0.8 pg/ml, p=0.055) in the BALF were also demonstrated in the 
Ozone/-24hr group compared with Ozone/saline group. Therapeutic treatment with 
iPSC-MSCs reversed the ozone-induced increase in eotaxin (36.8±2.5 pg/ml, p<0.01), 
IL-6 (47.8±3.6 pg/ml, p<0.05), IL-5 (4.6±0.9 pg/ml, p<0.05) and MIP-1α (4.8±0.6 
pg/ml, p<0.05) in the BALF. Both prophylactic and therapeutic treatments induced a 
trend of reduction in MCP-1 levels which did not reach statistical significance 
(Ozone/-24hr, 160.0±1.0 pg/ml; Ozone/+6hr, 157.9±2.8 pg/ml). 
The results indicated that iPSC-MCSs prevented and reversed ozone-induced 
elevation in inflammatory mediator levels in BALF, including eotaxin, IL-6, IL-5 and 
MIP-1α.   
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Figure 5. 3 Effects of iPSC-MSCs on inflammatory mediator levels in BALF after 
ozone exposure. Levels of MCP-1, eotaxin, IL-6, IL-5 and MIP-1α in BALF were 
measured using a MAGPIX Luminex multiplexing analyser. *p<0.05, **p<0.01 
compares to air/saline; #p<0.05, ##p<0.01 compared to air/-24hr, 
†
p<0.05, 
††
p<0.01 
compares to ozone/saline. 
 
 
 
  
166 
 
5.2.4. Effects of iPSC-MSCs on apoptosis and proliferation in ozone-exposed 
lung tissue 
Apoptosis in lung sections was detected using TUNEL staining (Figure 5.4A). 
Apoptotic cells were labeled green and the nuclei were labeled blue. The Ozone/saline 
group demonstrated significantly increased number of apoptotic cells in lung sections 
in comparison with the air/saline group (number/20x field: 21.7±2.9 vs. 3.7±0.4, 
p<0.05) (Figure 5.4B). Both Ozone/-24hr and Ozone/+6hr groups showed 
significantly reduced number of apoptotic cells compared with Ozone/saline group 
(number/20x field: 9.0±1.2, p<0.01 and 9.3±1.3, p<0.01 respectively) (Figure 5.4B). 
Proliferative cells in lung sections were identified by immunofluorescent staining 
against Ki-67, a marker of proliferation (Figure 5.5A). Ozone exposure significantly 
reduced the number of proliferating cells in lung sections (number/20x field: 54.6±5.5 
vs. 77.2±5.9, p<0.05) (Figure 5.5B). The Ozone/-24hr group did not show a 
significant difference in proliferating cell number compared to Air/-24hr group 
(number/20x field: 66.4±7.9, vs.71.5±6.4), indicating that negative effect of ozone on 
proliferation might be prevented by treatment with iPSC-MSCs (Figure 5.4B). 
However, the Ozone/-24hr group only showed a trend of increased proliferating cell 
number compared to Ozone/saline group which did not reach statistical significance. 
The Ozone/+6hr group also did not show a significant difference in the number of 
proliferating cells compared with the Ozone/saline group.  
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Figure 5. 4 Effects of iPSC-MSCs on ozone-induced apoptosis in mouse lungs. (A) 
Apoptotic cells were identified by TUNEL staining (green) indicated by the arrows. 
The nuclei were visualized by DAPI staining (blue). (B) Number of apoptotic cells in 
lung sections. Apoptotic cells were counted in five randomly selected 20x fields for 
each mouse using a fluorescent microscope. *p<0.05 compared to air/saline; 
††
p<0.01 
compares to ozone/saline. 
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Figure 5. 5 Effects of ozone and iPSC-MSCs on cellular proliferation in mouse 
lungs. (A) Detection of proliferating cells by Ki-67 staining (red). The nuclei were 
visualized by DAPI staining (blue). (B) Number of proliferative cells in lung sections. 
Proliferative cells were counted in five randomly selected 20x fields for each mouse 
using a fluorescent microscope. *p<0.05 compared to air/saline. 
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5.2.5. Effect of iPSC-MSCs on ozone-induced cellular ROS and mitochondrial 
dysfunction in mouse lungs 
Intact mitochondria and cytoplasmic fractions were extracted from lung tissue. 
The ROS levels in the cytoplasm fractions were measured by DCF assay (Figure 
5.6A). Ozone exposure significantly elevated the cytoplasmic ROS levels (RFU/mg 
protein: 3131±269.8 vs. 2061±123.9, p<0.01). When treated with iPSC-MSCs 24 
hours prior to ozone exposure, the cytoplasmic ROS levels were still significantly 
higher compared with the Air/-24hr group (RFU/mg protein: 2787±171.9 vs. 
2030±178.9, p<0.05). The Ozone/+6hr group also showed significantly higher level of 
cytoplasmic ROS compared with Air/saline group (RFU/mg protein: 2909±194.4 vs. 
2061±123.9, p<0.05). No significant reduction was observed in both Ozone/-24hr and 
Ozone/+6 groups in comparison with the Ozone/saline group.  
The mitochondrial ROS levels in the intact mitochondria were measured by 
MitoSOX staining (Figure 5.6B). Mitochondrial ROS level was significantly elevated 
in the Ozone/saline group compared with the Air/Saline group (RFU/mg protein: 
166.4±9.5 vs. 119.9±8.8, p<0.05). Both Ozone/-24hr and Ozone/+6hr groups 
demonstrated significantly reduced mitochondrial ROS levels compared to 
Ozone/saline group (RFU/mg protein: 122.8±10.0, p<0.05 and 62.9±10.3, p<0.01 
respectively). In addition, the mitochondrial ROS level in Ozone/+6hr group is 
significantly lower than the Ozone/-24hr group (p<0.01). 
Mitochondrial membrane potential (ΔΨm) of the intact mitochondria was 
accessed by JC-1 staining (Figure 5.6C). Exposure to ozone without treatment of 
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iPSC-MSCs reduced the ΔΨm in comparison to the Air/saline group (fold to 
Air/saline: 0.692±.0.057 vs. 1.00±0.041, p<0.01). The treatment of iPSC-MSCs 24 
hours prior to the ozone-exposure significantly improved the ΔΨm compared with the 
Ozone/saline group (fold to Air/saline: 1.004±.0.076 vs. 0.692±.0.057, p<0.01). 
However, the Ozone/+6hr group didn‟t show significant difference as compared with 
Ozone/saline group, and the ΔΨm was still significantly lower than the Air/saline 
group (fold to Air/saline: 0.778±.0.060 vs. 1.00±0.041, p<0.01). 
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Figure 5. 6 Effects of iPSC-MSCs on ozone-induced ROS and mitochondrial 
dysfunction in mouse lungs. Intact mitochondria and cytoplasmic fractions were 
isolated from mouse lungs. (A) Cytoplasmic ROS was measured by DCF staining. (B) 
Mitochondrial ROS was measured in intact mitochondria by MitoSOX staining. (C) 
ΔΨm was determined in intact mitochondria by JC-1 staining. *p<0.05, **p<0.01 
compared to air/saline; #p<0.05 compared to air/-24hr, 
†
p<0.05, 
††
p<0.01 compared to 
ozone/saline; 
§§
p<0.01 compared to ozone/-24hr. 
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5.3. Discussion 
This study demonstrated that intravenously administrated iPSC-MSCs were able 
to prevent ozone-induced AHR, airway inflammation, apoptosis, mitochondrial ROS 
and reduction in ΔΨm. The therapeutic administration of iPSC-MSCs failed to reverse 
ozone-induced AHR, airway inflammation and reduction in ΔΨm, but the 
ozone-induced apoptosis and mitochondrial ROS were reversed. Although the data 
also showed lack of effects on ozone-induced cytoplasmic ROS and reduction in 
proliferation, the findings suggested a protective role of iPSC-MSCs on 
ozone-induced lung damage. 
Ozone is a potent oxidant. High concentration of environmental ozone was 
reported to be associated with worsening of symptoms in patients with COPD and 
asthma (18, 74, 84, 173, 197, 239, 257). In mouse models, exposure to ozone is 
reported to induce airway oxidative stress, AHR and inflammation (54, 253, 272, 274, 
275). Oxidative stress-associated airway inflammation is believed to be a key 
component of the pathogenesis of COPD (65). Indeed, repeated exposure to ozone can 
lead to airway inflammation accompanied by destruction of alveolar structure, leading 
to an emphysema-like phenotype (203, 253). In the present study mice were exposed 
to ozone (3 ppm) for a single period of 3 hours. The recruitment of inflammatory cells 
to the lungs was robust after 24 hours, as indicated by increased cell counts in the 
BAL. Increased levels of inflammatory mediators including MCP-1, eotaxin, IL-6, 
IL-5 and MIP-1α were also observed in the BALF. These findings confirmed the 
induction of inflammation by ozone in the model. The prophylactic injection of 
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iPSC-MSCs prevented ozone-induced inflammation, as indicated by the reduction of 
both total cell counts in the BAL and levels of inflammatory mediators including 
eotaxin, IL-6, IL-5 and MIP-1α, in the BALF. On the other hand, administration of 
iPSC-MSCs after ozone exposure did not reverse the recruitment of inflammatory 
cells. However, it did reverse the induction of several inflammatory mediators in the 
lungs, including eotaxin, IL-6, IL-5 and MIP-1α, which suggested that iPSC-MSCs 
still had an anti-inflammatory effect. Failure to reverse inflammatory cell infiltration 6 
hours after exposure may be due to a stronger inflammatory response or due to the 
shorter length of treatment time in the therapeutic protocol (18 hours) compared to the 
prophylactic protocol (48 hours). These findings are in agreement with my results 
showing lack of therapeutic effects of iPSC-MSCs on AHR. Although, the 
anti-inflammatory role of iPSC-MSCs has been demonstrated by previous studies in 
allergic (244) and CS-induced airway inflammation models (as shown in previous 
chapters), the ability of iPSC-MSCs to ameliorate AHR has never been reported. AHR 
is a major clinical feature of asthma, however it is also observed in some patients with 
COPD (291). A previous study in an acute ozone-exposed mouse model demonstrated 
that ozone-induced AHR results from the activation of p38 mitogen-activated protein 
kinase (147). The exact mechanism of the action of iPSC-MSCs in this model requires 
further investigation. 
Excessive protease activity associated with oxidative stress and chronic 
inflammation is believed to lead to alveolar destruction in patients with COPD (68, 76, 
77, 189). However, accumulating evidence suggest that the imbalance between 
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apoptosis and proliferation may also contribute to the gradual alveolar destruction 
(67). In this study increased lung apoptosis and reduced proliferation was observed 
after ozone exposure, which is consistent with the imbalance between apoptosis and 
proliferation in the chronic CS-exposed model described in Chapter 3. Treatment with 
iPSC-MSCs, either before or after ozone exposure, reduced ozone-induced apoptosis, 
but the ozone-induced reduction in proliferation was not alleviated. These findings 
indicate a possibly higher anti-apoptotic ability of iPSC-MSCs than pro-proliferative 
ability in a context of oxidative stress.  
Mitochondrial dysfunction has been characterized in the ozone-exposed mouse 
model in a previous report (273). Ozone exposure can lead to reduced ATP levels, 
mitochondrial complex proteins expression and ΔΨm as well as increased 
mitochondrial ROS. The mitochondria-targeted antioxidant, MitoQ, was able to 
attenuate mitochondrial dysfunction in the model, as well as the ozone-induced AHR 
and inflammation, indicating the AHR and inflammation may be partly driven by 
mitochondrial dysfunction (273). Moreover, mitochondrial dysfunction can trigger the 
cellular apoptosis (90). Therefore, the effects of iPSC-MSCs on AHR, inflammation 
and apoptosis may all relate to its effects on ozone-induced mitochondrial dysfunction 
in lung. Indeed, the prophylactic administration of iPSC-MSCs reduced 
ozone-induced mitochondrial ROS and reduction in ΔΨm, in line with the effects on 
ozone-induced inflammation, AHR and apoptosis. The administration after ozone 
exposure only reversed the ozone-induced mitochondrial-ROS level, but not the 
reduction of ΔΨm. The findings are in agreement with the results of our co-culture 
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experiments described in the Chapter 4. There I show that iPSC-MSCs can prevent 
and reverse CSM-induced mitochondrial ROS, whereas they can prevent but not 
reverse CSM-induced ΔΨm loss. 
Despite the reduction in ozone-induced mitochondrial ROS by iPSC-MSCs, 
ozone-induced cytoplasmic ROS levels were not modulated by iPSC-MSCs. Such 
result may indicate a lack of anti-oxidant effects by iPSC-MSCs in the model. Further 
investigation on oxidative stress and anti-oxidant mechanisms in the lung should 
better address this issue. On the other hand, the data also suggested that mitochondrial 
and cytoplasmic ROS are differentially regulated in cells. Although the mechanisms 
by which iPSC-MSCs modulate mitochondrial ROS are unclear, the prevention of 
ΔΨm loss and the lack of effect on cytoplasmic ROS suggest that this possibly occurs 
through mechanisms that specifically target the mitochondria, such as mitochondrial 
transfer. 
This study has several limitations and further investigations are required. Firstly, 
although the acute exposure of ozone can induce AHR and inflammation, a model 
involving multiple ozone exposures would be more relevant to COPD (253). 
Investigation of effects of iPSC-MSCs on ozone-induced emphysema, AHR, 
inflammation and mitochondrial dysfunction in such model would be an important 
experiment to perform. Secondly, the mechanisms by which iPSC-MSCs prevent 
ozone-induced mitochondrial dysfunction and the associated inflammation, apoptosis 
and AHR remain unclear. Lastly, the effects of iPSC-MSCs on the oxidant and 
anti-oxidant balance in the lungs can be further investigated. 
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In summary, iPSC-MSCs prevented ozone-induced mitochondrial dysfunction as 
well as lung inflammation and apoptosis, and AHR. In the therapeutic protocol, 
iPSC-MSCs showed no effect on AHR and airway inflammation but reversed 
apoptosis and mitochondrial dysfunction in response to ozone. I demonstrate for the 
first time the capacity of iPSC-MSCs to prevent mitochondrial dysfunction and AHR 
in the lungs, highlighting iPSC-MSCs as promising candidates for the development of 
cell-based therapies for COPD. 
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Chapter 6. General Discussion 
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6.1. General Discussion 
In this study, I demonstrated a superior efficacy of iPSC-MSCs to attenuate 
chronic CS-exposure-induced lung emphysema, inflammation and apoptosis in rats 
compared to BM-MSCs, which was associated with a higher capacity for 
mitochondrial transfer from iPSC-MSCs to lung epithelium. In vitro studies also 
demonstrated a higher ability of iPSC-MSCs to transfer mitochondria to and attenuate 
CSM-induced ATP depletion in CSM-treated bronchial epithelial cells. In addition, 
iPSC-MSCs-CdM demonstrated better efficacy in attenuating CSM-induced apoptosis 
and reducing proliferation in bronchial epithelial cells compared to BM-MSCs, which 
was partly mediated by SCF. Therefore, iPSC-MSCs demonstrated higher capacity of 
both mitochondrial transfer and paracrine release of anti-apoptotic cytokines to 
bronchial epithelial cells. I then investigated whether such activities were able to 
restore mitochondrial health under oxidative stress. This study was carried out in vitro 
first in a CSM-treated model of ASMCs. Direct co-culture with iPSC-MSCs protected 
ASMCs from CSM-induced reduction in ΔΨm and elevation of mitochondrial ROS 
and apoptosis. However, when direct cell-cell contact was prevented, iPSC-MSCs 
only reduced CSM-induced mitochondrial ROS but not reduction of ΔΨm and 
increase of apoptosis in ASMCs. Mitochondrial transfer from iPSC-MSCs to ASMCs 
was observed in direct co-culture which was enhanced by CSM treatment. In line with 
the in vitro findings, in a mouse model of acute ozone exposure, intravenous 
administration of iPSC-MSCs protected lung tissue from ozone-induced 
mitochondrial dysfunction and apoptosis. Ozone-induced AHR and inflammation was 
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also reduced by iPSC-MSCs. In summary, I demonstrated that mitochondrial transfer 
activity from iPSC-MSCs was able to alleviate oxidative-stress-induced ATP 
depletion, mitochondrial dysfunction and apoptosis in target cells. The full capacity of 
iPSC-MSCs to achieve these effects may rely on combined mechanisms of both direct 
cell-cell contact and release of paracrine factors (Figure 6.1). The capacity of 
iPSC-MSCs to transfer their mitochondria to and protect airway cells from oxidative 
stress-induced damage is superior to that of BM-MSCs. 
 The study was initially motivated by three observations regarding current status 
of respiratory medicine and stem cells. First of all, current medications for COPD can 
only reduce symptoms, exacerbations, and improve health status and exercise 
tolerance, and no current medication is able to attenuate the progressive decline of 
lung function in COPD (263). As a disease predicted to be the 4th leading cause of 
death by 2030 (172) associated with enormous economic and social burden, seeking 
new treatments for COPD is an urgent and important task in respiratory medicine. 
Secondly, there have been numerous reports on the efficacy of MSCs in animal 
models of lung disease (269, 270). Despite a lack of knowledge of the underlining 
mechanisms, MSCs from BM, adipose or cord blood have been demonstrated to 
attenuate emphysema induced by CS, elastase or VEGF deficiency (94, 112, 151, 222, 
269, 270). However, in a clinical trial, intravenously infused BM-MSCs failed to 
modulate quality of life and lung function in patients with COPD (271). Although 
there are multiple variables that may contribute to the lack of efficacy such as dose 
and timing, the results still point out the potential gap between the pre-clinical models 
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and patients, and the possibility that current findings of therapeutic effects of MSCs in 
COPD-related models may not be necessarily translated into treatments for patients 
with COPD. Therefore, despite current studies already having demonstrated adequate 
efficacy of MSCs in pre-clinical models, the search for improved MSC therapies with 
more profound effects in pre-clinical models should not stop. After all, the clinical 
trial demonstrated extraordinary tolerance and safety of intravenously infused 
BM-MSCs in patients with severe COPD, leaving the door open for future trials. 
Thirdly, the in vitro derivation of iPSC-MSCs from iPSCs has provided a new 
opportunity to develop improved MSC therapy against COPD. Compared to 
BM-MSCs, iPSC-MSCs are more readily available in abundance and possess a higher 
ability of proliferation without loss of differentiation potential and telomerase activity 
(153). They may hold the hope of overcoming ageing-associated dysfunction of 
BM-MSCs by the induction of pluripotency during their generation. As age is an 
important risk factor for COPD, iPSC-MSCs may be a good candidate for getting one 
own source of MSCs. Moreover, the process of inducing somatic cells into iPSCs and 
differentiating iPSCs into iPSC-MSCs provided an opportunity to genetically 
manipulate the cells at different stages. Using MSCs as a vehicle for gene therapy 
may also be a future option to develop improved therapy against COPD (122). In 
summary, iPSC-MSCs may represent a novel and improved candidate for cell therapy 
of COPD. From the data presented in Chapter 3, my study demonstrated better 
efficacy of iPSC-MSCs than BM-MSCs in attenuating CS-induced lung emphysema, 
inflammation and apoptosis, possibly via higher activity of mitochondrial transfer and 
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paracrine secretion of cytokines such as SCF. My study has demonstrated the potential 
of iPSC-MSCs as an improved MSC therapy, hence providing a new option that may 
lead to a better treatment for COPD. 
 One striking observation from the study of CS-exposed rats is the mitochondrial 
transfer from iPSC-MSCs to epithelial cells, which led to focusing my attention to the 
other theme of the thesis, namely the oxidative stress-induced mitochondrial 
dysfunction in pulmonary cells. Developing new treatments for COPD relies on the 
understanding of the pathogenesis of COPD. One of the recent advances is the 
demonstration of mitochondrial dysfunction associated with COPD. Primary 
bronchial epithelial cells from ex-smokers with severe COPD have been shown to 
exhibit swelling and fragmented mitochondrial morphology which is similar to 
CSM-treated BEAS-2B cells (105). Primary ASMCs from patients with COPD were 
shown to have elevated mitochondrial ROS levels, and reduced ΔΨm, complex 
protein levels and respiratory function (273). Moreover, the mitochondria-targeted 
anti-oxidant MitoQ was able to reduce chronic ozone exposure-induced mitochondrial 
dysfunction, inflammation and AHR in mice, highlighting mitochondria as a potential 
target for COPD treatment (273). Meanwhile, despite a large number of reports on the 
efficacy of MSCs in lung disease models, their mechanisms of action remain largely 
unknown. One of the latest advances is the in vivo observation of mitochondrial 
transfer from BM-MSCs to pulmonary epithelial cells in an acute lung injury model 
(118). In other words, mitochondria are a novel target for COPD treatment as well as 
a novel player in the action of MSCs. Therefore, the second half of my study aimed to 
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investigate whether mitochondria for lung cells are damaged by oxidative stress, 
whether this damage can be prevented or reversed by iPSC-MSCs, and whether 
iPSC-MSCs exert such protective actions through mitochondrial transfer. The results 
demonstrated that CSM led to reduced ATP contents in BEAS-2B cells, and increased 
mitochondrial ROS, apoptosis and reduced ΔΨm in primary ASMCs in vitro. Acute 
ozone exposure also led to increased mitochondrial ROS and reduced ΔΨm in mouse 
lungs in vivo. This oxidative stress-induced mitochondrial dysfunction was alleviated 
by iPSC-MSCs either through direct co-culture in vitro, or through intravenous 
administration in vivo. Mitochondrial transfer was demonstrated from iPSC-MSCs to 
airway epithelium in the CS-exposed model in vivo, and from iPSC-MSCs to 
BEAS-2B cells and ASMCs in vitro. CSM enhanced mitochondrial transfer from 
iPSC-MSCs to both BEAS-2B cells and ASMCs. The enhanced mitochondria transfer 
may be driven by the need for repair, and may be responsible for the alleviation of 
CSM-induced mitochondrial dysfunction. Therefore this study demonstrated that 
oxidative stress can induce mitochondrial dysfunction of pulmonary cells in vitro and 
in vivo, and iPSC-MSCs are able to transfer mitochondria to these damaged cells in 
response to the oxidative stress-induced damage and alleviate the mitochondrial 
dysfunction.  
 Improved mitochondrial function may bring other potential benefits to the cell. 
Mitochondria serve as the powerhouse of the cells. It has been reported that CS 
exposure led to altered lung energy metabolism, with a switch of glucose metabolism 
toward pentose phosphate pathway and a reduced supply of substrate to mitochondria. 
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The transfer of mitochondria into the lung cells may help maintain the energy supply 
(4). In addition, as described in Chapter 1.1.4.7, mitochondria play an important role 
in regulating ROS generation and cell fate. Oxidant/anti-oxidant imbalance plays an 
important role in the pathogenesis of COPD, with the process of oxidative 
phosphorylation in mitochondria being a major source of intracellular ROS (149, 165). 
Severe mitochondrial damage may lead to depolarization of mitochondria and release 
of cytochrome c, and to mitochondrial pathways of cell apoptosis (90). Mitochondrial 
damage can also mediate autophagy and senescence, processes that could contribute 
to the development of COPD (11). 
 In general, mitochondrial dysfunction can be targeted using three different 
strategies: repair via scavenging excess ROS, reprogramming via regulatory pathways, 
and replacement by exogenous functional mitochondria (5). Mitochondria-targeted 
anti-oxidant such as MitoQ is a direct way to reduce mitochondrial ROS, which may 
subsequently improve other mitochondrial functions such as ΔΨm and respiration. 
This has been demonstrated in the chronic ozone-exposed mouse model (273). 
Nutrient overload and metabolic changes associated with obesity are common causes 
of mitochondrial stress (5) and improvement of mitochondrial function by exercise, 
diet and possibly pharmacotherapy such as metformin has been reported (5). Clinical 
trials on COPD have demonstrated the potential of metformin to reduce dyspnea and 
increase exercise capacity, but more comprehensive studies are awaited to confirm its 
efficacy (225). Both repair and reprogramming relies on the recovery of the current 
defective mitochondria, which may not be easy for cells of severely-damaged 
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mitochondria. Also, if mitochondrial DNA has been damaged, such strategies may not 
work. In such a situation, replacement of damaged mitochondria with fresh 
mitochondria may be a better strategy. Mitochondrial replacement can be achieved by 
microinjection, incubation with mitocytoplasts or intact purified mitochondria, and 
the cell-cell contact-dependent mitochondrial transfer from MSCs (225). The latter 
method used in my thesis, namely mitochondrial transfer, is the only way that does 
not involve any disturbance of the cells or involve isolating mitochondria and 
injecting the cells but involves a natural method of transferring organelles such as 
mitochondria between cells. It provides a perfect approach to deliver exogenous 
mitochondria into damaged cells. My study confirmed that mitochondrial transfer can 
occur in vivo following its first report in 2012 (118). Moreover, as iPSC-MSCs have a 
higher expanding ability than BM-MSCs, the approach we used therefore provided a 
more abundant source of mitochondrial donor.  
 Although mitochondrial transfer was demonstrated both in vivo and in vitro in 
this study, it should be noted that the recipient cells were human bronchial epithelial 
or ASMCs in the in vitro experiments, while in the in vivo study mitochondria were 
transferred from human MSCs into rodent lung cells. The functional compatibility 
between the human mitochondria and rodent lung cells was not tested in the current 
study. Previous reports have demonstrated the transfer of human mitochondria from 
human BM-MSCs to rat cardiomyocytes in vitro (204) and to AEC2s in mouse lungs 
(118), but the functional compatibility was not discussed. In a further study, despite 
reporting efficient mitochondrial fusion between mouse and human mitochondria 
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within 4 hours (288), the study demonstrated low compatibility between mouse 
nuclear and human mitochondrial genomes. Therefore the functional significance of 
the mitochondrial transfer observed in vivo in this thesis is largely unknown.  
 Two animal models have been used in this thesis to study the rescuing effect of 
MSCs. The first one is a rat model exposed to CS for 1 hour/day for 56 days, while 
the second one is a mouse model with a single ozone exposure for 3 hours. The two 
models are related in some aspects but also different. Both CS and ozone are potent 
sources of oxidants. Therefore, both models can be referred to as oxidative 
stress-induced lung damage, which makes them distinct from some other 
COPD-related models, such as elastase-induced emphysema in which oxidative stress 
is not the direct driving force. Cigarette smoking is the major risk factor of COPD, 
and chronic CS-exposure is a classic way to induce COPD-like phenotype such as 
airspace enlargement and lung inflammation. Although ozone is not a major cause of 
COPD, elevated ozone levels have been reported to increase hospital admission due to 
COPD (173). Exposure to ozone twice per week for 6 weeks can induce COPD-like 
phenotype in mice including emphysema, chronic inflammation, cell infiltration and 
steroid resistance (253, 272). Moreover, the ozone-exposed mouse model has been 
reported to exhibit a gene expression signature similar to that seen in human COPD 
(273). The major difference between the two models in the present study is that the 
CS-exposed model is a chronic model with multiple exposures, while the 
ozone-exposed model is an acute model with a single exposure period. The acute 
exposure of ozone cannot induce airspace enlargement, but infiltration of neutrophils 
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and other inflammatory cells was demonstrated and, as such, could be taken as a 
model mimicking an exacerbation of COPD which is a frequent manifestation of 
advanced COPD. In general, acute exposure indicates that the animals were 
responding to the stimulation based on a normal physiological condition, whereas in 
chronic models, along the progression of the damage, the animals respond to the 
stimulation based on a damaged, abnormal condition. While the efficacy of 
iPSC-MSCs in the chronic CS-exposed model specifically defines iPSC-MSCs as a 
promising candidate for MSC therapy of COPD, the efficacy of iPSC-MSCs in the 
acute ozone-induced model may provide a more general implication on an acute 
oxidative stress insult such as during an exacerbation. Although the acute 
ozone-exposed model did not exhibit airspace enlargement, this model has been used 
to investigate some parameters that have not been measured in the CS-exposed model, 
including AHR, cytosolic ROS, mitochondrial ROS and ΔΨm. Nevertheless, both 
models in the study have demonstrated inflammation and apoptosis in the lung. Using 
the two different models, I demonstrated the capacity of iPSC-MSCs to alleviate 
oxidative stress-induced lung damage in both acute and chronic setups. 
 The in vitro study involved two different airway cell types. Although both cell 
types were treated with CSM, it should be noted that the treatments were optimized 
based on different parameters. In the study on bronchial epithelial BEAS-2B cells, the 
concentration (2%) and length of treatment (24 hours) was adapted from a previous 
study, with an induction of IL-8 release without reduction of viability. As 
demonstrated in Chapter 3, such condition was sufficient to induce apoptosis and 
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reduce ATP content. In the study of primary ASMCs, the concentration of CS (10% or 
25%) and length of treatment (4 hours) was determined by the induction of 
mitochondrial dysfunction as measured by mitochondrial ROS and ΔΨm. The CSM 
stimulation was more acute and strong in the ASMCs study, leading to a more acute 
induction of apoptosis. Such difference may explain why the released cytokines from 
iPSC-MSCs (iPSC-MSCs-CdM) were able to attenuate CSM-induced apoptosis in 
BEAS-2B cells but not in ASMCs in the study. On the other hand, enhanced 
mitochondrial transfer has been detected from iPSC-MSCs to both BEAS-2B cells 
and ASMCs under the corresponding CSM treatments. Mitochondrial transfer and 
paracrine effects may serve as two different mechanisms of iPSC-MSCs‟ action. By 
using apoptosis as a functional output, it is clear that the relative contribution of 
mitochondrial transfer and paracrine effects varies among different target cell types 
and treatments. In the 24 hour-treated BEAS-2B cells, paracrine effects from 
iPSC-MSCs were sufficient to reduce apoptosis. By contrast, in the 4 hour-treated 
ASMCs, the anti-apoptotic efficacy fully relied on cell-cell contact that facilitated the 
mitochondrial transfer which is a more direct mechanism to rescue mitochondrial 
dysfunction. Such differences demonstrated the complexity and the dynamics of 
mechanisms of action of iPSC-MSCs. 
 The in vivo and in vitro data from different chapters complement each other very 
well in this study. The mitochondrial transfer from iPSC-MSCs to damaged cells in 
vivo in the CS-exposed model was also observed in vitro for both BEAS-2B cells and 
ASMCs. The anti-apoptotic effect of iPSC-MSCs in both CS- and ozone-exposed 
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animal models was also demonstrated in both BEAS-2B cells and ASMCs. The 
attenuation of mitochondrial dysfunction by iPSC-MSCs was demonstrated in vivo in 
ozone-exposed mice as well as in vitro in ASMCs. Moreover, both studies 
demonstrated time-dependent effects. In the CSM-treated ASMCs, iPSC-MSCs 
prevented but not reversed the CSM-induced mitochondrial dysfunction. Similarly, in 
the ozone-exposed mice, iPSC-MSCs prevented but not reversed the ozone-induced 
inflammation, AHR and reduction of ΔΨm in the lung. This may be explained by the 
fact that ASMCs or mice were treated with iPSC-MSCs for more time in the 
preventive protocols, or that the oxidative stress-induced damage has progressed to a 
stage that cannot be reversed by iPSC-MSCs. Interestingly, in the ozone-exposed 
mice, although the preventive treatment did not attenuate ozone-induced reduction of 
ΔΨm, it attenuated ozone-induced mitochondrial ROS in the lung. This is very similar 
to the effects of iPSC-MSCs-CdM or iPSC-MSCs in trans-well inserts in vitro, which 
also demonstrated reduction of CSM-induced mitochondrial ROS but no change in 
ΔΨm in ASMCs. In theory, excess mitochondrial ROS can lead to defective election 
transport chain which is responsible for proton transfer across the inner mitochondrial 
membrane and defective permeability transition pore which controls the permeability 
of inner membrane (170). Both effects lead to ΔΨm reduction. The reduction of 
mitochondrial ROS without effects on ΔΨm in the study may be because the reduced 
mitochondrial ROS levels were still high enough to induce a reduction in ΔΨm, or 
because there are other mechanisms regulating ΔΨm which were less targeted by 
iPSC-MSCs, such as cytosolic ROS levels. 
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 The most direct clinical implication of the study is that intravenously-infused 
iPSC-MSCs may exert a stronger effect in patients with COPD compared to 
BM-MSCs which have not been shown to be effective in the clinical trials. However, 
it is of concern that the genetic reprogramming may also change the safety profile of 
iPSC-MSCs compared to BM-MSCs. In a more general perspective, iPSC-MSCs may 
be effective in other oxidative stress-mediated airway diseases such as asthma. In 
addition, the higher mitochondria transfer capacity and abundant resource also 
suggests that iPSC-MSCs may serve as a useful mitochondrial donor to target 
mitochondrial dysfunction in various diseases.  
There are several limitations of the work in my thesis. Firstly, due to time 
limitations, not all parameters were investigated in all models. As mitochondrial 
dysfunction was not the initial focus of the study, mitochondrial ROS and ΔΨm were 
not measured in the CS-exposed rat model and CSM-treated BEAS-2B cells. 
Secondly, although inflammation was investigated in the in vivo models, there was no 
direct measurement of inflammation in the in vitro models. A common inflammatory 
measurement used in cell culture studies is measurement of released inflammatory 
mediators. However, as both cell types in the co-culture are from human, the secretory 
function of one particular cell type is difficult to ascertain. Thirdly, there are other 
potential mechanisms involved in iPSC-MSCs action which may also contribute to 
the efficacy observed in the study. For example, formation of TNTs may also facilitate 
transfer of other organelles such as lysosomes. iPSC-MSCs may also secrete 
protective microvesicles to lung cells. Lastly, mitochondrial ROS and ΔΨm may not 
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represent all the functions of mitochondria. A measurement of mitochondrial 
respiration profile would have been ideal to address the issue.  
 
6.2. Conclusion 
 I demonstrated the superior effects of iPSC-MSCs in attenuating CS-induced 
emphysema, inflammation and apoptosis in rat lung compared to BM-MSCs, which 
was attributed to higher mitochondrial transfer and paracrine release of cytokines 
including SCF. iPSC-MSCs can also alleviate oxidative stress-induced AHR, 
inflammation, mitochondrial dysfunction and apoptosis in mouse lungs. 
Mitochondrial transfer from iPSC-MSCs was able to alleviate 
oxidative-stress-induced ATP depletion, mitochondrial dysfunction and apoptosis in 
target cells. The full capacity of iPSC-MSCs to achieve this efficacy may rely on 
combined mechanisms of both direct cell-cell contact and release of paracrine factors.  
These findings support iPSC-MSCs as a promising candidate for the development 
of MSCs-based therapy against COPD, which may be driven by multiple 
mechanisms. 
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Figure 6. 1 Summary of the effects of iPSC-MSCs on oxidative stress-induced 
lung cell damage. The full capacity of iPSC-MSCs to alleviate oxidative 
stress-induced mitochondrial dysfunction and apoptosis may rely on combined 
mechanisms of both direct cell-cell contact and release of paracrine factors. SCF: stem 
cell factor; Mito-ROS: mitochondrial ROS; iPSC-MSCs: induced pluripotent stem 
cell-derived mesenchymal stem cells; ASMCs: airway smooth muscle cells; CS: 
cigarette smoke; AHR: airway hyper-responsiveness.  
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6.3. Future Studies 
Several future investigations can be extended from this study.  
In this study, the effects of iPSC-MSCs on mitochondrial dysfunction in animal 
models with COPD-like phenotypes have not been demonstrated. It would be 
important to further investigate effects of iPSC-MSCs on mitochondria of the lung in 
a chronic CS-/ozone-exposed models focusing particularly on the development of 
emphysema.  
In the study I used cytochalasin B or trans-well membrane to block the formation 
of TNTs between iPSC-MSCs and target cells. However, such methods are not 
selective blockers of mitochondrial transfer. A recent study has demonstrated that 
mitochondrial transfer is mediated by Miro-1 (6). Knock-down or over-expression of 
Miro-1 in BM-MSCs leads to reduced or enhanced mitochondrial transfer activity 
respectively. This would provide a more selective approach to block mitochondrial 
transfer without interruption of TNT formation. Regarding my study, the following 
investigations could be proposed. First, whether Miro-1 is also responsible for the 
mitochondrial transfer in iPSC-MSCs can be examined. Determination of efficacy of 
iPSC-MSCs and mitochondrial transfer after Miro-1 knock-down and over-expression 
would address the question. Second, how does CSM enhance mitochondrial transfer? 
One hypothesis is that CSM treatment can directly regulate capacity of mitochondrial 
transfer of iPSC-MSCs. This can be investigated by measurement of Miro-1 
expression in response to CSM and identification of the possible pathways involved, 
such as mitogen-activated protein kinase pathways, using specific inhibitors of these 
193 
 
pathways. On the other hand, the enhanced mitochondrial transfer may be a response 
to signals from injured target cells. How the recipient cells regulate the mitochondrial 
transfer will also require further investigation.  
Another important follow-up study is to determine whether iPSC-MSCs can 
improve mitochondrial function of primary ASMCs from patients with COPD. 
ASMCs from patients with COPD already demonstrated mitochondrial dysfunction 
compared to normal controls. How this would change the mitochondrial transfer 
between the ASMCs and iPSC-MSCs should also be investigated. 
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